US20220039812A1 - Method of delivering material or stimulus to a biological subject - Google Patents
Method of delivering material or stimulus to a biological subject Download PDFInfo
- Publication number
- US20220039812A1 US20220039812A1 US17/326,064 US202117326064A US2022039812A1 US 20220039812 A1 US20220039812 A1 US 20220039812A1 US 202117326064 A US202117326064 A US 202117326064A US 2022039812 A1 US2022039812 A1 US 2022039812A1
- Authority
- US
- United States
- Prior art keywords
- cells
- cell
- targeting
- projections
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 87
- 239000000463 material Substances 0.000 title abstract description 118
- 210000004027 cell Anatomy 0.000 claims abstract description 194
- 230000008685 targeting Effects 0.000 claims description 127
- 210000003491 skin Anatomy 0.000 claims description 86
- 210000001821 langerhans cell Anatomy 0.000 claims description 78
- 230000000694 effects Effects 0.000 claims description 15
- 238000013461 design Methods 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 210000003463 organelle Anatomy 0.000 abstract description 58
- 230000004044 response Effects 0.000 abstract description 30
- 210000003855 cell nucleus Anatomy 0.000 abstract description 18
- 230000000149 penetrating effect Effects 0.000 abstract description 10
- 239000000427 antigen Substances 0.000 description 136
- 108091007433 antigens Proteins 0.000 description 136
- 102000036639 antigens Human genes 0.000 description 136
- 210000001519 tissue Anatomy 0.000 description 61
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 60
- 239000010410 layer Substances 0.000 description 53
- 108090000623 proteins and genes Proteins 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 40
- 239000002245 particle Substances 0.000 description 40
- 238000004519 manufacturing process Methods 0.000 description 35
- 230000000975 bioactive effect Effects 0.000 description 30
- 238000000576 coating method Methods 0.000 description 27
- 239000000523 sample Substances 0.000 description 27
- 210000004940 nucleus Anatomy 0.000 description 26
- 230000008569 process Effects 0.000 description 26
- 239000011248 coating agent Substances 0.000 description 25
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 25
- 210000000434 stratum corneum Anatomy 0.000 description 24
- 229910052721 tungsten Inorganic materials 0.000 description 24
- 239000010937 tungsten Substances 0.000 description 24
- 210000000612 antigen-presenting cell Anatomy 0.000 description 23
- 230000001580 bacterial effect Effects 0.000 description 23
- 230000035515 penetration Effects 0.000 description 22
- 239000011859 microparticle Substances 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 229910052710 silicon Inorganic materials 0.000 description 20
- 239000010703 silicon Substances 0.000 description 20
- 210000002615 epidermis Anatomy 0.000 description 19
- 230000030833 cell death Effects 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 17
- 229910052737 gold Inorganic materials 0.000 description 17
- 239000010931 gold Substances 0.000 description 17
- 238000001890 transfection Methods 0.000 description 17
- 230000003612 virological effect Effects 0.000 description 17
- 238000003780 insertion Methods 0.000 description 16
- 230000037431 insertion Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 238000013459 approach Methods 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 238000010586 diagram Methods 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 10
- -1 fabrication methods Substances 0.000 description 10
- 230000002538 fungal effect Effects 0.000 description 10
- 238000011068 loading method Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 9
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 239000013566 allergen Substances 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 238000000708 deep reactive-ion etching Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 229910052709 silver Inorganic materials 0.000 description 9
- 239000004332 silver Substances 0.000 description 9
- 239000010936 titanium Substances 0.000 description 9
- 229910052719 titanium Inorganic materials 0.000 description 9
- 235000012431 wafers Nutrition 0.000 description 9
- 238000003491 array Methods 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 101150029707 ERBB2 gene Proteins 0.000 description 7
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 7
- 230000008512 biological response Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102100029974 GTPase HRas Human genes 0.000 description 6
- 101710091881 GTPase HRas Proteins 0.000 description 6
- 108010056995 Perforin Proteins 0.000 description 6
- 102000004503 Perforin Human genes 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 241000193738 Bacillus anthracis Species 0.000 description 5
- 238000011238 DNA vaccination Methods 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 206010037742 Rabies Diseases 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 210000004927 skin cell Anatomy 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 206010013023 diphtheria Diseases 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000003712 lysosome Anatomy 0.000 description 4
- 230000001868 lysosomic effect Effects 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000000605 viral structure Anatomy 0.000 description 4
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 3
- 201000005807 Japanese encephalitis Diseases 0.000 description 3
- 241000710842 Japanese encephalitis virus Species 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 240000001307 Myosotis scorpioides Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 3
- 201000005702 Pertussis Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000000270 basal cell Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000981 bystander Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 108010048032 cyclophilin B Proteins 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000000147 enterotoxin Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 238000005530 etching Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000000059 patterning Methods 0.000 description 3
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 3
- 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 3
- 210000000680 phagosome Anatomy 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 241000256844 Apis mellifera Species 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108010058432 Chaperonin 60 Proteins 0.000 description 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000228402 Histoplasma Species 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 101710164436 Listeriolysin O Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 240000005384 Rhizopus oryzae Species 0.000 description 2
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 238000001015 X-ray lithography Methods 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- QXZUUHYBWMWJHK-UHFFFAOYSA-N [Co].[Ni] Chemical compound [Co].[Ni] QXZUUHYBWMWJHK-UHFFFAOYSA-N 0.000 description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000004070 electrodeposition Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000012645 endogenous antigen Substances 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000001459 lithography Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000001755 magnetron sputter deposition Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical group OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000028043 self proteolysis Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- 238000004544 sputter deposition Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 108090000020 Alpha-catenin Proteins 0.000 description 1
- 102000003730 Alpha-catenin Human genes 0.000 description 1
- 102400000310 Alpha-dystroglycan Human genes 0.000 description 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 241001351995 Aphomia sociella Species 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 101100504181 Arabidopsis thaliana GCS1 gene Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000884007 Arachnomyces nodosetosus Species 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 241000235579 Basidiobolus Species 0.000 description 1
- 206010004272 Benign hydatidiform mole Diseases 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 241001465178 Bipolaris Species 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102100028906 Catenin delta-1 Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000255930 Chironomidae Species 0.000 description 1
- 241000498849 Chlamydiales Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000983417 Chrysomya bezziana Species 0.000 description 1
- 241001668502 Cladophialophora carrionii Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 108010065693 Clostridium perfringens theta-toxin Proteins 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 206010052465 Congenital poikiloderma Diseases 0.000 description 1
- 241001480517 Conidiobolus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241001315231 Cricotopus trifasciatus Species 0.000 description 1
- 241001527609 Cryptococcus Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000223208 Curvularia Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 description 1
- 108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 description 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 108010071885 Dystroglycans Proteins 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 101001095863 Enterobacteria phage T4 RNA ligase 1 Proteins 0.000 description 1
- 101710126487 Envelope glycoprotein B Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000223664 Exophiala jeanselmei Species 0.000 description 1
- 241000306559 Exserohilum Species 0.000 description 1
- 101150048576 FIM3 gene Proteins 0.000 description 1
- 241000045671 Falciformispora senegalensis Species 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 241001669595 Fonsecaea compacta Species 0.000 description 1
- 241000122864 Fonsecaea pedrosoi Species 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 241000427940 Fusarium solani Species 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 244000168141 Geotrichum candidum Species 0.000 description 1
- 235000017388 Geotrichum candidum Nutrition 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000033640 Hereditary breast cancer Diseases 0.000 description 1
- 241000487062 Histoplasma capsulatum var. capsulatum Species 0.000 description 1
- 241001354006 Histoplasma capsulatum var. duboisii Species 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 241000308514 Hortaea werneckii Species 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000006937 Hydatidiform mole Diseases 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 108010007403 Immediate-Early Proteins Proteins 0.000 description 1
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 229910001030 Iron–nickel alloy Inorganic materials 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000526687 Lacazia loboi Species 0.000 description 1
- 108010000851 Laminin Receptors Proteins 0.000 description 1
- 102000002297 Laminin Receptors Human genes 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000190144 Lasiodiplodia theobromae Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 241000222732 Leishmania major Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
- 241000144128 Lichtheimia corymbifera Species 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 108700027766 Listeria monocytogenes hlyA Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 241000736227 Lucilia sericata Species 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 241001444203 Madurella mycetomatis Species 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000375796 Medicopsis romeroi Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 102100025077 Melanoma-associated antigen 4 Human genes 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100481584 Mus musculus Tlr1 gene Proteins 0.000 description 1
- 241000257159 Musca domestica Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 241001547451 Neoscytalidium dimidiatum Species 0.000 description 1
- 241000322250 Neotestudina rosatii Species 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 208000004485 Nijmegen breakage syndrome Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241001531356 Phialophora verrucosa Species 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 241001326499 Piedraia hortae Species 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 101710183389 Pneumolysin Proteins 0.000 description 1
- 206010035718 Pneumonia legionella Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000235525 Rhizomucor pusillus Species 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 208000000791 Rothmund-Thomson syndrome Diseases 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000825258 Scopulariopsis brevicaulis Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000254179 Sitophilus granarius Species 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 241000045663 Trematosphaeria grisea Species 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010061610 Tva receptor Proteins 0.000 description 1
- 102000046255 Type III Sodium-Phosphate Cotransporter Proteins Human genes 0.000 description 1
- 108091006286 Type III sodium-phosphate co-transporters Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 102000012349 Uroplakins Human genes 0.000 description 1
- 108010061861 Uroplakins Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000219977 Vigna Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001455 anti-clotting effect Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 229910021419 crystalline silicon Inorganic materials 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 108010031971 delta catenin Proteins 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 210000003595 dermal dendritic cell Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000000609 electron-beam lithography Methods 0.000 description 1
- 238000000572 ellipsometry Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000001317 epifluorescence microscopy Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 210000000973 gametocyte Anatomy 0.000 description 1
- 108010084448 gamma Catenin Proteins 0.000 description 1
- 102000054078 gamma Catenin Human genes 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000005133 interdigitating dendritic cell Anatomy 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- UGKDIUIOSMUOAW-UHFFFAOYSA-N iron nickel Chemical compound [Fe].[Ni] UGKDIUIOSMUOAW-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 210000004684 kidney tubule cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000001247 metal acetylides Chemical class 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 108091008685 nuclear receptors type I Proteins 0.000 description 1
- 108091008686 nuclear receptors type II Proteins 0.000 description 1
- 102000027507 nuclear receptors type II Human genes 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 201000001219 parotid gland cancer Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000013031 physical testing Methods 0.000 description 1
- 208000005814 piedra Diseases 0.000 description 1
- 230000003114 pinocytic effect Effects 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 238000001020 plasma etching Methods 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 208000013860 rhabdoid tumor of the kidney Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 108010061514 sialic acid receptor Proteins 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 230000008417 skin turnover Effects 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 210000003046 sporozoite Anatomy 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 108010075210 streptolysin O Proteins 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 201000009862 superficial mycosis Diseases 0.000 description 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000003982 trichinellosis Diseases 0.000 description 1
- 201000007588 trichinosis Diseases 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 201000004435 urinary system cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 238000001771 vacuum deposition Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
- A61B17/205—Vaccinating by means of needles or other puncturing devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
Definitions
- the present invention relates to a device for delivery of material or stimulus to targets within a body to produce a desired response, and in particular to a device including a number of projections for penetrating a body surface.
- the invention can also relate to devices for delivering bioactive substances and other stimuli to living cells, to methods of manufacture of the device and to various uses of the device.
- the skin structure is shown in FIG. 11 , with a summary of key existing delivery methods.
- Non-invasive methods of delivery through the skin have been used, including patches, liquid solutions and creams. Their success is dependent upon the ability to breach the semi-permeable stratum corneum (SC) into the viable epidermis. Typically, larger biomolecules are unable to breach this barrier.
- SC stratum corneum
- Needle-free injection approaches include the high-speed liquid jet injector, which had a rise and fall in popularity in the mid twentieth century-and has recently seen a resurgence (Furth, P. A., Shamay, A. & Henninghausen, L. (1995) Gene transfer into mammalian cells by jet injection. Hybridoma, 14:149-152.).
- this method delivers jets of liquid to the epidermis and dermis (labelled (c) in Fig A), usually with a diameter >100 ⁇ m and not within key cells.
- the concentrated jet momentum many skin cells die. Delivery into the dermis also leads to patients reporting pain from injection.
- microparticles or gene gun
- drug or immunomodulatory agents formulated as or coated to particles
- FIG. 11( b ) A schematic of microparticles in the skin following ballistic delivery is shown in FIG. 11( b ) .
- the ability of this “scatter gun” approach to deliver genes and drugs to epidermal cells is highly limited and sensitive to biological variability in skin properties on the dynamic high strain rate ballistics process.
- the ballistic delivery of particles into the skin to target epidermal cells is extremely sensitive to the small variations in the stratum corneum-including the stratum corneum thickness, which varies massively with body site, age, sex, race and exposure to climatic conditions. (The quasi-static loading of skin with micro-nanostructures would be less sensitive to these differences).
- the compound effect of these two (and other) sources of variability is the gene gun/biolistics process does not consistently target epidermal cells-leading to inconsistent biological responses (e.g., in DNA vaccination).
- microparticles When the microparticles are delivered to the skin, it is unclear whether there are any adverse longer term effects. For example, in the case of insoluble particles, many of them slough off with the usual skin turnover. However, gold particles have been detected in the lymph nodes following ballistic particle delivery-presumably by migration with Langerhans cells. Uncertainty of adverse effects of these delivered materials would be removed by delivery routes that do not leave such materials in tissue site.
- microparticles when the microparticles successfully target cells, there is a significant probability they kill the cells they target.
- a typical ballistic delivery condition over 1 million 2-3 um diameter gold particles coated in DNA to the skin at 400-600 m/s, over a target diameter of 4 mm (Kendall, M. A. F., Mulholland, W. J., Tirlapur, U. K., Arbuthnott, E. S. & Armitage, M. (2003) Targeted delivery of micro-particles to epithelial cells for immunotherapy and vaccines: an experimental and probabilistic study. 6 th International Conference on Cellular Engineering. Aug. 20-22 2003, Sydney, Australia.).
- FIG. 13A shows the percentage of cells that had membrane rupture (i.e., death) as a function of the localized particle channel density.
- FIG. 13B we see schematically the way the data in FIG. 13A was achieved, relating “tracks” left by particle penetration to the death of cells in a layer of the viable epidermis.
- FIG. 13A shows that at a channel density above 0.01 channels/micron, all the cells in that layer are dead.
- FIG. 13C shows that cells are killed when the particle is passing up to 10 ⁇ m outside of the cell boundary. The mechanism of cell death is due to the propagation of stress and shock waves in the skin generated by the rapid deceleration of the microparticles (McSloy et al. (2004)).
- This parameter is also proportional to the particle momentum per-unit-area, which has been shown to drive the mechanism of particle penetration depth (Mitchell et al. (2003)). From FIG. 14 , we see a 1 ⁇ m radius gold particle (density 18000 kg/m 3 ) would need to impact the skin at ⁇ 600 m/s in order to penetrate to reach cells ⁇ 20 ⁇ m into the skin.
- FIG. 11( c ) shows that the most conceptually simple and appealing approach to gene delivery is the direct injection of naked DNA to live cell nuclei at a sub-micrometer scale that does not adversely damage the cell (Luo, D. & Saltzman, W. M. (2000) Synthetic DNA delivery systems. Nature Biotechnology, 18:33-36). Cell death is minimized by both the sub-micrometer scale of the injector and the low, quasi-static strain-rate of the probe (compared to ballistic delivery) resulting in low stress distributions.
- U.S. Pat. No. 6,503,231 The objective of U.S. Pat. No. 6,503,231 is to provide a microneedle array device for relatively painless, controlled, safe, convenient transdermal delivery of a variety of drugs and for biosampling. This is achieved by the microneedles breaching the tissue barrier (e.g., for skin: the stratum corneum) and then the therapeutic or diagnostic material is injected through the hollow microneedles into the tissue.
- tissue barrier e.g., for skin: the stratum corneum
- microneedles are to be hollow, with a length of 100 ⁇ m-1 mm, and claim 3 states the width of 1 ⁇ m-100 ⁇ m, with subsequent claims stating ways the hollow needles can be connected to reservoirs for the injection of liquids, fabrication methods, materials and examples of drugs to be delivered.
- U.S. Pat. No. 6,503,231 describes a patch suitable for delivering materials and/or energy across tissue barriers.
- the microneedles are hollow and/or porous to permit drug delivery at clinically relevant rates across skin or other tissue barriers, without damage, pain, or irritation to the tissue.
- microneedles array patch technologies have achieved only limited success to date.
- approaches configured to breach the stratum corneum to allow an enhanced take-up of drug in the viable epidermis.
- this has not been discussed in the patents referred to above, based upon reported research on ballistic particle delivery and cell death, the low strain rate of application, combined with the cases of smaller projections are likely to induce a lower incidence of cell death near the tips, than ballistic microparticle to delivery.
- these projections are removed from the tissue-alleviating the possibility of adverse effects of “carrier” materials delivered to the body, long term.
- microneedle arrays do not have the advantage of readily and directly targeting inside the skin cells.
- This cellular/organelle targeting capability is key in a range of existing and potential methods of vaccination, gene therapy, cancer treatment and immunotherapy (Needle-free epidermal powder immunization. Chen et al, Expert Rev. Vaccines 1(3) p265-276 (2002)) and diagnostic technologies.
- the present invention provides a device for delivery of material or stimulus to targets within a body to produce a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest, the device including a number of projections for penetrating a body surface, and wherein:
- the number of projections is selected to produce a desired response, the number being at least 500;
- a spacing between projections is at least partially determined based on an arrangement of the targets within the body.
- the number of projections is selected by:
- the likelihood P contact of a projection targeting a target of interest is at least partially based on:
- the number of targets to be targeted depends on the number of targets that need to be transfected to produce the desired response.
- the number of targets to be targeted is at least one of:
- the number of projections is at least one of:
- a maximum number of projections is based on at least one of:
- the projection spacing is based at least partially on at least one of:
- the spacing between at least some of the projections is selected to avoid multiple projections targeting a single target of interest.
- the spacing between at least some of the projections is selected to be greater than a diameter of the targets of interest.
- the spacing between at least some of the projections is selected to be approximately equal to the spacing between the targets of interest.
- projection dimensions are based at least partially on an arrangement of targets within the body.
- the projections typically have a diameter of at least one of:
- the projections typically have a projection length at least partially based on a depth of the targets below a surface of the body against which the device is to be applied in use.
- the projections include a support section and a targeting section.
- the targeting section has a diameter of less than at least one of:
- a length for the targeting section is at least:
- a length for the support section is at least partially based on a depth of the targets below a surface of the body against which the device is to be applied in use.
- the length for the support section is at least partially determined in accordance with properties of a surface of the body against which the device is to be applied in use.
- At least one of a support section length and the number of projections is at least partially based on a likelihood of a projection penetrating the targets:
- (a) ⁇ is the standard deviation from a mean location, accounting for the skin surface undulations.
- (b) D is a distance of the targets below a surface of the body against which the device is to be applied in use;
- Q is a number of standard deviations from a mean level of the surface of the body at which the device comes to rest in use;
- (d) B is a length of the support section
- (e) T is a length of a targeting section.
- a length for the support section is at least one of:
- the length of the delivery end section is greater than the target dimension.
- the projections within a targeting configuration have different dimensions.
- the projections are solid.
- the projections are non-porous and non-hollow.
- At least part of at least some of the projections are coated with a bioactive material.
- At least part of at least some of the projections are coated with a non-liquid material.
- a targeting section of at least some of the projections are coated.
- the coating is at least one of:
- the device typically includes at least some uncoated projections to thereby stimulate or perturb the targets in use.
- the device includes:
- each patch including a number of projections for penetrating a body surface, the number of patches being mounted to a flexible backing.
- the present invention provides a method of selecting constructional features for a device a for delivery of material or stimulus to targets within a body to produce to a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest, the device including a number of projections for penetrating a body surface, and wherein the method includes:
- the present invention provides a method of fabricating a device for delivery of material or stimulus to targets within a body to produce a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest, the device including a number of projections for penetrating a body surface, and wherein the method includes:
- the present invention provides a method of treating a subject the method including using a device for delivery of material or stimulus to targets within the subject's body to produce a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest, the device including a number of projections for penetrating a body surface, and wherein:
- the number of projections is selected to produce a desired response, the number being at least 500;
- a spacing between projections is at least partially determined based on an arrangement of the targets within the body.
- the present invention provides apparatus for delivery of material or stimulus to targets of interest within a body to produce a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest, the apparatus including:
- the plurality of projections are provided on a patch.
- the actuator includes:
- the releasing means is a tensioned string for holding the spring in compression.
- the releasing means is manually operated.
- the apparatus includes a number of arms, each arm being coupled to a respective spring and including a first end pivotally mounted to the structure and a second end coupled to a respective plurality of projections, and wherein activation of the releasing means causes each of the arms to be released from a retracted position to thereby cause projections on the respective patch to enter the body.
- the arms are circumferentially spaced around a part of the structure.
- the structure is flexible structure allowing the structure to be guided to a desired location within the body.
- the releasing means includes an inflatable structure coated with the plurality of projections.
- the number of projections is selected to produce a desired response, the number being at least 500;
- a spacing between projections is at least partially determined based on an arrangement of the targets within the body.
- FIGS. 1A and 1B are schematic diagrams of an example of device for delivery of material or stimulus to targets within a body
- FIG. 1C is a schematic diagram of an example of the device of FIG. 1A in use
- FIGS. 1D and 1E are schematic diagrams of examples of projections used in the device of FIG. 1A ;
- FIG. 2 is a flow chart of an example of the process of selecting device parameters
- FIGS. 3A and 3B are schematic diagrams of alternative examples of the device of FIG. 1A in use taking into account variations in surface properties and target locations;
- FIG. 4 is a flow chart of a second example of the process of selecting device parameters
- FIGS. 5A and 5B show examples of the relationship between the number of projections and total hits for targeting Langerhans cell nuclei and Langerhans cells respectively;
- FIG. 6 shows an example of the relationship between the total number of targeted LC and the patch surface area as a function of projection spacing geometry
- FIG. 7 is an SEM photograph of an example of a constructed patch
- FIG. 8 shows an example of the Transfection Probability vs Needle Spacing, for targeting of Langerhans cells
- FIGS. 9A to 9C show examples of projection viability against the projection height, for variation in the skin surface level standard deviation of 20 ⁇ m, 40 ⁇ m and 60 ⁇ m respectively;
- FIG. 10 is a schematic diagram of an alternative example of a patch
- FIG. 11 illustrates a schematic cross-section of skin structure: (a) half-section scale of a typical smaller needle and syringe (diameter ⁇ 0.5 mm); (b) penetration of microparticles following biolistic delivery; (c) idealized direct injection of a cell nucleus; (d) a micro-nanoprojection array;
- FIGS. 12A and 12B illustrate the effects of relative humidity (A) and ambient temperature (B) on to ballistic particle penetration into the skin;
- FIG. 13A is a graph showing the relationship between percentage cell death (membrane rupture) and particle density (McSloy (2004) MA Thesis, University of Oxford);
- FIG. 13B is a diagram showing how the data for FIG. 13A was retrieved (McSloy (2004) MA Thesis, University of Oxford);
- FIG. 13C is a graph showing membrane rupture versus distance of cell pathway
- FIG. 14 illustrates the particle penetration parameter (pvr) vs. penetration depth obtained by the ballistic delivery of gold microparticles into skin (Kendall et al. (2004), Journal of Biomechanics);
- FIG. 15 shows examples of organelles within the cell (http://niko.unl.edu/bs101/notes/chapter4.html);
- FIG. 16 is a schematic diagram of the skin structure
- FIG. 17 is an example of a histology micrograph of human skin with a Langerhans Cell (L) and Keratinocyte (K) stained. From Roitt et al, the height of which is approximately 50 ⁇ m;
- FIG. 18 illustrates the distribution of Langerhans Cells in a mouse ear (Kendall M. A. F., Mulholland W. J., Tirlapur U. K., Arbuthnott E. S., and Armitage, M. (2003) “Targeted delivery of micro-particles to epithelial cells for immunotherapy and vaccines: an experimental and probabilistic study”, The 6th International Conference on Cellular Engineering, Sydney, August 20-22);
- FIGS. 19A and 19B illustrate (A) a sample of canine buccal mucosal tissue and (B) the structure of the mucosa, Mitchell, T (2003) DPhil Thesis, Department of Engineering Science, University of Oxford;
- FIG. 20 illustrates the shape and dimensions of examples nanoneedles
- FIG. 21 illustrates the maximum needle length vs. nanoneedle diameter calculated using expression (3) and the Young's Modulus (E) values for Gold, Titanium, ZnO, PGCA, Silver and Tungsten (respectively: 77.2, 116, 111.2 and 7 GPa);
- FIGS. 22A-22C are a Transmission Electron Micrographs (TEM) of a micro-nanoprojection electropolished from tungsten at (A) ⁇ 500 magnification, (B) a bright field ⁇ 33000 magnification and (C) a dark field ⁇ 33000 magnification;
- TEM Transmission Electron Micrographs
- FIGS. 23A and 23B illustrate fluorescent microscope images of tungsten rods, (A) uncoated and (B) coated in eGFP plasmid DNA immersed in an ethidium bromide solution;
- FIGS. 24A-24D are examples of an optically sectioned Multi-Photon Microscopy (MPM) images of the agar after insertion of a DNA coated tungsten probe (A) on the surface (B) at a depth of 13 ⁇ m (C) at a depth of (32 ⁇ m). Also shown in (D) is an optical section at 32 ⁇ m of agar gel following insertion of a probe without a DNA coating;
- MPM Multi-Photon Microscopy
- FIG. 25 illustrates a photomicrograph of a micro-nanoprojection electropolished from tungsten used in skin tissue indentation experiment with scale bar;
- FIG. 26 illustrates two sample load-displacement curves in freshly excised mouse ear tissue obtained with the micro-nanoprojection shown in FIG. 25 ;
- FIG. 27 is a plan view diagram of possible alternative geometry of the nanoneedle
- FIG. 28 illustrates an example of a nanoneedle array or patch device
- FIG. 29 is a schematic diagram of an example of the nanoneedle array produced with 2PLSM.
- FIGS. 30A-30C illustrate sequences for producing a mask
- FIG. 31 is a schematic diagram of an example of a “Stepped” nanoneedle
- FIGS. 32A and 32B illustrate examples of an intradermal application of nanoneedle patches
- FIG. 33 is a schematic diagram of an example of an applicator, fitted with the patch for mucosal delivery;
- FIG. 34 illustrates the major respiratory organs
- FIGS. 35A-35C are schematic diagrams of an example of a deployable patch structure for targeting the lower airway and lung.
- FIG. 1A to 1E An example of a device for delivering material or stimulus targets within a body will now be described with reference to FIG. 1A to 1E .
- the device is in the form of patch 100 having a base 120 and a number of projections 110 .
- the base 120 and projections 110 may be formed from any suitable material, as will be described in more detail below, but in one example, are formed from a silicon type material, allowing the device to be fabricated using fabrication processes such as vapor deposition, silicon etching, Deep Reactive Ion Etching (DRIE), or the like.
- DRIE Deep Reactive Ion Etching
- the device has a width W and a breadth B with the projections 110 being separated by spacing S.
- the patch 100 is positioned against a surface of a subject, allowing the projections to enter the surface and provide stimulus or material to targets therein. An example of this is shown in FIG. 1C .
- the patch 100 is urged against a subject's skin shown generally at 150 , so that the projections 110 pierce the Stratum Corneum 160 , and enter the Viable Epidermis 170 to reach targets of interest, shown generally at 180 .
- FIGS. 1D and 1E Examples of suitable projections are shown in more detail in FIGS. 1D and 1E .
- the projection generally includes a targeting section 111 , intended to deliver the material or stimulus to targets within the body, and a support section 112 for supporting the targeting section 111 .
- the projection is formed from a conically shaped member, which tapers gradually along its entire length.
- the targeting section 111 is therefore defined to be the part of the projection having a diameter of less than d 2 .
- the structure of the projection may vary along its length to provide a targeting section 111 with a designed structure.
- the targeting section 111 is in the form of a substantially cylindrical shape, such that the diameter d 1 is approximately equal to the diameter d 2 .
- the support section has a length a, whilst the targeting section 111 has a length l.
- the diameter of the tip is indicated by d 1
- the diameter of the support section base is given by d 3 .
- the device is intended to deliver material or stimulus to specific targets within the body.
- the device is configured so as to ensure material or stimulus reaches specifically selected targets such as cells, cell organelles, cell nuclei, or the like.
- the device is designed to achieve this without requiring specific directional control of device application so as to ensure the projections reach the targets.
- the device is intended to ensure successful delivery of material or stimulus to specific targets within a subject, without requiring that the projections are aimed at the specific targets, but rather by allowing general placement in a suitable region.
- placement may to be as simple as placement anywhere on the user's skin in order to target Langerhans cells of the device on the subject.
- the device is provided with a particular configuration to ensure successful targeting. Accordingly, it is generally necessary to select patch parameters, such as the number of projections N, and spacing S between projections, to be dependent upon the intended use of the device. A mechanism for achieving this will now be described with reference to FIG. 2 .
- step 200 it is necessary to determine an arrangement of desired targets. This may be achieved in any one of a number of ways and will depend on the nature of the targets. Thus, for example if the targets are a specific type of cell, cell nuclei, or cell organelle, this information can be determined from literature or studies detailing the typical location of cells, or other targets, within the body.
- a number of projections required to elicit a desired response is determined. This can depend on a range of factors, such as the ability of projections to reach the desired targets, the ability of the projections to deliver material or stimulus to the targets, as well as the ability of the targets to elicit a response. Thus, for example, non-uniform distribution of targets within the body means that it is not possible to assume that each projection will deliver material or stimulus to a desired target during use of the device.
- the number of projections may be determined in any one of a number of ways. Thus, for example, this can include selecting a number of projections from a predetermined list outlining the number of projections required for specific uses. However, if the number has not previously been determined, for example, if the target has not previously been used, then some form of analysis is typically required.
- this is achieved by analyzing the distribution of targets within the body and then determining a likelihood of any one projection reaching a target. An indication of the number of targets to which stimulus or material must be delivered can then be used to determine an indication of the number of projections required.
- a desired response cannot be obtained with less than 500 projections. More typically at least 750 projections are required. However, in some instances, even more projections such as at least 1000, 2000, 5000, 7500, 10,000, 100,000, 1,000,000 or even 10,000,000 may be used, and specific examples will be described in more detail below.
- a projection spacing is determined at least partially based on the target arrangement at step 230 .
- the spacing may be determined in any one of a number of ways, but typically includes setting a lower spacing limit to ensure that only a single projection delivers material or stimulus to a single target.
- the maximum spacing S is typically set based on the required patch size (B ⁇ W) and/or the spacing between targets. It will be appreciated that whilst the example shown is rectangular, alternative shapes, such as circular, elliptical, hexagonal, or the like, may be used and that the use of a rectangular patch is for the purpose of example only.
- a patch is fabricated in accordance with the selected patch parameters, including the number of projections N and the spacing S. Fabrication may be achieved in a number of ways, as will be described in more detail below.
- this technique allows a patch to be provided with sufficient projections to ensure that a desired response is achieved by delivery of material or stimulus to specific targets. Furthermore, by utilizing a probabilistic analysis, this technique ensures that the required targeting will be achieved without requiring the individual projections to be aimed at the individual targets.
- the patch 100 may simply be inserted into a body at a general location, and does not need specialized apparatus to direct the projections towards specific cells or other targets within the body.
- the patch configuration and in particular the insertion of the patch into the body is as shown in FIG. 3A and FIG. 3B .
- this example is modified to take into account variations and undulations in the surface of the body, as well as variations in target depth.
- the patch 100 is urged against the surface 300 of the Stratum Corneum 310 .
- the surface 300 includes undulations, resulting in a mean surface level 320 shown by dotted to lines, with the patch base 120 resting against the surface 300 at a distance y above the mean level 320 .
- the projections 110 enter the Viable Epidermis 330 to deliver material or stimulus to targets 340 , which are generally arranged in a layer 350 , referred to as the target layer.
- targets 340 which are generally arranged in a layer 350 , referred to as the target layer.
- the Dermis is also shown at 360 in this example.
- the targets 340 are provided in a single layer with each target being approximately a constant depth D c below the Stratum Corneum 310 .
- the layer height h layer is therefore approximately equal to the diameter of the targets d c , with the targets separated by a spacing S c . It would be appreciated by persons skilled in the art that in this instance the targets may therefore be Langerhans Cells, or the like.
- the targets 340 are dispersed vertically through the Viable Epidermis 330 , so that the target layer 350 has a greater height h layer than in the previous example. Additionally, in the example, the depth of the targets is calculated on the basis of the mean layer depth, as shown.
- a desired target and corresponding target arrangement is determined.
- the target selected will depend on the intended application.
- the target may be cells, cell nuclei or cell organelles.
- different types of cells may need to be targeted.
- cells such as Langerhans Cells may be stimulated for providing an immunological response, whereas cells such as squamous or basal cells may need to be targeted to treat cell carcinoma.
- An example of other potential targets will be described in more detail below.
- Determining the target arrangement typically involves determining parameters relating to the target such as target depth D c , target diameter d c , layer height h layer and target spacing S c . Thus these correspond to the parameters outlined above with respect to FIGS. 3A and 3B .
- the diameter of the targeting section 111 for at least some of the projections is determined.
- the diameter of the targeting section is typically based on the size of the target.
- the diameter of the targeting section does not usually exceed the scale of the target, as this may lead to target necrosis. In general this leads to an upper limit for targeting section diameters of:
- projections having a larger diameter for example to cause cell necrosis.
- at least some of the projections have a diameter greater than 1 82 m, which can be used to induce bystander responses.
- all of the projections have a diameter greater than 1 82 m to thereby kill targets.
- the projection length is determined.
- the projection length is based on the depth of the target layer D c and the layer height h layer .
- the length of the supporting section of a can be selected so that the targeting section 111 at least reaches the target layer within the body, but typically does not extend a large distance beyond the target layer.
- the length a of the support section 112 is typically given by:
- the length l of the targeting section 111 is typically selected to be at least equal to the layer height h layer to ensure penetration of targets within the layer 340 , so that:
- the skin of the body is not generally flat but is undulating. As a result, this means that the base 120 of the device 100 generally sits a distance y above the mean skin level 320 . To take this into account, the length of the support section 112 may be increased such that.
- LC Langerhans cells
- the surface of the skin is normally distributed
- the LC reside exactly 17 82 m below the surface just above the basal layer (Arbuthnott, 2003, Emislom et al, 1995), in the case of the Balb/c mouse ear.
- the depth of LC varies significantly from site to site within a given animal of human model, and there is typically variation in the depth of LC between models-for example the depth of LC in humans is greater than in mice.
- the patch typically comes to rest two standard deviations away from the mean skin level
- the needles have a viable tip length of 20 82 m (i.e., l, (defined as 111 ) is 20 ⁇ m. Penetration by any other part of the needle other than this tip causes cell death.
- the skin's surface is normally distributed with mean 0 and standard deviation ⁇ .
- the Langerhans cells lie D c microns directly below the skin's surface.
- the patch comes to rest Q standard deviations from the skin's mean level.
- the needles have body (unviable) length support section a and tip (viable) length l.
- ⁇ is the standard deviation from a mean location, accounting for the skin surface undulations.
- D c is a distance of the cells of interest below a surface of the body against which the device is to be applied in use
- Q is a number of standard deviations from a mean level of the surface of the body at which the device comes to rest in use
- a is a length of the support section
- l is a length of a targeting section.
- the skin surface level is normally distributed on a local scale, which is typically a safe assumption based on histology samples, although if the area inspected is too large, global curvature invalidates the assumption.
- the patch comes to rest at a distance y of two standard deviations away from mean skin level.
- a model allows support section and targeting section lengths a, l to be selected to ensure a predetermined probability of the targeting section 111 successfully reaching the targets.
- the probability is selected to be one, to ensure successful delivery of the material or stimulus.
- lower probabilities may be selected, with this being taken into account in determining the number of projections provided, as will be described in more detail below.
- the likelihood of a single targeting event is determined. In particular, this is the likelihood of a projection, assuming the projection reaches the target layer 350 , of delivering material to or stimulus to a respective target 340 .
- the targeting section 111 is effectively a point diameter cylinder that extends into the target layer 350 .
- the likelihood of a single targeting event is given by the volume of the target divided by the volume of the layer.
- V layer is the volume of the layer containing cells of interest
- V tar is the volume including the target to which material or stimulus can be delivered.
- the volume to which stimulus or material may be to delivered may be significantly greater than the size of the physical target itself, depending on the delivery mechanism used.
- the target volume V tar will be larger than the volume of the cell.
- equation (2) still holds, but it can be assumed that the projection has its own volume (V pro ), and in this case the probability of contact is modified to change V tar to take into account the additional probe volume.
- V pro volume of the targeting section within the target layer
- N tar is the number of targets, with diameter d c .
- Equation (3) can be modified to take into account variations in target size and shape, and probe size and shape.
- equation (3) becomes:
- V tar N Tar (2 d 1 +d c ) 2 d c ( 4 )
- the number of targeting events required is determined. This is typically determined on the basis of studies performed indicating the number of targets to which material or stimuli must be delivered in order for a biological response to be affected. Often, this is determined by parametric empirical studies.
- At least one cell when it is desired to deliver DNA to transfect Langerhans cells, at least one cell must be targeted. However, it is believed that to ensure a successful biological response, at least 10 cells, and more preferably at least 100 cells and up to or over 1,000 cells are targeted. It will be appreciated however that for different delivery mechanisms a different number of targets may be desirable.
- step 450 having determined the number of targeting events required (N), it is possible to use this and the probability of a single targeting event to determine a number of projections required, which is given by:
- T is the total number of delivery events required to produce the desired response.
- T is defined as a range, that can vary significantly between application and/or model (i.e., animal or human).
- FIGS. 5A and 5B Specific examples of this are shown in FIGS. 5A and 5B , for the targeting of Langerhans cell nuclei and Langerhans cells respectively.
- a Langerhans Cell (LC) penetrated by one needle remains viable. If it is penetrated by any more than one projection cell death occurs.
- LC Langerhans Cell
- a projection contacts the target site (e.g., cell nucleus or cytosol)
- the desired biological “event” occurs each time.
- the probability of the event happening. For example, if cell transfection is required, then the probability of this event through the delivery of DNA to nucleus via a projection is ⁇ 0.9, whereas the probability of the same event from the coated projection entering only the cytoplasm is ⁇ 0.1 (Nagasaki 2005).
- a dead cell cannot be transfected.
- LC are assumed as spherical with 10 ⁇ m diameter.
- Nuclei of LC are assumed to be spherical, with a diameter of 4 82 m (Arbuthnott, 2003).
- LC are oval with dimensions circa 11.25 ⁇ 6 ⁇ m but to simplify the model, the average of these two figures is taken as the diameter of 10 ⁇ m.
- the LC density is 895 cells/mm 2 (Choi. et al 1987). With LC uniformly distributed in the suprabasal region (Numahara et al. 2001) this gives a center to center spacing of approximately 30 microns, justifying the spacing assumption. For simplicity, it is assumed that the LC spacing of 1000 cells/mm 2 , giving a planar spacing between cell centers of 32 ⁇ m.
- FIG. 5A shows the relationship between the number of projections and total hits is given for the patches 100 described above, with a range of depth probabilities (P depth ), for targeting Langerhans cell nuclei.
- FIG. 5B shows the relationship between the number of projections and total hits is given for the patches 100 described above, with a range of depth probabilities (i.e., the probability of a viable targeting of the target layer 350 ), for targeting Langerhans cells.
- this requires at least 500 projections and more typically at least 1,000 projections for targeting LC and 10,000 projections for targeting LC nuclei. Specific examples of this will be described in more detail below.
- the projection spacing (S) is then determined based on the target diameter and target spacing. It is usual to assume that no more than one projection should enter a single cell this; will typically lead to cell death. Accordingly, it is typical to select a projection spacing which is at least greater than a cell diameter, such that:
- patches are made below a certain upper limit defined by practical utility to the targeting site of the patient or animal.
- the surface area could be approaching the surface area of the abdomen (e.g., ⁇ 400 cm 2 , or 20 ⁇ 20 cm, say). It would not be practical to achieve such larger surface areas over surfaces with “bulk” curvature (such as the abdomen example, or arm) with one large rigid patch.
- surface area can be achieved using the patch shown in FIG. 10 .
- the patch 100 is formed from several smaller patches 1000 provided on a flexible backing material 1010 . The patch assembly could be extended to wrap around the patient site 1020 .
- an upper limit on the spacing S is typically selected to ensure that the desired number of projections fit on a patch of the desired size.
- FIG. 6 A specific example of this is shown in FIG. 6 , in which the relationship between the total number of targeted LC (T) and the patch surface area (mm 2 ) as a function of spacing geometry, is shown.
- the projection spacing S is typically of the order of spacing of the targets S c .
- the patch can be fabricated at step 470 .
- this will typically require considerations are taken into account to ensure the projections are sufficiently robust to withstand penetration of the Stratum Corneum and Viable Epidermis without breaking.
- Example manufacturing processes will be described in more detail below, and an example of a constructed patch 100 is shown in FIG. 7 .
- the device has 9795 projections, with a spacing of 70 82 m (S), over a surface area of 48 mm 2 .
- the projections are solid, non-porous and non-hollow.
- the use of solid projections enhances the projection strength, thereby reducing the likelihood of projection breakage, which in turn helps maximize successful delivery of material or stimulus to the targets.
- solid projections simplify device fabrication processes, allowing for the production of cheaper patches than for the case of porous or hollow projections. This in turn further enhances the suitability of the patch for use in medical environments.
- At least the targeting section 111 with a non-liquid bioactive material, such as DNA.
- the patch 100 may also be fabricated to perturb targets so as to induce “bystander” interactions. This may be used, for example, so that cell death is used to release molecules to activate nearby targeted cells. This can be achieved in a number of manners, such as by providing a mixture of coated and uncoated projections, as well as by providing projections of differing dimensions including clusters of more than 1 projection to target individual cells and/or larger scale tips to damage cells or other targets, upon insertion/residence/retrieval.
- the LC diameter is ⁇ 10 ⁇ m, so that to satisfy the requirements set out above, namely that S ⁇ d c , so S ⁇ 10 ⁇ m.
- the diameter of the base of the projections d 3 is likely to be above 6.5 ⁇ m, and a “clearance” will be needed between each projection, so for practical reasons, the minimum projection spacing (S) is at least 10 ⁇ m.
- FIG. 8 shows an example of the Transfection Probability vs Needle Spacing, for targeting of Langerhans cells with a spacing of 32 ⁇ m.
- the S ⁇ d c criterion and practical considerations of minimum size of the base d 3 suggest the spacing is to at least be 10 ⁇ m, as discussed above.
- FIG. 9A to 9C show the fraction of projections (P depth ) that are smaller than 1 ⁇ m in diameter and penetrate to 17 82 m in the epidermis (the depth of LC), against the projection height, for skin level standard deviation of 20 82 m, 40 ⁇ m and 60 82 m respectively.
- Illustrative stimuli or material that can be delivered with the device of the present invention include any or more of: small chemical or biochemical compounds including drugs, metabolites, amino acids, sugars, lipids, saponins, and hormones; macromolecules such as complex carbohydrates, phospholipids, peptides, polypeptides, peptidomimetics, and nucleic acids; or other organic (carbon containing) or inorganic molecules; and particulate matter including whole cells, bacteria, viruses, virus-like particles, cell membranes, dendrimers and liposomes.
- small chemical or biochemical compounds including drugs, metabolites, amino acids, sugars, lipids, saponins, and hormones
- macromolecules such as complex carbohydrates, phospholipids, peptides, polypeptides, peptidomimetics, and nucleic acids
- organic (carbon containing) or inorganic molecules or particulate matter including whole cells, bacteria, viruses, virus-like particles, cell membranes, dendrimers and liposomes.
- the stimulus or material is selected from nucleic acids, illustrative examples of which include DNA, RNA, sense oligonucleotides, antisense oligonucleotides, ribozymes, small interfering oligonucleotides (siRNAs), micro RNAs (miRNAs), repeat associated RNAs (rasiRNA), effector RNAs (eRNAs), and any other oligonucleotides known in the art, which inhibit transcription and/or translation of a mutated or other detrimental protein.
- the nucleic acid is in the form of an expression vector from which a polynucleotide of interest is expressible.
- the polynucleotide of interest may encode a polypeptide or an effector nucleic acid molecule such as sense or antisense oligonucleotides, siRNAs, miRNAs and eRNAs.
- the stimulus or material is selected from peptides or polypeptides, illustrative examples of which include insulin, proinsulin, follicle stimulating hormone, insulin like growth factor-1, insulin like growth factor-2, platelet derived growth factor, epidermal growth factor, fibroblast growth factors, nerve growth factor, colony stimulating factors, transforming growth factors, tumor necrosis factor, calcitonin, parathyroid hormone, growth hormone, bone morphogenic protein, erythropoietin, hemopoietic growth factors, luteinizing hormone, glucagon, glucagonlike peptide-1, anti-angiogenic proteins, clotting factors, anti-clotting factors, atrial natriuretic factor, plasminogen activators, bombesin, thrombin, enkephalinase, vascular endothelial growth factor, interleukins, viral antigens, non-viral antigens, transport proteins, and antibodies.
- peptides or polypeptides illustrative examples of
- the stimulus or material is selected from receptor ligands.
- receptors include Fc receptor, heparin sulfate receptor, vitronectin receptor, Vcam-1 receptor, hemaglutinin receptor, Pvr receptor, Icam-1 receptor, decay-accelerating protein (CD55) receptor, Car (coxsackievirus-adenovirus) receptor, integrin receptor, sialic acid receptor, HAVCr-1 receptor, low-density lipoprotein receptor, BGP (biliary glycoprotien) receptor, aminopeptidease N receptor, MHC class-1 receptor, laminin receptor, nicotinic acetylcholine receptor, CD56 receptor, nerve growth factor receptor, CD46 receptor, asialoglycoprotein receptor Gp-2, alpha-dystroglycan receptor, galactosylceramide receptor, Cxcr4 receptor, Glvrl receptor, Ram-1 receptor, Cat receptor, Tva receptor, BLVRcp1 receptor, MHC class-2 receptor, to
- the stimuli or material are selected from antigens including endogenous antigens produced by a host that is the subject of the stimulus or material delivery or exogenous antigens that are foreign to that host.
- the antigens may be in the form of soluble peptides or polypeptides or polynucleotides from which an expression product (e.g., protein or RNA) is producible.
- Suitable endogenous antigens include, but are not restricted to, cancer or tumor antigens.
- Non-limiting examples of cancer or tumor antigens include antigens from a cancer or tumor selected from ABL1 proto-oncogene, AIDS related cancers, acoustic neuroma, acute lymphocytic leukemia, acute myeloid leukemia, adenocystic carcinoma, adrenocortical cancer, agnogenic myeloid metaplasia, alopecia, alveolar soft-part sarcoma, anal cancer, angiosarcoma, aplastic anemia, astrocytoma, ataxia-telangiectasia, basal cell carcinoma (skin), bladder cancer, bone cancers, bowel cancer, brain stem glioma, brain and CNS tumors, breast cancer, CNS tumors, carcinoid tumors, cervical cancer, childhood brain tumors, childhood cancer, childhood leukemia, childhood soft tissue sarcoma, chondrosarcoma, choriocarcinoma, chronic lymphocytic leukemia, chronic myeloid
- the cancer or tumor relates to melanoma.
- melanoma-related antigens include melanocyte differentiation antigen (e.g., gp100, MART, Melan-A/MART-1, TRP-1, Tyros, TRP2, MC1R, MUC1F, MUC1R or a combination thereof) and melanoma-specific antigens (e.g., BAGE, GAGE-1, gp100In4, MAGE-1 (e.g., GenBank Accession No.
- MAGE-3 MAGE4, PRAME, TRP2IN2, NYNSO1a, NYNSO1b, LAGE1, p97 melanoma antigen (e.g., GenBank Accession No. M12154) p5 protein, gp75, oncofetal antigen, GM2 and GD2 gangliosides, cdc27, p21ras, gp100 Pmel117 or a combination thereof.
- GenBank Accession No. M12154 p5 protein, gp75, oncofetal antigen, GM2 and GD2 gangliosides, cdc27, p21ras, gp100 Pmel117 or a combination thereof.
- tumor-specific antigens include, but are not limited to: etv6, aml1, cyclophilin b (acute lymphoblastic leukemia); Ig-idiotype (B cell lymphoma); E-cadherin, ⁇ -catenin, ⁇ -catenin, ⁇ -catenin, p120ctn (glioma); p21ras (bladder cancer); p21ras (biliary cancer); MUC family, HER2/neu, c-erbB-2 (breast cancer); p53, p21ras (cervical carcinoma); p21ras, HER2/neu, c-erbB-2, MUC family, Cripto-1protein, Pim-1 protein (colon carcinoma); Colorectal associated antigen (CRC)-CO17-1A/GA733, APC (colorectal cancer); carcinoembryonic antigen (CEA) (colorectal cancer; choriocarcinoma); cyclophilin
- Transplantation antigens are suitably selected from transplantation antigens, allergens as well as antigens from pathogenic organisms.
- Transplantation antigens can be derived from donor cells or tissues from, e.g., heart, lung, liver, pancreas, kidney, neural graft components, or from the donor antigen-presenting cells bearing MHC loaded with self antigen in the absence of exogenous antigen.
- Non-limiting examples of allergens include Fel d 1 (i.e., the feline skin and salivary gland allergen of the domestic cat Felis domesticus, the amino acid sequence of which is disclosed International Publication WO 91/06571), Der p I, Der p II, Der fI or Der fII (i.e., the major protein allergens from the house dust mite dermatophagoides, the amino acid sequence of which is disclosed in International Publication WO 94/24281).
- Fel d 1 i.e., the feline skin and salivary gland allergen of the domestic cat Felis domesticus, the amino acid sequence of which is disclosed International Publication WO 91/06571
- Der p I, Der p II, Der fI or Der fII i.e., the major protein allergens from the house dust mite dermatophagoides, the amino acid sequence of which is disclosed in International Publication WO 94/24281).
- allergens may be derived, for example from the following: grass, tree and weed (including ragweed) pollens; fungi and molds; foods such as fish, shellfish, crab, lobster, peanuts, nuts, wheat gluten, eggs and milk; stinging insects such as bee, wasp, and hornet and the chirnomidae (non-biting midges); other insects such as the housefly, fruitfly, sheep blow fly, screw worm fly, grain weevil, silkworm, honeybee, non-biting midge larvae, bee moth larvae, mealworm, cockroach and larvae of Tenibrio molitor beetle; spiders and mites, including the house dust mite; allergens found in the dander, urine, saliva, blood or other bodily fluid of mammals such as cat, dog, cow, pig, sheep, horse, rabbit, rat, guinea pig, mouse and gerbil; airborne particulates in general; latex; and protein detergent additives
- Exemplary pathogenic organisms include, but are not limited to, viruses, bacteria, fungi parasites, algae and protozoa and amoebae.
- Illustrative viruses include viruses responsible for diseases including, but not limited to, measles, mumps, rubella, poliomyelitis, hepatitis A, B (e.g., GenBank Accession No. E02707), and C (e.g., GenBank Accession No. E06890), as well as other hepatitis viruses, influenza, adenovirus (e.g., types 4 and 7), rabies (e.g., GenBank Accession No.
- Epstein-Barr virus and other herpesviruses such as papillomavirus, Ebola virus, influenza virus, Japanese encephalitis (e.g., GenBank Accession No. E07883), dengue (e.g., GenBank Accession No. M24444), hantavirus, Sendai virus, respiratory syncytial virus, othromyxoviruses, vesicular stomatitis virus, visna virus, cytomegalovirus and human immunodeficiency virus (HIV) (e.g., GenBank Accession No. U18552). Any suitable antigen derived from such viruses are useful in the practice of the present invention.
- herpesviruses such as papillomavirus, Ebola virus, influenza virus, Japanese encephalitis (e.g., GenBank Accession No. E07883), dengue (e.g., GenBank Accession No. M24444), hantavirus, Sendai virus, respiratory s
- illustrative retroviral antigens derived from HIV include, but are not limited to, antigens such as gene products of the gag, pol, and env genes, the Nef protein, reverse transcriptase, and other HIV components.
- hepatitis viral antigens include, but are not limited to, antigens such as the S, M, and L proteins of hepatitis B virus, the pre-S antigen of hepatitis B virus, and other hepatitis, e.g., hepatitis A, B, and C, viral components such as hepatitis C viral RNA.
- influenza viral antigens include, but are not limited to, antigens such as hemagglutinin and neuraminidase and other influenza viral components.
- measles viral antigens include, but are not limited to, antigens such as the measles virus fusion protein and other measles virus components.
- rubella viral antigens include, but are not limited to, antigens such as proteins E1 and E2 and other rubella virus components; rotaviral antigens such as VP7sc and other rotaviral components.
- cytomegaloviral antigens include, but are not limited to, antigens such as envelope glycoprotein B and other cytomegaloviral antigen components.
- respiratory syncytial viral antigens include antigens such as the RSV fusion protein, the M2 protein and other respiratory syncytial viral antigen components.
- herpes simplex viral antigens include, but are not limited to, antigens such as immediate early proteins, glycoprotein D, and other herpes simplex viral antigen components.
- varicella zoster viral antigens include antigens such as 9P 1 , gpII, and other varicella zoster viral antigen components.
- Non-limiting examples of Japanese encephalitis viral antigens include antigens such as proteins E, M-E, M-E-NS 1, NS 1, NS 1-NS2A, 80%E, and other Japanese encephalitis viral antigen components.
- Representative examples of rabies viral antigens include, but are not limited to, antigens such as rabies glycoprotein, rabies nucleoprotein and other rabies viral antigen components.
- Illustrative examples of papillomavirus antigens include, but are not limited to, the L1 and L2 capsid proteins as well as the E6/E7 antigens associated with cervical cancers, See Fundamental Virology, Second Edition, eds. Fields, B. N. and Knipe, D. M., 1991, Raven Press, New York, for additional examples of viral antigens.
- fungi include Acremonium spp., Aspergillus spp., Basidiobolus spp., Bipolaris spp., Blastomyces dermatidis, Candida spp., Cladophialophora carrionii, Coccoidiodes immitis, Conidiobolus spp., Cryptococcus spp., Curvularia spp., Epidermophyton spp., Exophiala jeanselmei, Exserohilum spp., Fonsecaea compacta, Fonsecaea pedrosoi, Fusarium oxysporum, Fusarium solani, Geotrichum candidum, Histoplasma capsulatum var.
- representative fungal antigens that can be used in the compositions and methods of the present invention include, but are not limited to, candida fungal antigen components; histoplasma fungal antigens such as heat shock protein 60 (HSP60) and other histoplasma fungal antigen components; cryptococcal fungal antigens such as capsular polysaccharides and other cryptococcal fungal antigen components; coccidiodes fungal antigens such as spherule antigens and other coccidiodes fungal antigen components; and tinea fungal antigens such as trichophytin and other coccidiodes fungal antigen components.
- candida fungal antigen components histoplasma fungal antigens such as heat shock protein 60 (HSP60) and other histoplasma fungal antigen components
- cryptococcal fungal antigens such as capsular polysaccharides and other cryptococcal fungal antigen components
- coccidiodes fungal antigens such as spherule antigens
- bacteria include bacteria that are responsible for diseases including, but not restricted to, diphtheria (e.g., Corynebacterium diphtheria ), pertussis (e.g., Bordetella pertussis, GenBank Accession No. M35274), tetanus (e.g., Clostridium tetani, GenBank Accession No. M64353), tuberculosis (e.g., Mycobacterium tuberculosis ), bacterial pneumonias (e.g., Haemophilus influenzae.
- diphtheria e.g., Corynebacterium diphtheria
- pertussis e.g., Bordetella pertussis, GenBank Accession No. M35274
- tetanus e.g., Clostridium tetani, GenBank Accession No. M64353
- tuberculosis e.g., Mycobacterium tuberculosis
- cholera e.g., Vibrio cholerae
- anthrax e.g., Bacillus anthracis
- typhoid plague
- shigellosis e.g., Shigella dysenteriae
- botulism e.g., Clostridium botulinum
- salmonellosis e.g., GenBank Accession No. L03833
- peptic ulcers e.g., Helicobacter pylori
- Legionnaire's Disease Lyme disease
- bacterial antigens which can be used in the compositions and methods of the invention include, but are not limited to: pertussis bacterial antigens such as pertussis toxin, filamentous hemagglutinin, pertactin, F M2, FIM3, adenylate cyclase and other pertussis bacterial antigen components; diphtheria bacterial antigens such as diphtheria toxin or toxoid and other diphtheria bacterial antigen components; tetanus bacterial antigens such as tetanus toxin or toxoid and other tetanus bacterial antigen components, streptococcal bacterial antigens such as M proteins and other streptococcal bacterial antigens.
- pertussis bacterial antigens such as pertussis toxin, filamentous hemagglutinin, pertactin, F M2, FIM3, adenylate cyclase and other pertussis
- protozoa examples include protozoa that are responsible for diseases including, but not limited to, malaria (e.g., GenBank Accession No. X53832), hookworm, onchocerciasis (e.g., GenBank Accession No. M27807), schistosomiasis (e.g., GenBank Accession No. LOS 198), toxoplasmosis, trypanosomiasis, leishmaniasis, giardiasis (GenBank Accession No. M33641), amoebiasis, filariasis (e.g., GenBank Accession No. J03266), borreliosis, and trichinosis.
- malaria e.g., GenBank Accession No. X53832
- hookworm e.g., GenBank Accession No. M27807
- schistosomiasis e.g., GenBank Accession No. LOS 198
- toxoplasmosis trypanos
- protozoal antigens which can be used in the compositions and methods of the invention include, but are not limited to: plasmodium falciparum antigens such as merozoite surface antigens, sporozoite surface antigens, circumsporozoite antigens, gametocyte/gamete surface antigens, blood-stage antigen pf 155/RESA and other plasmodial antigen components; toxoplasma antigens such as SAG-1, p30 and other toxoplasmal antigen components; schistosomae antigens such as glutathione-S-transferase, paramyosin, and other schistosomal antigen components; leishmania major and other leishmaniae antigens such as gp63, lipophosphoglycan and its associated protein and other leishmanial antigen components; and trypanosoma cruzi antigens such as the 75-77 kDa antigen, the 56 kDa antigen and other trypano
- toxins include, but are not restricted to, staphylococcal enterotoxins, toxic shock syndrome toxin; retroviral antigens (e.g., antigens derived from HIV), streptococcal antigens, staphylococcal enterotoxin-A (SEA), staphylococcal enterotoxin-B (SEB), staphylococcal enterotoxin 1-3 (SE 1-3 ), staphylococcal enterotoxin-D (SED), staphylococcal enterotoxin-E (SEE) as well as toxins derived from mycoplasma, mycobacterium, and herpes viruses.
- retroviral antigens e.g., antigens derived from HIV
- retroviral antigens e.g., antigens derived from HIV
- streptococcal antigens e.g., antigens derived from HIV
- SEB staphylococcal enterotoxin-B
- SE 1-3 staphylococcal enter
- the antigen is delivered to antigen-presenting cells.
- antigen-presenting cells include professional or facultative antigen-presenting cells.
- Professional antigen-presenting cells function physiologically to present antigen in a form that is recognized by specific T cell receptors so as to stimulate or energies a T lymphocyte or B lymphocyte mediated immune response.
- Professional antigen-presenting cells not only process and present antigens in the context of the major histocompatability complex (MHC), but also possess the additional immunoregulatory molecules required to complete T cell activation or induce a tolerogenic response.
- MHC major histocompatability complex
- Professional antigen-presenting cells include, but are not limited to, macrophages, monocytes, B lymphocytes, cells of myeloid lineage, including monocytic-granulocytic-DC precursors, marginal zone Kupffer cells, microglia, T cells, Langerhans cells and dendritic cells including interdigitating dendritic cells and follicular dendritic cells.
- Non-professional or facultative antigen-presenting cells typically lack one or more of the immunoregulatory molecules required to complete T lymphocyte activation or energy.
- non-professional or facultative antigen-presenting cells include, but are not limited to, activated T lymphocytes, eosinophils, keratinocytes, astrocytes, follicular cells, microglial cells, thymic cortical cells, endothelial cells, Schwann cells, retinal pigment epithelial cells, myoblasts, vascular smooth muscle cells, chondrocytes, enterocytes, thymocytes, kidney tubule cells and fibroblasts.
- the antigen-presenting cell is selected from monocytes, macrophages, B lymphocytes, cells of myeloid lineage, dendritic cells or Langerhans cells.
- the antigen-presenting cell expresses CD11c and includes a dendritic cell or Langerhans cell. In some embodiments the antigen-presenting cell stimulates an immune response. In other embodiments, the antigen-presenting cell induces a tolerogenic response.
- exogenous antigen to an antigen-presenting cell can be enhanced by methods known to practitioners in the art. For example, several different strategies have been developed for delivery of exogenous antigen to the endogenous processing pathway of antigen-presenting cells, especially dendritic cells. These methods include insertion of antigen into pH-sensitive liposomes (Zhou and Huang, 1994, Immunomethods, 4:229-235), osmotic lysis of pinosomes after pinocytic uptake of soluble antigen (Moore et al., 1988, Cell, 54:777-785), coupling of antigens to potent adjuvants (Aichele et al., 1990, J. Exp.
- an antigen may be linked to, or otherwise associated with, a cytolysin to enhance the transfer of the antigen into the cytosol of an antigen-presenting cell of the invention for delivery to the MHC class I pathway.
- cytolysins include saponin compounds such as saponin-containing Immune Stimulating Complexes (ISCOMs) (see, e.g., Cox and Coulter, 1997, Vaccine 15(3): 248-256 and U.S. Pat. No. 6,352,697), phospholipases (see, e.g., Camilli et al., 1991, J. Exp. Med.
- pore-forming toxins e.g., an a-toxin
- natural cytolysins of gram-positive bacteria such as listeriolysin O (LLO, e.g., Mengaud et al., 1988, Infect. Immun. 56: 766-772 and Portnoy et al., 1992, Infect. Immun. 60: 2710-2717
- LLO listeriolysin O
- SLO streptolysin O
- PFO perfringolysin O
- cytolysins may be advantageously used.
- listeriolysin exhibits greater pore-forming ability at mildly acidic pH (the pH conditions within the phagosome), thereby facilitating delivery of vacuole (including phagosome and endosome) contents to the cytoplasm (see, e.g., Portnoy et al., Infect. Immun. 1992, 60: 2710-2717).
- the cytolysin may be provided together with a pre-selected antigen in the form of a single composition or may be provided as a separate composition, for contacting the antigen-presenting cells.
- the cytolysin is fused or otherwise linked to the antigen, wherein the fusion or linkage permits the delivery of the antigen to the cytosol of the target cell.
- the cytolysin and antigen are provided in the form of a delivery vehicle such as, but not limited to, a liposome or a microbial delivery vehicle selected from virus, bacterium, or yeast.
- a delivery vehicle such as, but not limited to, a liposome or a microbial delivery vehicle selected from virus, bacterium, or yeast.
- the delivery vehicle is non-virulent.
- the delivery vehicle is a non-virulent bacterium, as for example described by Portnoy et al. in U.S. Pat. No. 6,287,556, comprising a first polynucleotide encoding a non-secreted functional cytolysin operably linked to a regulatory polynucleotide which expresses the cytolysin in the bacterium, and a second polynucleotide encoding one or more pre-selected antigens.
- Non-secreted cytolysins may be provided by various mechanisms, e.g., absence of a functional signal sequence, a secretion incompetent microbe, such as microbes having genetic lesions (e.g., a functional signal sequence mutation), or poisoned microbes, etc.
- a secretion incompetent microbe such as microbes having genetic lesions (e.g., a functional signal sequence mutation), or poisoned microbes, etc.
- a wide variety of nonvirulent, non-pathogenic bacteria may be used; preferred microbes are relatively well characterized strains, particularly laboratory strains of E. coli, such as MC4100, MC1061, DH5 ⁇ , etc.
- Other bacteria that can be engineered for the invention include well-characterized, nonvirulent, non-pathogenic strains of Listeria monocytogenes, Shigella flexneri, mycobacterium, Salmonella, Bacillus subtilis, etc.
- the bacteria are attenuated to be non-re
- the delivery vehicles described above can be used to deliver one or more antigens to virtually any antigen-presenting cell capable of endocytosis of the subject vehicle, including phagocytic and non-phagocytic antigen-presenting cells.
- the subject methods generally require microbial uptake by the target cell and subsequent lysis within the antigen-presenting cell vacuole (including phagosomes and endosomes).
- the antigen is produced inside the antigen-presenting cell by introduction of a suitable expression vector as for example described above.
- the antigen-encoding portion of the expression vector may comprise a naturally-occurring sequence or a variant thereof, which has been engineered using recombinant techniques.
- the codon composition of an antigen-encoding polynucleotide is modified to permit enhanced expression of the antigen in a target cell or tissue of choice using methods as set forth in detail in International Publications WO 99/02694 and WO 00/42215.
- codon-optimized polynucleotides at least one existing codon of a parent polynucleotide is replaced with a synonymous codon that has a higher translational efficiency in a target cell or tissue than the existing codon it replaces.
- the replacement step affects 5, 10, 15, 20, 25, 30%, more preferably 35, 40, 50, 60, 70% or more of the existing codons of a parent polynucleotide.
- expression vectors of this type can be derived from viral DNA sequences including, but not limited to, adenovirus, adeno-associated viruses, herpes-simplex viruses and retroviruses such as B, C, and D retroviruses as well as spumaviruses and modified lentiviruses.
- Suitable expression vectors for transfection of animal cells are described, for example, by Wu and Ataai (2000, Curr. Opin. Biotechnol. 11(2):205-208), Vigna and Naldini (2000, J. Gene Med.
- the above described examples provide a device for the delivery of a bioactive material (agent) or other stimulus to an internal site in the body, comprising a plurality (number) of projections that can penetrate a body surface so as to deliver the bioactive material or stimulus to the required site.
- the number of projections is selected to be at least 500, to thereby induce a biological response.
- the exact number of projections is determined in accordance with the above described equations, thereby maximizing the chance of delivery of material or stimulus to the target.
- the delivery end portion of the projection may also be dimensioned so as to be capable of insertion into targeted cells to deliver the bioactive material or stimulus without appreciable damage to the targeted cells or specific sites therein.
- the dimensions of the delivery end portion of the microprojections including the length or diameter, can be selected which enables delivery of the agent or stimulus to targeted cells and internal components within cells.
- the nanoneedles are typically solid (non-hollow) in cross-section. This leads to a number of technical advantages which include: reliable delivery of bioactive material or stimulus; ease and cost of manufacturing, and increased strength.
- projections may be coated on the outside of the nanoneedles. This provides a higher probability of delivering the coating to the depth of interest compared to microparticle delivery from a gene gun and thus is more efficient.
- nanoneedles may be used for delivery not only through the skin but through other body surfaces, including mucosal surfaces, to cellular sites below the outer layer or layers of such surfaces.
- internal site is to be understood as indicating a site below the outer layer(s) of skin and other tissues for which the devices of the present invention are to be used.
- these nanoneedles may be used to deliver stimuli to cells or cell components other than those resulting from the administration of bioactive agents such as drugs and antigenic materials for example. Mere penetration of cellular sites with nanoneedles may be sufficient to induce a beneficial response, as indicated hereinafter.
- the device is suitable for intracellular delivery.
- the device is suitable for delivery to specific organelles within cells.
- organelles to which the device can be applied include a cell nucleus, endoplasmic reticulum, ribosome, or lysosome for example.
- the device having a needle support section, that is to say the projections comprise a suitable support section, of sufficient length to reach the desired site and a (needle) delivery end section having a length no greater than 20 microns and a maximum width no greater than 5 microns, preferably no greater than 2 microns.
- the maximum width of the delivery end section is no greater than 1000 nm, even more preferably the maximum width of the delivery end section is no greater than 500 nm.
- the device can be used for delivery intradermally.
- This device may have a needle support section, that is to say the projections comprise a suitable support section, of length at least 10 microns and a (needle) delivery end section having a length no greater than 20 microns and a maximum width no greater than 5 microns, preferably no greater than 2 microns.
- the maximum width of the delivery end section is usually no greater than 1000 nm, even more preferably the maximum width of the delivery end section is no greater than 500 nm.
- the device is for mucosal delivery.
- This device may have a needle support section, that is to say the projections comprise a suitable support section, of sufficient length to reach the desired site, such as of length at least 100 microns and a (needle) delivery end section having a length no greater than 20 microns and a maximum width no greater than 5 microns, preferably no greater than 2 microns.
- the device of the invention is for delivery to lung or other internal organ or tissue.
- the device is for in-vitro delivery to tissue, cell cultures, cell lines, organs, artificial tissues and tissue engineered products.
- This device typically has a needle support section, that is to say the projections comprise a suitable support section, of length at least 5 microns and a needle delivery end section having a length no greater than 20 microns and a maximum width no greater than 5 microns, preferably no greater than 2 microns.
- the device comprises projections in which the (needle) delivery end section and support length, that is to say the “needle support section”, is coated with a bioactive material across the whole or part of its length.
- the (needle) delivery end section and support length may be coated on selective areas thereof. This may depend upon the bioactive material being used or the target selected for example.
- a bioactive material is releasably incorporated into the material of which the needle, or projection, is composed. All, or part of the projection may be constructed of a biocompatible, biodegradable polymer (such as Poly Lactic Acid (PLA), PolyGlycolic Acid (PGA) or PGLA or Poly Glucleic Acid), which is formulated with the bioactive material of choice.
- PHA Poly Lactic Acid
- PGA PolyGlycolic Acid
- PGLA Poly Glucleic Acid
- At least the delivery end section of the needle is composed of a biodegradable material.
- a device in which the needle has no bioactive material on or within it.
- the targeted cell or organelle is perturbed/stimulated by the physical disruption caused by the (delivery end of the) nanoneedle (projection).
- This physical stimulus may, for example, be coupled with electric stimulus as a form of specific nanoelectroporation of particular organelles or the cell.
- the bioactive material or stimulus delivered by the device of the invention may be any suitable material or stimulus which gives the desired effect at the target site.
- bioactive materials which are not intended to be limiting with respect to the invention include polynucleotides and nucleic acid or protein molecules, antigens, allergens, adjuvants, molecules, elements or compounds.
- the device may be coated with materials such as biosensors, nanosensors or MEMS.
- the device is provided in the form of a patch containing a plurality of needles (projections) for application to a body surface.
- a multiplicity of projections can allow multiple cells and organelles to be targeted and provided with a bioactive material or stimulus at the same time.
- the patch may be of any suitable shape, such as square or round for example.
- the overall number of projections per patch depends upon the particular application in which the device is to be used.
- the patch has at least 10 needles per mm, and more preferably at least 100 needles per mm 2 . Considerations and specific examples of such a patch are provided in more detail below.
- the device of the invention is constructed from biocompatible materials such as Titanium, Gold, Silver or Silicon, for example. This may be the entire device, or alternatively it may only be the projections or the delivery end section of the projections which are made from the biocompatible materials.
- DRIE Deep Reactive Ion Etching
- Another manufacturing method for the device utilizes manufacturing from a male template constructed with X-ray lithography, electrodeposition and molding (LIGA).
- the templates are then multiply inserted into a soft polymer to produce a plurality of masks.
- the masks are then vacuum deposited/sputtered with the material of choice for the nanoprojections, such as titanium, gold, silver, or tungsten. Magnetron sputtering may also be applied, see the construction section below.
- the device is constructed of silicon.
- the device may be for a single use or may be used and then recoated with the same or a different bioactive material or other stimulus, for example.
- the device comprises projections which are of differing lengths and/or diameters (or thicknesses depending on the shape of the projections) to allow targeting of different targets within the same use of the device.
- the target of interest is within the cells.
- the position and shape of key organelles within the cells are shown in FIG. 15 .
- All eucaryotic cells have the same basic set of membrane enclosed organelles.
- the number and volume of the key organelles varies with cell type.
- the probability of targeting the nucleus, for example, in a cell is given by the volume of the nucleus vs. the remainder of the cell.
- the starting point is the cell membrane, which is ⁇ 10 nm thick.
- a range of drugs, vaccines and other compounds can be delivered to cells.
- the Endoplasmic Reticulum (a convoluted envelope, 75 nm in thickness) may be targeted within RNA to transfect cells in the areas of Vaccination or Gene Therapy.
- Lysosomes which are 200-500 nm in size can be targeted for release of enzymes to induce autolysis (cell death).
- MHC Class I an effective cellular response
- DNA material is delivered intact to the cell nucleus.
- the type and scale of organelles within cells has been presented. Now the location of these cells within the tissue is identified. The selected tissue routes are.
- the skin is one convenient route for drug and vaccine delivery.
- a schematic of the skin is shown in FIG. 16 .
- a full description of the anatomy of the skin is given in textbooks.
- a closer view of a histology section of skin is shown in FIG. 17 in a photomicrograph. Respective thicknesses of layers vary between species and sites.
- FIG. 17 shows a stained LC, marked as “L”, residing above the basal layer.
- the spatial distribution of LC is illustrated in a 3D distribution of LC in a mouse, FIG. 18 (Kendall M. A. F., Mulholland W. J., Tirlapur U. K., Arbuthnott E. S., and Armitage, M. (2003) “Targeted delivery of micro-particles to epithelial cells for immunotherapy and vaccines: an experimental and probabilistic study”, The 6th International Conference on Cellular Engineering, Sydney, August 20-22).
- LC typically about 1000 LC per square mm and they reside just above the basement membrane of the viable epidermis (i.e., 30-80 ⁇ m deep). Importantly, the depth of LC varies significantly with the biological variability of the tissue, including rete ridges etc.
- LC residing 30-80 ⁇ m below the skin surface.
- SC and cell membranes are to be breached.
- organelles within the LC are to be targeted to elicit particular responses.
- MHC I responses whereby intact DNA is to be delivered to cell the nucleus.
- mRNA can be delivered to the Endoplasmic Reticulum or the cytoplasm.
- cancerous cells within the VE may be directly targeted.
- the cells to be targeted are deeper in the tissue, approaching hundreds of microns (600 82 m to 800 ⁇ m) (British Journal of Dermatology 149(5) Page 1035-2003).
- FIG. 19A shows a photomicrograph of a histology section of the mucosa and FIG. 19B shows the structure of the mucosa.
- the physiology of the mucosa is similar to the skin. However there are some notable differences:
- the mucosa does not have a stratum corneum
- the epithelium is 600-800 82 m thick. This is considerably deeper than the epidermis of the skin (the exact thickness varies with site, age and species).
- a depth D c of 600-800 82 m is required.
- the epithelial cells on the lining of the lung are the target for various gene therapy approaches. These cells are underneath a mucous/liquid lining, which may be 10-100 82 m thick. Therefore this lining needs to be overcome. In the example of gene therapy for the treatment of Cystic Fibrosis, this lining is to be overcome to target celial cells on the surface of the epithelium.
- Cells within other the internal organs can also be targeted for a range of applications, such as:
- Heart e.g., for angiogenesis blood vessel formation.
- Tissue, cell-lines, tissue culture, excised organs, tissue engineered constructs and artificial tissues may also be targeted, in-vitro. Examples include:
- growth factors and/or genes e.g., in tissue engineering and wound healing.
- Nanoneedles are configured to penetrate the cell membrane with minimal damage, targeting the organelles of interest.
- the overall dimensions of the nanoneedle projection are shown in FIG. 20 .
- the nanoneedle is divided into two main sections:
- the radius of the tip (r) is to be as small as practicable with limits set by manufacturing methods and material considerations, where usually the diameter at the distal end of l is d 1 . Usually di ⁇ 2r.
- the diameter of the upper end of l is defined as d 2 .
- the effective diameter, tapering from d 1 to d 2 is to be considerably less than the diameter of the cell (d cell ) or other target. It is shown in Table 1 approximately that 10 ⁇ m ⁇ d cell ⁇ 30 ⁇ m. So, approximately, d 1 ⁇ 10 ⁇ m, preferably ⁇ 1 ideally in some cases ⁇ 500 nm.
- the scale of d 1 is to be of the order of the organelle of interest.
- the projection along l tapers out to a larger diameter (d 2 >d 1 ) that still is less than the diameter of the cell ( ⁇ d cell ).
- the length of the targeting section (l) is sufficient to ensure that the organelle of interest is targeted (i.e., l>organelle dimension). For example, in targeting the cell nucleus, l>3-6 ⁇ m). Ideally, l is even longer to account for variation in cell depth location (e.g., as shown by the variation in the Langerhans cell depth Figure A) and increase the probability of the desired needle-organelle contact.
- the upper length of l is determined by the combination of material properties, needle shape and loading to ensure that the needle does not break under mechanical loading. Engineering analyses shows this mechanical loading is mostly compression, with tension and bending moments. Good engineering practice to ensure the material does not break includes Euler buckling, fracture mechanics, and work-to-failure. In considering a population of projections in an array, statistical methods (e.g., Weibull statistics) and other related methods may be applied to ensure a very small fraction of the projection population breaks.
- the support section of the micro-nanoprojection (a) is sufficient to bring the targeting section of the cell (l) into contact with the cells/organelles of interest.
- FIG. 20 shows that a, l and the overall length of the projection (L) are related by:
- section 2 the depths of cells for various applications in intradermal, mucosal, lung and internal organ delivery are outlined.
- the rationale and approximate values of a for targeting these individual sites are presented as examples.
- a is the sum of the desired depth in the tissue and an allowance above the target (for instance for tissue surface curvature).
- This dimension in epidermal delivery is usually ⁇ 200 ⁇ m in length, and preferably ⁇ 100 ⁇ m in length-depending on the tissue species and site.
- this depth is even greater with a ⁇ 1000 ⁇ m, and preferably ⁇ 600 ⁇ m.
- the targeting of basal cells in the epithelium of the mucosa an a of 600-800 ⁇ m is required.
- the local bather of the mucous lining to the cells is 50-100 ⁇ m thus a would be of the order of 100 ⁇ m in this case.
- ⁇ y is the yield stress of the tissue.
- FIG. 21 plots the cell/organelle targeting section length (l) as a function of diameter for six materials. Note that these are upper limit calculations of the loading effects.
- a brittle material such as silicon would also require fracture (and other) analyses that may lead to more conservative (i.e., larger) dimensions-these numbers throughout this section are simply illustrative.
- Table 1 lists the thickness of the Endoplasmic Reticulum envelope to be 75 nm. Choosing titanium, the organelle targeting section is set at 400 nm over a length of 5 ⁇ m. As shown in Table 2, the remainder of the components are identical to those set out in Example 1.
- FIG. 20 shows an axi-symmetric design for the nanoneedle. Alternative shapes may be used with:
- FIG. 27 One possible example of an alternative shape taking on these features is shown in plan view in FIG. 27 .
- PowderJect and Bio-Rad patents and protocols such as: http://plantsciences.montana.edu/wheat-transformation/biolisti.htm); J. E. Biewenga, O. H. Destree, L. H. Schrama, “Plasmid-mediated gene transfer in neurons using the biolistics technique”, J. Neurosci. Methods 71(1997) 67-75; S. Novakovic, M. Knezevic, R. Golouh, B. Jezersek, “Transfection of mammalian cells by the methods of receptor mediated gene transfer and particle bombardment”, J. Exp. Clin. Cancer Res. 18 (1999) 531-536; H. Wellmann, B. Kaltschmidt, C.
- UV light exposure of a hydrogen-terminated silicon (100) surface coated with alkenes functionalized with N-hydroxysuccinimide ester groups result in the covalent attachment of the alkene as a monolayer on the surface.
- Submicron-scale patterning of surfaces is achieved by illumination with an interference pattern obtained by the transmission of 248 nm excimer laser light through a phase mask.
- the N-hydroxysuccinimide ester surface act as a template for the subsequent covalent attachment of aminohexyl-modified DNA oligonucleotides. Oligonucleotide patterns, with feature sizes of 500 nm, are reliably produced over large areas.
- the patterned surfaces are characterized with atomic force microscopy, scanning electron microscopy, epifluorescence microscopy and ellipsometry.
- Complementary oligonucleotides are hybridized to the surface-attached oligonucleotides with a density of ⁇ 7 ⁇ 10 12 DNA oligonucleotides per square centimeter (for example).
- Some-possible coating combinations include:
- the cell is perturbed/stimulated by the physical disruption of the micro-nanoprojection structure.
- This physical stimulus can be coupled with electric stimulus as a form of specific nanoelectroporation of particular organelles or the cell.
- the bioactive material can coat the whole surface of the nanoneedle (over the length L).
- the targeting section (l) can be selectively coated by only immersing this part of the needle in the coating media.
- different combinations of various coatings can be made on the one nanoneedle (combinations of DNA and adjuvants, proteins, cytokines, inhibitors etc.).
- different coatings may be provided on different individual micro-nanoprojections.
- the micro-nanoprojections may also be coated with nanobiosensors (e.g., quantum dots, nanomachines, MEMS) using a range of coating protocols.
- nanobiosensors e.g., quantum dots, nanomachines, MEMS
- All, or part of the micro-nanoprojection can be constructed of a biocompatible, biodegradable polymer (such as Poly Lactic Acid (PLA), Poly Glucleic Acid (PGA) or PGLA), which is formulated with the bioactive material of choice.
- PHA Poly Lactic Acid
- PGA Poly Glucleic Acid
- PGLA Poly Glucleic Acid
- the micro-nanoprojections may then be inserted and, as they dissolve, the bioactive material will enter the organelle(s)/cells.
- access to the organelles may be by the following:
- the bioactive material can stay on the surface of the nanoneedle, but elicit the response within the organelle/cell.
- bioactive material bonds can be broken by exposure of enzymes, proteins or hydration within the cell/organelle.
- This section outlines the simplest embodiment of the nanoneedle concept: an individual projection, coated on the surface with a bioactive material (here DNA coded for GFP to transfection), used to deliver this material to a living cell, in-vitro, where a biological response is measured (transfection) and the cell is alive.
- a bioactive material here DNA coded for GFP to transfection
- the electropolishing set-up used a solution of distilled water with 4% NaOH molar.
- the following settings were used:
- electropolishing was ceased when probe length began to diminish (detected by visual sighting by naked human eye).
- FIGS. 22A-B shows Transmission Electron Microscopy (TEM) of an electropolished Tungsten tip at two different resolutions, with the scale bar in FIG. 22A of 20 ⁇ m, and in FIG. 22B of 0.11 ⁇ m.
- FIGS. 22B and 22C show the minimum tip size (d 1 ) is ⁇ 100 nm (i.e., r ⁇ 50 nm).
- the cell targeting length (l) is approximately 20 ⁇ m-defined by where the diameter (d 2 ) remains less than ⁇ 1 ⁇ m.
- the tungsten micro-nanoprojections were coated by adapting a protocol devised for the coating of gold microparticles for biolistic delivery developed by O'Brien and Lummis (2002) “An improved method of preparing microcarriers for biolistic transfection”, Brain Research Protocols 10 (2002) 12-15.
- the adapted protocol is as follows:
- FIGS. 23A and 23B show images of lengths of tungsten wire (280 82 m diameter) imaged with a fluorescent microscope with uncoated wire in FIG. 23A and DNA coated wire (using the described protocol, above) immersed in a liquid with a propidium iodide stain (red fluorescing dye) in FIG. 23B .
- tungsten wire 280 82 m diameter
- DNA coated wire using the described protocol, above
- red fluorescing dye red fluorescing dye
- DNA coated projections were inserted into an agar (3%) gel stained with acridine orange (green fluorescing dye). This gel (without the stain) is routinely used for in-vitro testing of biolistic to devices for DNA vaccination and other applications.
- the uncoated and coated tungsten rods were inserted and removed by hand into the agar (to a depth >1 mm) for a cycle duration of approximately 1 second.
- FIGS. 24A-24D show optically sectioned Multi-Photon Microscopy (MPM) images of the agar after insertion of a DNA coated tungsten probe on the surface in FIG. 24A , at a depth of 13 ⁇ m in FIG. 24B , at a depth of (32 82 m) in FIG. 24C .
- FIG. 24D shows an optical section at 32 82 m of agar gel following insertion of a probe without a DNA coating.
- the described electropolished tungsten micro-nanoprojections coated with GFP plasmid DNA were tested, with the objective of determining whether the DNA could be delivered to transfect the cell, without damaging the cell.
- the cell line is called A549 which is a human lung carcinoma (epithelial) cell line.
- Cells were cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal calf serum at 37° C., 5% CO 2 .
- DMEM Dulbecco's modified eagle medium
- One of the Petri dishes with cells was set aside as a control.
- the other two Petri dishes were probed with the micro-nanoprojections. In total, 6 micro-nanoprojection systems were used.
- Probing of the cells was performed with a microinjection system (Eppendorf Femtoject and Injectman NI2 microinjection kit) fitted to an inverted fluorescent microscope (Zeiss Axiovert 25 microscope with stage heater).
- a microinjection system Eppendorf Femtoject and Injectman NI2 microinjection kit
- an inverted fluorescent microscope Zeiss Axiovert 25 microscope with stage heater
- micro-nanoprojection were fitted into the standard microinjection holder and then moved with course and fine adjustment of a motorized X-Y-Z axis controller to just contact the cell membrane, before retraction of less than 1 82 m.
- a cycle time of probing was set between limits of 0.1 and 15 seconds, with a traverse distance of 3-5 ⁇ m-then the cycle was automatically performed on the system.
- the probe was replaced and refitted with a replacement.
- 10 cells were perturbed with a micro-nanoprojection coated in eGFP plasmid DNA.
- micro-nanoprojections coated in DNA can individually target cells, transfecting them and not kill them.
- a micro-nanoproprojection was fabricated of Tungsten with a tip radius (r) of ⁇ 400 nm.
- the tissue was freshly excised Balb/C mice ears (age 8-10 weeks), which were glued to a metal cylinder holder.
- the reported stratum corneum and viable epidermis thicknesses of these samples are respectively ⁇ 5 82 m and 12 82 m (Arbuthnott (2003)).
- FIG. 26 shows two typical sample results of loading-unloading curves achieved to a depth of ⁇ 50 ⁇ m. These results show that the micro-nanoprojection probe penetrated through the epidermis and well into the dermis without damage. The difference in magnitude between the curves is typical of biological variability observed in bio-viscoelastic tissue. Importantly, unlike ballistic particle delivery, the depth of penetration is not dependent upon this variability-rather the length of projection.
- the projections did not break-the loading experiment was simply stopped at a 50 82 m setting on the experimental apparatus. This was confirmed by imaging with projections with a microscope after the experiment. This experiment was repeated 20 times, confirming the engineering analyses of probe structure required to target cells in the skin is applicable and valid.
- the next logical step is to extend the concept to arrays of patches targeting tissue sites.
- patch arrangements each designed for a particular targeting need of cells, organelles and/or tissue sites.
- FIG. 28 shows a schematic of an array of the described micro-nanoprojections configured on a patch, with the spacing between micro-nanoprojections defined as (S) and the patch breadth defined as (B).
- S the spacing between micro-nanoprojections
- B the patch breadth
- the patch including the micro-nanoprojections are held in place for a sufficient time for the “event” (biological, physical or other) to take place. This may be instantaneous, or in other cases could take days, weeks or months.
- Patches may be applied to the tissue site once, or a multitude of times depending upon the effect desired.
- the overall size (B ⁇ B) of the patch and spacing (S) between the micro-nanoprojections is determined by the application.
- the patch could be square (B ⁇ B), circular, elliptic, or any other suitable shape.
- the square dimensions are quoted throughout.
- the size is to be less than 15 ⁇ 15 mm (B), with 1 ⁇ S ⁇ 1000 ⁇ m, preferably with 10 ⁇ S ⁇ 100 ⁇ m.
- Example 1 is the targeting of nuclei of Langerhans cells.
- MHC 1 desired cellular
- the cell/organelle targeting sections (l) are coated in DNA.
- the micro-nanoprojection structure is coated in DNA.
- the probability of contact with a LC nucleus is 0.0131. This probability is ⁇ 1000-1500 times higher than a typical probability of a direct “hit” with the biolistics approach and microparticles. Furthermore, the transfection comparison is even more favorable for the micro-nanoprojection patch, given far fewer cells are killed than by the gene gun.
- Table 3 is a summary of configurations of patches that may be used. At one end of the range, a spacing of 100 rods/mm 2 corresponds to a patch surface area of 76 mm 2 , with a spacing (S) of 100 82 m, a breadth of 8.7 mm and a total number of rods of over 7000. Increasing density of rods to 1000/nm 2 results in a reduction in patch size to less than 3 mm ⁇ 3 mm.
- the Nanoneedle Diameter d1 Is Assumed to Be 1 ⁇ m. Area of patch Spacing (S) Breadth of Rod/mm 2 (mm 2 ) ( ⁇ m) patch (B) ( ⁇ m) Total Rods 100 15.8 100 4.0 1578 500 3.2 45 1.8 1578 1000 1.5 32 1.3 1578
- the analysis is also applied to the targeting of the Endoplasmic Reticulum (Example 2 from Table 2), which may be required for targeted RNA delivery.
- the probability of a single needle contacting the Endoplasmic Reticulum is 0.031.
- the size of patch ranges from 8 ⁇ 8 mm to 2.5 ⁇ 2.5 mm
- the Nanoneedle Diameter Is Assumed to be 400 nm Area of patch Spacing (S) Breadth of Rod/mm 2 (mm 2 ) ( ⁇ m) patch (B) ( ⁇ m) Total Rods 100 65 100 8.0 6451 500 13 45 3.60 6451 1000 6.5 32 2.54 6451
- a patch may also have combinations of micro-nanoprojections, with different geometries.
- the length (L) or indeed the other parameters in FIG. 20 may be varied throughout the patch, either in defined sequences, clusters and/or randomly (within limits).
- the diameter of the projection may be increased on individual micro-nanoprojections significantly in order to induce cell death at controlled locations. This, for example, may be used to induce bystander biological responses (e.g., stimulation/inflammation/activation) to neighboring healthy cells-which could have or will be interacting with described, smaller micro-nanoprojections configured for minimal cell damage.
- the bioactive or other stimulus is to be coated or part of the nanoneedle array.
- the choice of bioactive is determined by the application and target organelles or cells of interest. This range encompasses, but is not restricted to:
- Polynucleotides DNA (all variants), RNA (all variants), proteins, antigens, allergens and adjuvants, molecules, compounds.
- Biosensor molecules and compounds and materials Biosensor molecules and compounds and materials.
- nanoneedle array on a patch (e.g., FIG. 19 ) in a scaleable process for high throughput manufacturing with minimal human input.
- Construction to be of a medical grade material e.g., Gold, Silver, Titanium, Tungsten or PLA, PGA, PGLA, Silicon
- the patch geometry of manufacture is summarized in Table 3, with an area of patch ⁇ 76.4 mm 2 , a spacing of 100 ⁇ m and the minimum tip size of 1 82 m (d 1 ).
- Table 3 A schematic of this array on patch is shown in FIG. 29 .
- the techniques can be applied to a range of geometries.
- DRIE Deep Reactive Ion Etching
- chromium was sputter deposited then lithographically patterned as an array of dots onto 3 inch (75 mm) 100 oriented silicon wafers.
- the array of dots had a center-to-center spacing of 100 ⁇ m, and in some earlier test cases, 10-20 ⁇ m.
- the diameter of the dots 1 82 m, and in other cases, 3 82 m, 5 82 m, and 10 ⁇ m.
- Deep Reactive Ion Etching (DRIE, Oxford Instruments, Bristol, UK) was then carried out to obtain the desired by profile by adjusting the etch rate.
- the typical instrument conditions included a 20 standard cm 3 /min (sccm) SF 6 and 15 sccm (O 2 ) at a pressure of 20 Pa. Power was varied. The etching process was performed at cryo-cooled conditions, achieving temperatures of ⁇ 100 to ⁇ 150° C. Lower etch rates were used for the tapered sections, whereas higher rates were used for the more parallel sections. Micro-nanoprojection fabrication was finished when the chromium masks became fully undercut and fell off the projection tips. The process is completed in less than 100 minutes, resulting in several patch configurations on the wafer.
- the patches were then cut from the silicon wafer, with a dedicated cutter.
- an additional, thicker material is affixed to the back surface (i.e., the surface without the projections).
- This process is repeated to fabricate a large quantity of micro-nanoprojection array patches.
- a variation of the described DRIE method may also be applied to other materials, including Silicon Carbide (SiC).
- SiC Silicon Carbide
- This constructional embodiment example applies to a broader range of micro-nanoprojections materials than those described in the constructional embodiment Example 1. These materials include Metals, polymers, silicon and oxides/carbides.
- this case illustrates a method of fabricating tungsten micro-nanoprojection arrays on a patch. Three of the steps in this production process are discussed.
- LIGA is used (a German acronym for X-ray lithography, electrodeposition and molding). This template will serve in the production of several molds in a soft polymer. LIGA, which utilizes a Synchroton, is ideal for creating the template because it has a very high resolution ( ⁇ 20 nm), can fabricate in metals, and will easily fabricate a patch (maximum component size is 3.4 inches in the Axsun technologies system). Fabrication protocols to construct the template are detailed in Chapter 6 of Madou M. J. “Fundamentals of Microfabrication. The science of miniaturization”, CRC Press, 2002 manuals and literature from companies (e.g., AXSUN Technologies, Ca, USA).
- Nickel is selected as the material from which the micro-nanoprojection array template is constructed.
- LIGA could be used to make individual patches directly (e.g., of gold or silver-which are both biocompatible) in large quantities. With current costs of the LIGA technology, this is not practical-but with LIGA technology advances, this could be feasible in the future.
- Step 2 Construction of a Mask (Female Component)
- LIGA is not used to mass-fabricate micro-nanoprojection array patches for direct use with the tissue in large numbers. However, here it can be used as a template for many multi-stage processes. As one example, the template is used for multiple insertions into a soft polymer to produce a mask, as shown in FIGS. 30A-30C , performed in the following steps:
- FIG. 30A Insertion of the template directly into the soft polymer. This is repeated several times to produce many indentations in the polymer with a given mask.
- FIG. 30B Allowing the soft polymer to harden, or “cure” with the addition of catalysts and or temperature.
- FIG. 30C Remove the template to leave behind a mask.
- Step 3 Final Construction of the Nanoneedle Array with the Mask
- the masks are then be placed in a vacuum chamber and deposited with a vacuum deposition/sputtering process.
- the material to be sputtered is a biocompatible inert material, such as titanium, gold, or silver.
- the polymer surface is treated with an air discharge before the chamber is pumped down to a vacuum at 27 degrees C.
- the titanium, gold or silver film is then deposited.
- Commercial sputtering machines may be used in this process (such as the VarianVM8 Sputterer).
- the mask can then be removed by immersion of a liquid (e.g., alcohols) to dissolve it.
- a liquid e.g., alcohols
- a mask (female) can be directly manufactured using Two-Photon Stereo Lithography (2PSL), in which the geometry co-ordinates shown in FIG. 30(C) are applied to construct the desired shape with the photosensitive resin.
- 2PSL Two-Photon Stereo Lithography
- the technique works by scanning with a femtosecond laser in a liquid photosensitive resin bath.
- the two-photon effect ensures that solidification occurs only where the energy of the laser is concentrated to a femtolitre volume (typically 200 nm ⁇ 200 nm ⁇ 400 nm, x, y, z).
- the method of manufacture is to start at the tip of the nanoneedle (marked A in FIG. 29 ) and then work up the needle to the base.
- the same approach applies to the rest of the nanoneedles.
- the process is fully automated with a motorized x-y stage with the laser co-ordinates determined from engineering drawings of the structure. Therefore, thousands of nanoneedles can be constructed in a scaleable process.
- the technique allows complicated 3D structures to be constructed by the scanning of a pulsed (80 MHz), femtosecond pulse length laser concentrating light at 400-1000 nm to a femtolitre volume to induce a two photon excitation of the material and induce solidification.
- the nanoneedles may be constructed with a photosensitive polymer/resin, (such as the commercial grade SCR 500) or an alternative impregnated with Silver (following Stellacci et al. 2002).
- a photosensitive polymer/resin such as the commercial grade SCR 500
- silver followeding Stellacci et al. 2002.
- Young's Modulus of SCR 500 is 0.49 Gpa compared with
- the technique is rapidly improving and may be a possible fabrication method in the future.
- nanoneedles are constructed with silicon, with a 200 nm tip for a length of 5 ⁇ m followed by two other parallel sections separated by tapered sections.
- This structure may be constructed by Electron Beam Lithography and Reactive Ion Etching, a standard technique in to the microelectronics industry. The manufacturing approach has been applied by Henry et al. (Journal of Pharmaceutical Sciences 87(8), 1998) and in Lebouitz and Pisano et al. (U.S. Pat. No. 5,928,207) in the construction of microneeedles.
- FIG. 31 shows the structure produced with one of these techniques.
- each parallel section may be constructed with silicon 100 wafers and the tapered sections constructed with silicon 111 (or other) wafer material-where the angle of the taper is a preferred etching line of the material.
- the shown shape is made from 5 wafers (one wafer per geometry).
- a gradual taper mold can be constructed from the one silicon wafer.
- the silicon arrays may be used as masters for microarray molds.
- the patch is inserted into the skin either by user control or by mechanical, electrical or other controlled means. All these options are possible, as the magnitude of the forces is low.
- the insertion force is approximately calculated to be less than 1 N (based on 7000 probes, 1 82 m in diameter piercing tissue with a yield of 20 MPa).
- the time of insertion, residence and removal from the tissue can be controlled by user and/or the described mechanical/electrical means.
- FIGS. 32A and 32B One embodiment of a simple application system for the patch is shown in FIGS. 32A and 32B .
- the application system 3300 is formed from a structure in the form of a housing or body 3310 .
- the body 3310 defines a cavity 3320 having an opening 3330 .
- a patch 100 having a number of projections 110 provided on a base 120 , is moveably mounted within the cavity 3320 . This may be achieved in any one of a number of manners, to but typically involves having the patch 100 suitable sized to allow movement along the cavity towards and away from the opening 3330 .
- the patch 100 is mounted to an actuator, so that in use the patch may be moved from a retracted position shown in FIG. 32A , to an extended position shown in 32 B.
- the actuator may be of any suitable form, but in one example, includes a spring 3340 and a releasing means 3350 .
- the spring 3340 In the retracted position, the spring 3340 is biased against the patch 100 , thereby urging the patch 100 towards the opening 3330 , with the patch 100 being retained in the retracted position by the releasing member 3350 .
- the releasing means When the releasing means is activated, for example, by having an operator release the wire, the spring 3340 urges the patch 100 towards the opening 3330 , so that the projections 110 extend therethrough.
- the micro-nanoprojections patch In the retracted position ( FIG. 32( a ) ) the micro-nanoprojections patch is recessed and thus protected, preventing accidental administration.
- Other packaging/devices may also be used for these purposes, for example a protective cap to be removed before administration.
- the patch is attached to a compressed spring that is held in place by a tensioned string.
- the releasing means typically is arranged so that the patch 100 is retained in the retracted position until the releasing means is activated.
- the patch 100 may be retained in position by a clip that is released upon activation of the releasing means. This allows the operator to position the device against the subject's skin 3360 without having to retain the patch in the retracted position.
- the string. is released by a means (e.g., pressing a button, not shown in FIG. 32 ) and the patch is released to enter the tissue surface ( FIG. 32( b ) ).
- the described patch arrangements may be fitted to an applicator designed to safely transport the patch into the mouth and to accurately locate on to the mucosal site. This could be done by using the described intradermal patch in the mouth.
- FIG. 33 shows one example of and applicator for mucosal delivery for the buccal mucosa (mouth).
- the patch arrangement from FIG. 32 in the form of the application system 3300 is coupled to an arm 3400 , allowing the application system 3300 to be positioned in otherwise hard to reach places.
- the spring arrangement allows the patch to be applied, but other mechanisms equally could be used.
- the applicator could have a button at the distal end of the arm 3400 from the patch to allow the operator to release the patch onto the mucosal site.
- Other features may include a knurled surface towards the distal end to aid user grip.
- FIG. 34 shows a schematic of the physiology of the airways in a human.
- an applicator that can flexibly and compactly reach these sites, target the sites, and then retract, is required.
- FIGS. 35A-35C show a deployable structure embodiment for targeting these sites.
- the apparatus includes an application system 3600 mounted to a flexible structure, such as an arm, allowing the application system 3600 to be inserted into a passageway 3620 , such as an airway, of the subject.
- a flexible structure such as an arm
- the flexible structure may be in the form of a manipulable fiberscope, or the like.
- the application system includes a structure such as a body 3630 , having a number of arms 3640 movably mounted thereto, to allow the arms to move between a retracted position shown in FIG. 35B and an extended position shown in FIG. 35C .
- the arms 3640 are typically biased towards the extended position, and are retained in the retracted position, using a releasing mechanism, such as a clip or the like. It will be appreciated that this may be similar to the releasing means described above with respect to FIG. 34 .
- patches 100 are mounted to the arms, so that when the arms are released, the patches are urged against a surface 3621 of the passageway 3620 , allowing the projections 110 provided on each patch to penetrate the surface 3621 , and deliver material or stimulus to prospective targets.
- the eight arms 3640 are provided in two sets of four, with the four arms in each set being circumferentially spaced around the body 3630 , as shown in FIG. 35C .
- FIG. 35A The flexible structure ( FIG. 35A ) is guided through the throat to the site of interest.
- This device may be fitted with imaging/illumination systems to help guidance.
- FIG. 35B shows the system in location in a “retracted” position.
- the arms fitted with the patches are held in place against a spring load with pivot points.
- the arms are released ( FIG. 35C ), with the springs providing the force for location on the tissue.
- the device does not need to be exactly centralized as the arms are self-locating. By tension with wires, the arms are retracted, and the device is removed through the throat.
- the arms are replaced by an inflatable structure (a “sock”) fully coated by the micro-nanoprojections on the outside surface.
- a “sock” When deflated, this sock would be held in a structure which would look similar to FIG. 35A on the outside.
- the sock When in place, the sock would be inflated via a pressurized gas, locating on the tissue wall. This approach would be particularly useful where large surfaces need targeting, such as the lung.
- the pressure is released with a valving arrangement and the sock collapses back into flexible targeting system and the device is removed.
- liver, kidney, heart are not as readily accessed as those described above.
- more invasive means are required to expose the site of interest before targeting.
- One example is a more compact “catheter” version of the described lower airway/lung targeting devices, reaching the site via keyhole routes.
- Another embodiment is surgery to fully open the site before application with the patch.
- the micro-nanoprojections may be fitted to patches for in-vitro targeting, allowing a high-throughput targeting of cells.
- larger patches with thousands and perhaps millions of projections could be mechanically lowered onto cell monolayers, and then removed, similar to a mechanical “press” arrangement. This could, for instance, allow a mass transfection of cells, in-vitro.
- cells are dynamically moving in a shallow fluid stream. As these cells move, they pass below large plates with thousands, and perhaps millions of micro-nanoprojections. These plates pressing into this cell layer repeatably, in a synchronized manner so that each pressing cycle targets the appropriate batch of cells.
Abstract
A device for delivery of material or stimulus to targets within a body to produce a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest. The device includes a number of projections for penetrating a body surface, with the number of projections being selected to produce a desired response, and the number being at least 500. A spacing between projections is also at least partially determined based on an arrangement of the targets within the body.
Description
- The current application is a continuation of U.S. Ser. No. 11/496,053 filed on Jul. 27, 2006, which is a continuation-in-part (CIP) of International Application Number PCT/GB2005/000336 which designates the U.S. and has an International Filing Date of 31 Jan. 2005 and which was published as International Publication No. WO2005/072630 on 11 Aug. 2005. The entirety of International Application Number PCT/GB2005/000336 is hereby incorporated herein by reference.
- The present invention relates to a device for delivery of material or stimulus to targets within a body to produce a desired response, and in particular to a device including a number of projections for penetrating a body surface. The invention can also relate to devices for delivering bioactive substances and other stimuli to living cells, to methods of manufacture of the device and to various uses of the device.
- The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that the prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavor to which this specification relates.
- In recent years, attempts have been made to devise new methods of delivering drugs and other bioactive materials, for vaccination and other purposes, which provide alternatives that are more convenient and/or enhanced in performance to the customary routes of administration such as intramuscular and intradermal injection. Limitations of intradermal injection include: cross-contamination through needle-stick injuries in health workers; injection phobia from a needle and syringe; and most importantly, as a result of its comparatively large scale and method of administration, the needle and syringe cannot target key cells in the outer skin layers (
FIG. 11(a) ). This is a serious limitation to many existing and emerging strategies for the prevention, treatment and monitoring of a range of untreatable diseases. - The skin structure is shown in
FIG. 11 , with a summary of key existing delivery methods. Non-invasive methods of delivery through the skin have been used, including patches, liquid solutions and creams. Their success is dependent upon the ability to breach the semi-permeable stratum corneum (SC) into the viable epidermis. Typically, larger biomolecules are unable to breach this barrier. - Alternatively, there are many more “invasive” means to breach the SC for pharmaceutical delivery to the viable epidermis. Simple methods include: tape stripping with an abrasive tape to or sandpaper and the application of depilatory agents. Amongst the more advanced technologies are electroporation, ablation by laser or heat, radiofrequency high voltage currents, iontopheresis, liposomes, sonophoresis. Many of these approaches remain untested for complex entities such as vaccines and immunotherapies. Moreover, they do not specifically deliver entities within key skin cells.
- Needle-free injection approaches include the high-speed liquid jet injector, which had a rise and fall in popularity in the mid twentieth century-and has recently seen a resurgence (Furth, P. A., Shamay, A. & Henninghausen, L. (1995) Gene transfer into mammalian cells by jet injection. Hybridoma, 14:149-152.). However, this method delivers jets of liquid to the epidermis and dermis (labelled (c) in Fig A), usually with a diameter >100 μm and not within key cells. Furthermore, as a result of the concentrated jet momentum, many skin cells die. Delivery into the dermis also leads to patients reporting pain from injection.
- The ballistic, needle-free delivery of microparticles (or gene gun) offers a route for delivering biological agents directly into cells of the skin. In this needle-free technique, pharmaceutical or immunomodulatory agents, formulated as or coated to particles, are accelerated in a high-speed gas jet at sufficient momentum to penetrate the skin (or mucosal) layer and to achieve a pharmacological effect. A schematic of microparticles in the skin following ballistic delivery is shown in
FIG. 11(b) . The ability of this “scatter gun” approach to deliver genes and drugs to epidermal cells is highly limited and sensitive to biological variability in skin properties on the dynamic high strain rate ballistics process. These effects are discussed in Kendall, M. A. F., Rishworth, S., Carter, F. V. & Mitchell, T. J. (2004) “The effects of relative humidity and ambient temperature on the ballistic delivery of micro-particles into excised porcine skin.” J. Investigative Dermatology, 122(3):739-746.).; and Kendall, M. A. F., Mitchell, T. J. & Wrighton-Smith, P. (2004) Intradermal ballistic delivery of microparticles into excised human skin for drug and vaccine applications. J. Biomechanics, 37(11):1733-1741. - First, the ballistic delivery of particles into the skin to target epidermal cells is extremely sensitive to the small variations in the stratum corneum-including the stratum corneum thickness, which varies massively with body site, age, sex, race and exposure to climatic conditions. (The quasi-static loading of skin with micro-nanostructures would be less sensitive to these differences).
- Second, it has been shown that even when all these parameters are strictly controlled-and the only parameter varied is the climatic relative humidity (15%-95%), or, independently, temperature (20° C.-40° C.)-the result is a large variation in penetration depth. These results are shown in
FIG. 12 , with particle penetration as a function of ambient relative humidity (FIG. 12A ) and ambient temperature (FIG. 12B ) plotted along with theoretical calculations of particle penetration and measured stratum corneum thickness. This variation alone is significant and sufficient to make the difference between particles breaching the stratum corneum, or not. - The compound effect of these two (and other) sources of variability is the gene gun/biolistics process does not consistently target epidermal cells-leading to inconsistent biological responses (e.g., in DNA vaccination).
- Interestingly, it has also been shown that the high strain-rate loading of the skin under ballistic particle impact (approximately 106 per second) increases the stratum corneum breaking stress by up to a factor of 10 compared to quasi-static values-due to a ductile-to-brittle change in the skin mechanical properties. This means that the tissue is more difficult to penetrate as the particle impact velocity is increased. Therefore it is desirable to devise a way to deliver micro/nanostructures to the skin at lower strain-rates than the ballistic approach to exploit the weaker stratum corneum.
- When the microparticles are delivered to the skin, it is unclear whether there are any adverse longer term effects. For example, in the case of insoluble particles, many of them slough off with the usual skin turnover. However, gold particles have been detected in the lymph nodes following ballistic particle delivery-presumably by migration with Langerhans cells. Uncertainty of adverse effects of these delivered materials would be removed by delivery routes that do not leave such materials in tissue site.
- Moreover, when the microparticles successfully target cells, there is a significant probability they kill the cells they target. Consider a typical ballistic delivery condition: over 1 million 2-3 um diameter gold particles coated in DNA to the skin at 400-600 m/s, over a target diameter of 4 mm (Kendall, M. A. F., Mulholland, W. J., Tirlapur, U. K., Arbuthnott, E. S. & Armitage, M. (2003) Targeted delivery of micro-particles to epithelial cells for immunotherapy and vaccines: an experimental and probabilistic study. 6th International Conference on Cellular Engineering. Aug. 20-22 2003, Sydney, Australia.). Reported experiments with these conditions using cell death stains (ethidium bromide/acridin orange) show that microparticles impacting the skin do kill cells (McSloy, N. J., Raju, P. A. & Kendall, M. A. F. (2004) The effects of shock waves and particle penetration in skin on cell viability following gene gun delivery. British Society for Gene Therapy, 1st Annual Conference. Oxford, UK, Mar. 28-30 2004; Raju, P. A. & Kendall, M. A. F. (2004) Epidermal cell viability following the ballistic delivery of DNA vaccine microparticles. DNA Vaccines2004-the Gene Vaccine Conference. 17-19 Nov. 2004, Monte Carlo, Monaco.).
-
FIG. 13A shows the percentage of cells that had membrane rupture (i.e., death) as a function of the localized particle channel density. InFIG. 13B we see schematically the way the data inFIG. 13A was achieved, relating “tracks” left by particle penetration to the death of cells in a layer of the viable epidermis. Clearly,FIG. 13A shows that at a channel density above 0.01 channels/micron, all the cells in that layer are dead. Indeed,FIG. 13C shows that cells are killed when the particle is passing up to 10 μm outside of the cell boundary. The mechanism of cell death is due to the propagation of stress and shock waves in the skin generated by the rapid deceleration of the microparticles (McSloy et al. (2004)). The rapid rise time of these stress waves in the skin, and their magnitude both contribute to cell death and the results are consistent with the findings reported by Doukas, A. G. & Flotte, T. J. (1996). Physical characterization and biological effects of laser-induced stress waves. Ultrasound in Medicine and Biology, 22(2):151-164. The effects of shock waves and particle penetration in the skin on cell viability following gene gun delivery. Masters Thesis, Department of Engineering Science, University of Oxford.). This mechanism of ballistic particle penetration killing cells negatively affects the ability of the direct and efficient delivery of genes and drugs to the cells. - This cell death effect of ballistic particle delivery could be reduced by significantly decreasing the particle size to the nanometer regime-thereby reducing the stresses on the cells. However, another limitation of the gene gun is that it is unsuitable in delivering sub-micron sized particles to cells. This is illustrated by the following. As reported (Kendall, M. A. F., Mitchell, T. J. & Wrighton-Smith, P. (2004) Intradermal ballistic delivery of micro-particles into excised human skin for drug and vaccine applications. J Biomechanics, 37(11):1733-1741), and shown in
FIG. 14 , ballistic particle penetration is proportional to the particle impact parameter, pvr, which is the product of the particle density (p), velocity (v) and radius (r). This parameter is also proportional to the particle momentum per-unit-area, which has been shown to drive the mechanism of particle penetration depth (Mitchell et al. (2003)). FromFIG. 14 , we see a 1 μm radius gold particle (density 18000 kg/m3) would need to impact the skin at ˜600 m/s in order to penetrate to reach cells ˜20 μm into the skin. - Experimental results show that reducing the particle radius, say, by an order of magnitude, to 100 nm, and placing it in a standard biolistic device leads to negligible particle impact in the skin. Indeed from
FIG. 14 we see delivery to a 20 μm depth would need an impact velocity of ˜6000 m/s, which is impractical for two reasons: 1) these hypervelocity conditions can not be safely achieved with a system configured for human use (they are usually achieved with massive free-piston shock tunnels); 2) even if 6000 m/s was obtained in the free-jet, a gas impingement region above the skin would seriously decrease the particle velocity-it is possible that the particle would not even hit the skin at all. Interestingly if a method was conceived to safely and practically deliver nanoparticles to the skin at higher velocity (e.g., the stated case of an 100 nm radius gold particle at a velocity of ˜6000 m/s), the cell death benefit of smaller scale would be offset by higher peak stresses-killing more cells-and higher strain rates that are likely to further “toughen” the skin, making delivery even more difficult. - In conclusion, these collective facts rule out the gene gun as a viable option for delivering nanoparticles and therefore precludes it from many of the developments in biomolecules, drugs and sensors at this scale.
- The huge research effort in micro- and nanotechnologies provides tremendous potential for simple and practical cell targeting strategies to overcome many limitations of current biolistic (and other) cell targeting approaches. For example,
FIG. 11(c) shows that the most conceptually simple and appealing approach to gene delivery is the direct injection of naked DNA to live cell nuclei at a sub-micrometer scale that does not adversely damage the cell (Luo, D. & Saltzman, W. M. (2000) Synthetic DNA delivery systems. Nature Biotechnology, 18:33-36). Cell death is minimized by both the sub-micrometer scale of the injector and the low, quasi-static strain-rate of the probe (compared to ballistic delivery) resulting in low stress distributions. Although this is a very efficient gene and bioagent delivery route, the to drawback is that such precise targeting by direct microinjection can only be achieved one cell at a time and with great difficulty to the operator in vivo. Hence, the method is slow, laborious and impractical. - Researchers have overcome some of these disadvantages for transdermal drug delivery by fabricating arrays of micrometer-scale projections (thousands on a patch) to breach the stratum corneum for the intradermal delivery of antigens and adjuvants to humans and other mammals.
- In the scientific literature, the first description of this technique appears to be the paper Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery. S. Henry et al, J. Pharmaceutical Sci. vol. 87(8) p 922-925 (1998), with the accompanying patent of U.S. Pat. No. 6,503,231. The objective of U.S. Pat. No. 6,503,231 is to provide a microneedle array device for relatively painless, controlled, safe, convenient transdermal delivery of a variety of drugs and for biosampling. This is achieved by the microneedles breaching the tissue barrier (e.g., for skin: the stratum corneum) and then the therapeutic or diagnostic material is injected through the hollow microneedles into the tissue. Specifically, in
claim 1 of U.S. Pat. No. 6,503,231, it is stated that the microneedles are to be hollow, with a length of 100 μm-1 mm, andclaim 3 states the width of 1 μm-100 μm, with subsequent claims stating ways the hollow needles can be connected to reservoirs for the injection of liquids, fabrication methods, materials and examples of drugs to be delivered. Thus, U.S. Pat. No. 6,503,231 describes a patch suitable for delivering materials and/or energy across tissue barriers. The microneedles are hollow and/or porous to permit drug delivery at clinically relevant rates across skin or other tissue barriers, without damage, pain, or irritation to the tissue. - Other related microneedle devices in the patent literature are U.S. Pat. Nos. 5,527,288 and 5,611,806. More recently published patent applications on this topic are WO02/085446, WO02/085447, WO03/048031, WO03/053258 and WO02/100476A2.
- These microneedles array patch technologies have achieved only limited success to date. Generally, there are a range of approaches configured to breach the stratum corneum to allow an enhanced take-up of drug in the viable epidermis. Although this has not been discussed in the patents referred to above, based upon reported research on ballistic particle delivery and cell death, the low strain rate of application, combined with the cases of smaller projections are likely to induce a lower incidence of cell death near the tips, than ballistic microparticle to delivery. Also, unlike ballistic microparticle delivery, these projections are removed from the tissue-alleviating the possibility of adverse effects of “carrier” materials delivered to the body, long term.
- However, unlike biolistic targeting (
FIG. 11(b) ), and the direct injection of cells (FIG. 11(c) ), these microneedle arrays do not have the advantage of readily and directly targeting inside the skin cells. This cellular/organelle targeting capability is key in a range of existing and potential methods of vaccination, gene therapy, cancer treatment and immunotherapy (Needle-free epidermal powder immunization. Chen et al, Expert Rev. Vaccines 1(3) p265-276 (2002)) and diagnostic technologies. - Whilst U.S. Pat. No. 5,457,041 describes a patch for targeting cells, this is only suitable for use in vitro, and requires specialized apparatus to direct the micro-needles towards identified cells. The apparatus uses a microscope, to allow an operator to locate the cells in the sample tissue, and then direct the application of the micro-needles appropriately. As a result, this makes the device unsuitable for use in clinical environments, and limits the ability of the device to elicit a desired biological response.
- Therefore, there still remains a need to provide projection-based technology which achieves a more accurately directed delivery of the active agent or stimulus to the desired site of action surrounding or within cells, without appreciable damage to them.
- In a first broad form the present invention provides a device for delivery of material or stimulus to targets within a body to produce a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest, the device including a number of projections for penetrating a body surface, and wherein:
- a) the number of projections is selected to produce a desired response, the number being at least 500; and,
- b) a spacing between projections is at least partially determined based on an arrangement of the targets within the body. Typically the number of projections is selected by:
- a) determining a likelihood of a projection targeting at least one of the targets;
- b) determining a number of targets to be targeted; and,
- c) determining the number of projections using the determined likelihood and the determined number of targets.
- Typically the likelihood Pcontact of a projection targeting a target of interest is at least partially based on:
-
- ii) where:
-
- (a) Vlayer is the volume of the layer containing targets,
- (b) Vtar is the volume including the target of interest to which material or stimulus can be delivered.
- Typically the number of targets to be targeted depends on the number of targets that need to be transfected to produce the desired response.
- Typically the number of targets to be targeted is at least one of:
- a) at least 10;
- b) at least 100;
- c) at least 1000;
- d) at least 10000;
- e) at least 100000;
- f) at least 1000000; and,
- g) at least 10000000.
- Typically the number of projections is at least one of:
- a) at least 10;
- b) at least 100;
- c) at least 1000;
- d) at least 10000;
- e) at least 100000;
- f) at least 1000000; and,
- g) at least 10000000.
- Typically a maximum number of projections is based on at least one of:
- a) the total surface area of the target site available;
- b) a minimum projection spacing (S); and,
- c) an upper limit in active material or stimulus to be delivered
- Typically the projection spacing is based at least partially on at least one of:
- a) a size of the targets of interest; and,
- b) a spacing between the targets of interest.
- Typically the spacing between at least some of the projections is selected to avoid multiple projections targeting a single target of interest.
- Typically the spacing between at least some of the projections is selected to be greater than a diameter of the targets of interest.
- Typically the spacing between at least some of the projections is selected to be approximately equal to the spacing between the targets of interest.
- Typically the spacing S between at least one of:
- a) 1 μm≤S≤10000 μm; and,
- b) 10 μm≤S≤200 μm.
- Typically projection dimensions are based at least partially on an arrangement of targets within the body.
- Typically at least some of the projections have a diameter of at least one of:
- a) less than the size of targets; and,
- b) of the order of the size of targets within the targets.
- Typically at least some of the projections have a projection length at least partially based on a depth of the targets below a surface of the body against which the device is to be applied in use.
- Typically the projections include a support section and a targeting section.
- Typically the targeting section has a diameter of less than at least one of:
- a) 1μm; and,
- b) 0.5 um.
- Typically a length for the targeting section is at least:
- a) less than 0.5 um; and,
- b) less than 1.0 um; and,
- c) less than 2.0 um.
- Typically a length for the support section is at least partially based on a depth of the targets below a surface of the body against which the device is to be applied in use.
- Typically the length for the support section is at least partially determined in accordance with properties of a surface of the body against which the device is to be applied in use.
- Typically at least one of a support section length and the number of projections is at least partially based on a likelihood of a projection penetrating the targets:
-
- where:
- (a) σ is the standard deviation from a mean location, accounting for the skin surface undulations.
- (b) D is a distance of the targets below a surface of the body against which the device is to be applied in use;
- (c) Q is a number of standard deviations from a mean level of the surface of the body at which the device comes to rest in use;
- (d) B is a length of the support section; and,
- (e) T is a length of a targeting section.
- Typically a length for the support section is at least one of:
- a) for epidermal delivery <200 μm;
- b) for dermal cell delivery <1000 μm;
- c) for delivery to basal cells in the epithelium of the mucosa 600-800 μm; and,
- d) for lung delivery of the order of 100 μm in this case.
- Typically the length of the delivery end section is greater than the target dimension.
- Typically at least some of the projections within a targeting configuration have different dimensions.
- Typically the projections are solid.
- Typically the projections are non-porous and non-hollow.
- Typically at least part of at least some of the projections are coated with a bioactive material.
- Typically at least part of at least some of the projections are coated with a non-liquid material.
- Typically at least part of a targeting section of at least some of the projections are coated.
- Typically the coating is at least one of:
- a) nanoparticles;
- b) a nucleic acid or protein;
- c) an antigen, allergen, or adjuvant;
- d) parasites, bacteria, viruses, or virus-like particles;
- e) quantum dots, SERS tags, raman tags or other nanobiosensors;
- f) metals or metallic compounds; and,
- g) molecules, elements or compounds.
- Typically the device includes at least some uncoated projections to thereby stimulate or perturb the targets in use.
- In one example, the device includes:
- a) a flexible substrate; and,
- b) a number of patches, each patch including a number of projections for penetrating a body surface, the number of patches being mounted to a flexible backing.
- In a second broad form the present invention provides a method of selecting constructional features for a device a for delivery of material or stimulus to targets within a body to produce to a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest, the device including a number of projections for penetrating a body surface, and wherein the method includes:
- a) selecting the number of projections to produce a desired response, the number being at least 500; and,
- b) selecting a spacing between projections at least partially based on an arrangement of the targets within the body.
- In a third broad form the present invention provides a method of fabricating a device for delivery of material or stimulus to targets within a body to produce a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest, the device including a number of projections for penetrating a body surface, and wherein the method includes:
- a) selecting the number of projections to produce a desired response, the number being at least 500;
- b) selecting a spacing between projections at least partially based on an arrangement of the targets within the body; and,
- c) fabricating the device using the selected number of projections, and the selected spacing
- In a fourth broad form the present invention provides a method of treating a subject the method including using a device for delivery of material or stimulus to targets within the subject's body to produce a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest, the device including a number of projections for penetrating a body surface, and wherein:
- a) the number of projections is selected to produce a desired response, the number being at least 500; and,
- b) a spacing between projections is at least partially determined based on an arrangement of the targets within the body.
- In a fifth broad form the present invention provides apparatus for delivery of material or stimulus to targets of interest within a body to produce a desired response, the targets being at least one of cells of interest, cell organelles of interest and cell nuclei of interest, the apparatus including:
- a) a structure;
- b) a plurality of projections movably mounted to the structure for penetrating a body surface;
- c) an actuator for selectively releasing the plurality of projections mounted on the movable structure from a retracted position such that upon contact with the body surface the plurality of projections enter the body.
- Typically the plurality of projections are provided on a patch.
- Typically the actuator includes:
- a) a spring coupled to the structure and the at least one patch; and,
- b) a releasing means for releasing the spring, to thereby release the plurality of projections from the retracted position.
- Typically the releasing means is a tensioned string for holding the spring in compression.
- Typically the releasing means is manually operated.
- Typically the apparatus includes a number of arms, each arm being coupled to a respective spring and including a first end pivotally mounted to the structure and a second end coupled to a respective plurality of projections, and wherein activation of the releasing means causes each of the arms to be released from a retracted position to thereby cause projections on the respective patch to enter the body.
- Typically the arms are circumferentially spaced around a part of the structure.
- Typically the structure is flexible structure allowing the structure to be guided to a desired location within the body.
- Typically the releasing means includes an inflatable structure coated with the plurality of projections.
- Typically:
- a) the number of projections is selected to produce a desired response, the number being at least 500; and,
- b) a spacing between projections is at least partially determined based on an arrangement of the targets within the body.
- An example of the present invention will now be described with reference to the accompanying drawings, in which:
-
FIGS. 1A and 1B are schematic diagrams of an example of device for delivery of material or stimulus to targets within a body; -
FIG. 1C is a schematic diagram of an example of the device ofFIG. 1A in use; -
FIGS. 1D and 1E are schematic diagrams of examples of projections used in the device ofFIG. 1A ; -
FIG. 2 is a flow chart of an example of the process of selecting device parameters; -
FIGS. 3A and 3B are schematic diagrams of alternative examples of the device ofFIG. 1A in use taking into account variations in surface properties and target locations; -
FIG. 4 is a flow chart of a second example of the process of selecting device parameters; -
FIGS. 5A and 5B show examples of the relationship between the number of projections and total hits for targeting Langerhans cell nuclei and Langerhans cells respectively; -
FIG. 6 shows an example of the relationship between the total number of targeted LC and the patch surface area as a function of projection spacing geometry; -
FIG. 7 is an SEM photograph of an example of a constructed patch; -
FIG. 8 shows an example of the Transfection Probability vs Needle Spacing, for targeting of Langerhans cells; -
FIGS. 9A to 9C show examples of projection viability against the projection height, for variation in the skin surface level standard deviation of 20 μm, 40 μm and 60 μm respectively; -
FIG. 10 is a schematic diagram of an alternative example of a patch; -
FIG. 11 illustrates a schematic cross-section of skin structure: (a) half-section scale of a typical smaller needle and syringe (diameter ˜0.5 mm); (b) penetration of microparticles following biolistic delivery; (c) idealized direct injection of a cell nucleus; (d) a micro-nanoprojection array; -
FIGS. 12A and 12B illustrate the effects of relative humidity (A) and ambient temperature (B) on to ballistic particle penetration into the skin; -
FIG. 13A is a graph showing the relationship between percentage cell death (membrane rupture) and particle density (McSloy (2004) MA Thesis, University of Oxford); -
FIG. 13B is a diagram showing how the data forFIG. 13A was retrieved (McSloy (2004) MA Thesis, University of Oxford); -
FIG. 13C is a graph showing membrane rupture versus distance of cell pathway; -
FIG. 14 illustrates the particle penetration parameter (pvr) vs. penetration depth obtained by the ballistic delivery of gold microparticles into skin (Kendall et al. (2004), Journal of Biomechanics); -
FIG. 15 shows examples of organelles within the cell (http://niko.unl.edu/bs101/notes/chapter4.html); -
FIG. 16 is a schematic diagram of the skin structure; -
FIG. 17 is an example of a histology micrograph of human skin with a Langerhans Cell (L) and Keratinocyte (K) stained. From Roitt et al, the height of which is approximately 50 μm; -
FIG. 18 illustrates the distribution of Langerhans Cells in a mouse ear (Kendall M. A. F., Mulholland W. J., Tirlapur U. K., Arbuthnott E. S., and Armitage, M. (2003) “Targeted delivery of micro-particles to epithelial cells for immunotherapy and vaccines: an experimental and probabilistic study”, The 6th International Conference on Cellular Engineering, Sydney, August 20-22); -
FIGS. 19A and 19B illustrate (A) a sample of canine buccal mucosal tissue and (B) the structure of the mucosa, Mitchell, T (2003) DPhil Thesis, Department of Engineering Science, University of Oxford; -
FIG. 20 illustrates the shape and dimensions of examples nanoneedles; -
FIG. 21 illustrates the maximum needle length vs. nanoneedle diameter calculated using expression (3) and the Young's Modulus (E) values for Gold, Titanium, ZnO, PGCA, Silver and Tungsten (respectively: 77.2, 116, 111.2 and 7 GPa); -
FIGS. 22A-22C are a Transmission Electron Micrographs (TEM) of a micro-nanoprojection electropolished from tungsten at (A) ×500 magnification, (B) a bright field ×33000 magnification and (C) a dark field ×33000 magnification; -
FIGS. 23A and 23B illustrate fluorescent microscope images of tungsten rods, (A) uncoated and (B) coated in eGFP plasmid DNA immersed in an ethidium bromide solution; -
FIGS. 24A-24D are examples of an optically sectioned Multi-Photon Microscopy (MPM) images of the agar after insertion of a DNA coated tungsten probe (A) on the surface (B) at a depth of 13 μm (C) at a depth of (32 μm). Also shown in (D) is an optical section at 32 μm of agar gel following insertion of a probe without a DNA coating; -
FIG. 25 illustrates a photomicrograph of a micro-nanoprojection electropolished from tungsten used in skin tissue indentation experiment with scale bar; -
FIG. 26 illustrates two sample load-displacement curves in freshly excised mouse ear tissue obtained with the micro-nanoprojection shown inFIG. 25 ; -
FIG. 27 is a plan view diagram of possible alternative geometry of the nanoneedle; -
FIG. 28 illustrates an example of a nanoneedle array or patch device; -
FIG. 29 is a schematic diagram of an example of the nanoneedle array produced with 2PLSM; -
FIGS. 30A-30C illustrate sequences for producing a mask; -
FIG. 31 is a schematic diagram of an example of a “Stepped” nanoneedle; -
FIGS. 32A and 32B illustrate examples of an intradermal application of nanoneedle patches; -
FIG. 33 is a schematic diagram of an example of an applicator, fitted with the patch for mucosal delivery; -
FIG. 34 illustrates the major respiratory organs; and, -
FIGS. 35A-35C are schematic diagrams of an example of a deployable patch structure for targeting the lower airway and lung. - An example of a device for delivering material or stimulus targets within a body will now be described with reference to
FIG. 1A to 1E . - In this example, the device is in the form of
patch 100 having a base 120 and a number ofprojections 110. Thebase 120 andprojections 110 may be formed from any suitable material, as will be described in more detail below, but in one example, are formed from a silicon type material, allowing the device to be fabricated using fabrication processes such as vapor deposition, silicon etching, Deep Reactive Ion Etching (DRIE), or the like. - In the example shown, the device has a width W and a breadth B with the
projections 110 being separated by spacing S. - In use, the
patch 100 is positioned against a surface of a subject, allowing the projections to enter the surface and provide stimulus or material to targets therein. An example of this is shown inFIG. 1C . - In this example, the
patch 100 is urged against a subject's skin shown generally at 150, so that theprojections 110 pierce theStratum Corneum 160, and enter theViable Epidermis 170 to reach targets of interest, shown generally at 180. - Examples of suitable projections are shown in more detail in
FIGS. 1D and 1E . - In each example, the projection generally includes a targeting
section 111, intended to deliver the material or stimulus to targets within the body, and asupport section 112 for supporting the targetingsection 111. - In the example of
FIG. 1D , the projection is formed from a conically shaped member, which tapers gradually along its entire length. In this example, the targetingsection 111 is therefore defined to be the part of the projection having a diameter of less than d2. - As an alternative example however, the structure of the projection may vary along its length to provide a
targeting section 111 with a designed structure. In this example, the targetingsection 111 is in the form of a substantially cylindrical shape, such that the diameter d1 is approximately equal to the diameter d2. In either case, the support section has a length a, whilst the targetingsection 111 has a length l. The diameter of the tip is indicated by d1, whilst the diameter of the support section base is given by d3. - In use, the device is intended to deliver material or stimulus to specific targets within the body. Thus, rather than just operating to deliver material to, for example, the blood supply, or tissue within the body, the device is configured so as to ensure material or stimulus reaches specifically selected targets such as cells, cell organelles, cell nuclei, or the like. Furthermore, the device is designed to achieve this without requiring specific directional control of device application so as to ensure the projections reach the targets. In other words, the device is intended to ensure successful delivery of material or stimulus to specific targets within a subject, without requiring that the projections are aimed at the specific targets, but rather by allowing general placement in a suitable region. Thus, for example placement may to be as simple as placement anywhere on the user's skin in order to target Langerhans cells of the device on the subject.
- To achieve this, the device is provided with a particular configuration to ensure successful targeting. Accordingly, it is generally necessary to select patch parameters, such as the number of projections N, and spacing S between projections, to be dependent upon the intended use of the device. A mechanism for achieving this will now be described with reference to
FIG. 2 . - In this example, at
step 200 it is necessary to determine an arrangement of desired targets. This may be achieved in any one of a number of ways and will depend on the nature of the targets. Thus, for example if the targets are a specific type of cell, cell nuclei, or cell organelle, this information can be determined from literature or studies detailing the typical location of cells, or other targets, within the body. - At step 210 a number of projections required to elicit a desired response is determined. This can depend on a range of factors, such as the ability of projections to reach the desired targets, the ability of the projections to deliver material or stimulus to the targets, as well as the ability of the targets to elicit a response. Thus, for example, non-uniform distribution of targets within the body means that it is not possible to assume that each projection will deliver material or stimulus to a desired target during use of the device.
- The number of projections may be determined in any one of a number of ways. Thus, for example, this can include selecting a number of projections from a predetermined list outlining the number of projections required for specific uses. However, if the number has not previously been determined, for example, if the target has not previously been used, then some form of analysis is typically required.
- In one example, this is achieved by analyzing the distribution of targets within the body and then determining a likelihood of any one projection reaching a target. An indication of the number of targets to which stimulus or material must be delivered can then be used to determine an indication of the number of projections required.
- As will be described in more detail below, in general a desired response cannot be obtained with less than 500 projections. More typically at least 750 projections are required. However, in some instances, even more projections such as at least 1000, 2000, 5000, 7500, 10,000, 100,000, 1,000,000 or even 10,000,000 may be used, and specific examples will be described in more detail below.
- Once a number of projections has been selected, a projection spacing is determined at least partially based on the target arrangement at
step 230. - The spacing may be determined in any one of a number of ways, but typically includes setting a lower spacing limit to ensure that only a single projection delivers material or stimulus to a single target. The maximum spacing S is typically set based on the required patch size (B×W) and/or the spacing between targets. It will be appreciated that whilst the example shown is rectangular, alternative shapes, such as circular, elliptical, hexagonal, or the like, may be used and that the use of a rectangular patch is for the purpose of example only.
- At step 240 a patch is fabricated in accordance with the selected patch parameters, including the number of projections N and the spacing S. Fabrication may be achieved in a number of ways, as will be described in more detail below.
- By selecting at least a number of projections N required to elicit a desired response, this allows a patch to be provided with sufficient projections to ensure that a desired response is achieved by delivery of material or stimulus to specific targets. Furthermore, by utilizing a probabilistic analysis, this technique ensures that the required targeting will be achieved without requiring the individual projections to be aimed at the individual targets. Thus, in contrast to other prior art techniques, the
patch 100 may simply be inserted into a body at a general location, and does not need specialized apparatus to direct the projections towards specific cells or other targets within the body. - A more detailed example of the process will now be described. For the purpose of this example the patch configuration, and in particular the insertion of the patch into the body is as shown in
FIG. 3A andFIG. 3B . In particular, this example is modified to take into account variations and undulations in the surface of the body, as well as variations in target depth. - In this example, the
patch 100 is urged against thesurface 300 of theStratum Corneum 310. Thesurface 300 includes undulations, resulting in amean surface level 320 shown by dotted to lines, with thepatch base 120 resting against thesurface 300 at a distance y above themean level 320. - The
projections 110 enter theViable Epidermis 330 to deliver material or stimulus totargets 340, which are generally arranged in alayer 350, referred to as the target layer. The Dermis is also shown at 360 in this example. - In the example of
FIG. 3A thetargets 340 are provided in a single layer with each target being approximately a constant depth Dc below theStratum Corneum 310. In this example, the layer height hlayer is therefore approximately equal to the diameter of the targets dc, with the targets separated by a spacing Sc. It would be appreciated by persons skilled in the art that in this instance the targets may therefore be Langerhans Cells, or the like. - In the example of
FIG. 3B , thetargets 340 are dispersed vertically through theViable Epidermis 330, so that thetarget layer 350 has a greater height hlayer than in the previous example. Additionally, in the example, the depth of the targets is calculated on the basis of the mean layer depth, as shown. - An example of the process for selecting a device configuration to take into account the arrangements in
FIGS. 3A and 3B will now be described in more detail with reference toFIG. 4 . - At step 400 a desired target and corresponding target arrangement is determined.
- The target selected will depend on the intended application. Thus, for example, the target may be cells, cell nuclei or cell organelles. Additionally, different types of cells may need to be targeted. Thus, for example, cells such as Langerhans Cells may be stimulated for providing an immunological response, whereas cells such as squamous or basal cells may need to be targeted to treat cell carcinoma. An example of other potential targets will be described in more detail below.
- Determining the target arrangement typically involves determining parameters relating to the target such as target depth Dc, target diameter dc, layer height hlayer and target spacing Sc. Thus these correspond to the parameters outlined above with respect to
FIGS. 3A and 3B . - At
step 410 the diameter of the targetingsection 111 for at least some of the projections is determined. - The diameter of the targeting section is typically based on the size of the target. Thus, for example, the diameter of the targeting section does not usually exceed the scale of the target, as this may lead to target necrosis. In general this leads to an upper limit for targeting section diameters of:
-
d 1≤1 μm and d2≤2 μm. - However, it will be appreciated that smaller diameters such as 500 nm, or below, may be used, as described in specific examples below. Additionally or alternatively, it may be desirable to include projections having a larger diameter, for example to cause cell necrosis. In one example, at least some of the projections have a diameter greater than 1 82 m, which can be used to induce bystander responses. In other examples, all of the projections have a diameter greater than 1 82 m to thereby kill targets.
- At
step 420 the projection length is determined. In one example, the projection length is based on the depth of the target layer Dc and the layer height hlayer. Thus, the length of the supporting section of a can be selected so that the targetingsection 111 at least reaches the target layer within the body, but typically does not extend a large distance beyond the target layer. In this example, the length a of thesupport section 112 is typically given by: -
(D c +h layer/2)≥a≥(D c −h layer/2) - Similarly the length l of the targeting
section 111 is typically selected to be at least equal to the layer height hlayer to ensure penetration of targets within thelayer 340, so that: -
l≥h layer - As shown in the examples of
FIGS. 3A and 3B however the skin of the body is not generally flat but is undulating. As a result, this means that thebase 120 of thedevice 100 generally sits a distance y above themean skin level 320. To take this into account, the length of thesupport section 112 may be increased such that. -
(y+D c +h layer/2)≥a≥(y+D c −h layer/2) - Alternatively, a probabilistic analysis can be used to determine the likelihood of a viable to projection of a given length reaching the targets with the body. This will depend on a number of factors, examples of which, for the targeting of Langerhans cells (LC), include:
- The surface of the skin is normally distributed
- It is assumed that the LC reside exactly 17 82 m below the surface just above the basal layer (Arbuthnott, 2003, Emislom et al, 1995), in the case of the Balb/c mouse ear. In reality, there may be a small variation in depth of LC. For example, the depth of LC varies significantly from site to site within a given animal of human model, and there is typically variation in the depth of LC between models-for example the depth of LC in humans is greater than in mice.
- The patch typically comes to rest two standard deviations away from the mean skin level
- The needles have a viable tip length of 20 82 m (i.e., l, (defined as 111) is 20 μm. Penetration by any other part of the needle other than this tip causes cell death.
- The skin's surface is normally distributed with mean 0 and standard deviation σ.
- Within the model:
- The Langerhans cells lie Dc microns directly below the skin's surface.
- The patch comes to rest Q standard deviations from the skin's mean level.
- The needles have body (unviable) length support section a and tip (viable) length l.
- In this example, the likelihood of viable targeting of targets at the defined depths (Pdepth) is given by:
-
- where:
- σ is the standard deviation from a mean location, accounting for the skin surface undulations.
- Dc is a distance of the cells of interest below a surface of the body against which the device is to be applied in use;
- Q is a number of standard deviations from a mean level of the surface of the body at which the device comes to rest in use;
- a is a length of the support section; and,
- l is a length of a targeting section.
- In this example it is assumed that the skin surface level is normally distributed on a local scale, which is typically a safe assumption based on histology samples, although if the area inspected is too large, global curvature invalidates the assumption. At first instance, it is assumed that the patch comes to rest at a distance y of two standard deviations away from mean skin level.
- The use of such a model allows support section and targeting section lengths a, l to be selected to ensure a predetermined probability of the targeting
section 111 successfully reaching the targets. In one example, the probability is selected to be one, to ensure successful delivery of the material or stimulus. Alternatively, lower probabilities may be selected, with this being taken into account in determining the number of projections provided, as will be described in more detail below. - At
step 430, the likelihood of a single targeting event is determined. In particular, this is the likelihood of a projection, assuming the projection reaches thetarget layer 350, of delivering material to or stimulus to arespective target 340. - In one example, it is assumed that the targeting
section 111 is effectively a point diameter cylinder that extends into thetarget layer 350. In this instance the likelihood of a single targeting event is given by the volume of the target divided by the volume of the layer. -
- where:
- Vlayer is the volume of the layer containing cells of interest,
- Vtar is the volume including the target to which material or stimulus can be delivered.
- In this regard it will be appreciated that the volume to which stimulus or material may be to delivered may be significantly greater than the size of the physical target itself, depending on the delivery mechanism used. Thus, for example, if material to be delivered to a cell is absorbed when placed within the vicinity of the cell, then the target volume Vtar will be larger than the volume of the cell.
- However, in a more detailed example, equation (2) still holds, but it can be assumed that the projection has its own volume (Vpro), and in this case the probability of contact is modified to change Vtar to take into account the additional probe volume. In one example, if the projection is as shown in
FIG. 1E , in which d1=d2, the volume of the targeting section within the target layer is given by: -
- where:
- Ntar is the number of targets, with diameter dc.
- Equation (3) can be modified to take into account variations in target size and shape, and probe size and shape. When d1 and dc are constant, equation (3) becomes:
-
V tar =N Tar(2d 1 +d c)2 d c ( 4 ) - So for a region of target layer of size z×z, where a projection reaches through the target layer, and containing a number of targets Ntar, the probability is given by:
-
- The above example assumes that the projection reaches fully through the target layer 350 (i.e., Pdepth=1). However, this may not occur, and accordingly the above described equation can be utilized to take into account the probability of the projection reaching the relevant cell layer, as described in equation (1) above.
- So the general expression for the probability of a projection targeting the targets of interest (e.g., key cells, nuclei, etc.), defined as Ptar is:
-
P tar =P contact ×P depth (6) - It will be appreciated that in the event that the projection lengths a, l are selected such that Pdepth=1, then Ptar=Pcontact.
- At
step 440 the number of targeting events required is determined. This is typically determined on the basis of studies performed indicating the number of targets to which material or stimuli must be delivered in order for a biological response to be affected. Often, this is determined by parametric empirical studies. - For example, when it is desired to deliver DNA to transfect Langerhans cells, at least one cell must be targeted. However, it is believed that to ensure a successful biological response, at least 10 cells, and more preferably at least 100 cells and up to or over 1,000 cells are targeted. It will be appreciated however that for different delivery mechanisms a different number of targets may be desirable.
- At
step 450, having determined the number of targeting events required (N), it is possible to use this and the probability of a single targeting event to determine a number of projections required, which is given by: -
N=T/P tar - where:
- T is the total number of delivery events required to produce the desired response.
- Often in immunotherapeutic and drug applications (including vaccines), T is defined as a range, that can vary significantly between application and/or model (i.e., animal or human).
- Specific examples of this are shown in
FIGS. 5A and 5B , for the targeting of Langerhans cell nuclei and Langerhans cells respectively. - In these examples it is assumed that:
- A Langerhans Cell (LC) penetrated by one needle remains viable. If it is penetrated by any more than one projection cell death occurs.
- When a projection contacts the target site (e.g., cell nucleus or cytosol), the desired biological “event” occurs each time. In reality, there is probability of the event happening. For example, if cell transfection is required, then the probability of this event through the delivery of DNA to nucleus via a projection is ˜0.9, whereas the probability of the same event from the coated projection entering only the cytoplasm is ˜0.1 (Nagasaki 2005).
- A dead cell cannot be transfected.
- Penetration by a needle with a diameter greater than 1 μm will cause cell death.
- LC are assumed as spherical with 10 μm diameter.
- Nuclei of LC are assumed to be spherical, with a diameter of 4 82 m (Arbuthnott, 2003).
- All LC lie just above the basal layer between the epidermis and dermis (as reported by Kendall et al. (2003).
- LC are oval with dimensions circa 11.25×6 μm but to simplify the model, the average of these two figures is taken as the diameter of 10 μm. In one example of young Balb/C mice the LC density is 895 cells/mm2 (Choi. et al 1987). With LC uniformly distributed in the suprabasal region (Numahara et al. 2001) this gives a center to center spacing of approximately 30 microns, justifying the spacing assumption. For simplicity, it is assumed that the LC spacing of 1000 cells/mm2, giving a planar spacing between cell centers of 32 μm.
-
FIG. 5A shows the relationship between the number of projections and total hits is given for thepatches 100 described above, with a range of depth probabilities (Pdepth), for targeting Langerhans cell nuclei. -
FIG. 5B shows the relationship between the number of projections and total hits is given for thepatches 100 described above, with a range of depth probabilities (i.e., the probability of a viable targeting of the target layer 350), for targeting Langerhans cells. - Typically this requires at least 500 projections and more typically at least 1,000 projections for targeting LC and 10,000 projections for targeting LC nuclei. Specific examples of this will be described in more detail below.
- At
step 460 the projection spacing (S) is then determined based on the target diameter and target spacing. It is usual to assume that no more than one projection should enter a single cell this; will typically lead to cell death. Accordingly, it is typical to select a projection spacing which is at least greater than a cell diameter, such that: -
S≥d c - More preferably it is typical to select a size for the projection spacing based on a preferred overall patch size. In particular, it is preferred that patches are made below a certain upper limit defined by practical utility to the targeting site of the patient or animal.
- For example, if the targeting site is the skin of the human abdomen, then the surface area could be approaching the surface area of the abdomen (e.g., ˜400 cm2, or 20×20 cm, say). It would not be practical to achieve such larger surface areas over surfaces with “bulk” curvature (such as the abdomen example, or arm) with one large rigid patch. In one example, surface area can be achieved using the patch shown in
FIG. 10 . In this example, thepatch 100 is formed from severalsmaller patches 1000 provided on aflexible backing material 1010. The patch assembly could be extended to wrap around thepatient site 1020. - In any event, an upper limit on the spacing S is typically selected to ensure that the desired number of projections fit on a patch of the desired size.
- A specific example of this is shown in
FIG. 6 , in which the relationship between the total number of targeted LC (T) and the patch surface area (mm2) as a function of spacing geometry, is shown. In this example, the probability of penetration to the cell depth is assumed to be one (i.e., Pdepth=1) for simplicity. - Irrespective of this, the projection spacing S is typically of the order of spacing of the targets Sc.
- Once the spacing is selected the patch can be fabricated at
step 470. In general, this will typically require considerations are taken into account to ensure the projections are sufficiently robust to withstand penetration of the Stratum Corneum and Viable Epidermis without breaking. Example manufacturing processes will be described in more detail below, and an example of a constructedpatch 100 is shown inFIG. 7 . In this example, the device has 9795 projections, with a spacing of 70 82 m (S), over a surface area of 48 mm2. - In general, a number of factors regarding the patch fabrication should be noted.
- Typically the projections are solid, non-porous and non-hollow. The use of solid projections enhances the projection strength, thereby reducing the likelihood of projection breakage, which in turn helps maximize successful delivery of material or stimulus to the targets. Also, solid projections simplify device fabrication processes, allowing for the production of cheaper patches than for the case of porous or hollow projections. This in turn further enhances the suitability of the patch for use in medical environments.
- To achieve delivery of material, it is typical to coat at least the targeting
section 111 with a non-liquid bioactive material, such as DNA. - The
patch 100 may also be fabricated to perturb targets so as to induce “bystander” interactions. This may be used, for example, so that cell death is used to release molecules to activate nearby targeted cells. This can be achieved in a number of manners, such as by providing a mixture of coated and uncoated projections, as well as by providing projections of differing dimensions including clusters of more than 1 projection to target individual cells and/or larger scale tips to damage cells or other targets, upon insertion/residence/retrieval. - A number of specific examples will now be described.
- Transfection Probability
- In this example, which focuses on the transfection of Langerhans cells, a number of additional practical considerations may also be taken into account.
- In particular, if the model of a point targeting section with no radius is used, this predicts an idealized projection spacing S=6.5 μm, as used in the example of
FIG. 8 . In this case, the LC diameter is ˜10 μm, so that to satisfy the requirements set out above, namely that S≥dc, so S≥10 μm. - Also, for structural reasons, the diameter of the base of the projections d3 is likely to be above 6.5 μm, and a “clearance” will be needed between each projection, so for practical reasons, the minimum projection spacing (S) is at least 10 μm.
-
FIG. 8 shows an example of the Transfection Probability vs Needle Spacing, for targeting of Langerhans cells with a spacing of 32 μm. The S≥dc criterion and practical considerations of minimum size of the base d3 suggest the spacing is to at least be 10 μm, as discussed above. - Needle Length Optimization
- For this example, the sensitivity of needle length to standard deviation of the skin surface is shown in
FIG. 9A to 9C . In particular, these show the fraction of projections (Pdepth) that are smaller than 1 μm in diameter and penetrate to 17 82 m in the epidermis (the depth of LC), against the projection height, for skin level standard deviation of 20 82 m, 40 μm and 60 82 m respectively. - It is clear from this, that the magnitude of skin undulations has a strong influence over the choice of optimum projection length.
- Minimum Number of Projections
- In one example, for targeting a single LC nucleus the likelihood of contact of a projection is given by Pcontact=0.031, using equation (2) above, and data regarding LC nuclei size, set out in more detail below. The value of Pdepth defined in equation (1), above has a range of 0-1, and with N=500, Pdepth=0.064.
- Utilizing this, it can be seen that a viable range of lengths result in targeting of a single cell, as shown below.
-
SD Needle (roughness) length needed FIG. (μm) (T = 1; N = 500) 9A 20 >80 μm. 9B 40 >130 μm. 9C 60 >160 μm - All of these cases in the table above are well away from the optimal lengths for the projections (i.e., where Pdepth is a maximum in
FIGS. 9A-9C ), so they do represent a “poor” case scenario, where the device is not tuned well for the target (device tuning would be improved by reducing the needle length to closer to the optimal regions shown inFIG. 9A-9C , for example). However, the target of LC nuclei is very well defined. So, on balance, a minimum of 500 projections is needed before there is a reasonable statistical chance of just one targeting event. - It will be appreciated that it is typical however to deliver to more than one target, and accordingly, it is typical for a greater number of projections to be provided.
- For example, the direct targeting of 2 LC nuclei (i.e., T=2) would be achieved with the device configurations in the table above with 1000 projections (i.e., N=1000).
- Similarly, the direct targeting of 10 LC nuclei (i.e., T=10) would be achieved with the device configurations in the table above with 5000 projections (i.e., N=5000).
- In the case of targeting situations with a lower Pcontact, for instance in targeting a sparsely-populated dermal dendritic cell phenotype (not in a tightly defined layer like LC), greater than the minimum of 500 projections would be needed for at least one single targeting event. For example, if Pcontact is 1/10 of the stated LC case (i.e., Pcontact=0.0031), then applying a similar analysis, and adjusting for the deeper location of cells to maintain Pdepth=0.064, then 5000 projections would be needed for the one targeting event.
- Again, it will be appreciated that it is typical however to deliver to more than one target, and accordingly, it is typical for a greater number of projections to be provided.
- Maximum Number of Projections
- The upper limit of projections is typically defined by a range of parameters. These include the total surface area of the target site available, and the minimum projection spacing (S). For example, in previously stated case of a human abdomen, with the patch assembly wrapped around to the back (i.e., ˜800 cm2), and the minimum spacing for targeting cells (S=10 μm) results in 8,000,000 projections. Another consideration is the payload to be delivered to the target site, where for a given application there is an upper limit in active material or stimulus to be delivered. Here, if a given mass of active material is coated to a single projection, then the total number of projections would be selected such that the total payload is less than this upper limit.
- In any event, it will be appreciated from the above that it is typical to use at least 500 projections, but more typically at least 750, 1000, 2000, 5000, 7500, 10,000, 100,000 projections, and even as many as 10,000,000 projections.
- Delivery
- Illustrative stimuli or material that can be delivered with the device of the present invention include any or more of: small chemical or biochemical compounds including drugs, metabolites, amino acids, sugars, lipids, saponins, and hormones; macromolecules such as complex carbohydrates, phospholipids, peptides, polypeptides, peptidomimetics, and nucleic acids; or other organic (carbon containing) or inorganic molecules; and particulate matter including whole cells, bacteria, viruses, virus-like particles, cell membranes, dendrimers and liposomes.
- In some embodiments, the stimulus or material is selected from nucleic acids, illustrative examples of which include DNA, RNA, sense oligonucleotides, antisense oligonucleotides, ribozymes, small interfering oligonucleotides (siRNAs), micro RNAs (miRNAs), repeat associated RNAs (rasiRNA), effector RNAs (eRNAs), and any other oligonucleotides known in the art, which inhibit transcription and/or translation of a mutated or other detrimental protein. In illustrative examples of this type, the nucleic acid is in the form of an expression vector from which a polynucleotide of interest is expressible. The polynucleotide of interest may encode a polypeptide or an effector nucleic acid molecule such as sense or antisense oligonucleotides, siRNAs, miRNAs and eRNAs.
- In other embodiments, the stimulus or material is selected from peptides or polypeptides, illustrative examples of which include insulin, proinsulin, follicle stimulating hormone, insulin like growth factor-1, insulin like growth factor-2, platelet derived growth factor, epidermal growth factor, fibroblast growth factors, nerve growth factor, colony stimulating factors, transforming growth factors, tumor necrosis factor, calcitonin, parathyroid hormone, growth hormone, bone morphogenic protein, erythropoietin, hemopoietic growth factors, luteinizing hormone, glucagon, glucagonlike peptide-1, anti-angiogenic proteins, clotting factors, anti-clotting factors, atrial natriuretic factor, plasminogen activators, bombesin, thrombin, enkephalinase, vascular endothelial growth factor, interleukins, viral antigens, non-viral antigens, transport proteins, and antibodies. In still other embodiments, the stimulus or material is selected from receptor ligands. Illustrative examples of receptors include Fc receptor, heparin sulfate receptor, vitronectin receptor, Vcam-1 receptor, hemaglutinin receptor, Pvr receptor, Icam-1 receptor, decay-accelerating protein (CD55) receptor, Car (coxsackievirus-adenovirus) receptor, integrin receptor, sialic acid receptor, HAVCr-1 receptor, low-density lipoprotein receptor, BGP (biliary glycoprotien) receptor, aminopeptidease N receptor, MHC class-1 receptor, laminin receptor, nicotinic acetylcholine receptor, CD56 receptor, nerve growth factor receptor, CD46 receptor, asialoglycoprotein receptor Gp-2, alpha-dystroglycan receptor, galactosylceramide receptor, Cxcr4 receptor, Glvrl receptor, Ram-1 receptor, Cat receptor, Tva receptor, BLVRcp1 receptor, MHC class-2 receptor, toll-like receptors (such as TLR-1 to -6) and complement receptors.
- In specific embodiments, the stimuli or material are selected from antigens including endogenous antigens produced by a host that is the subject of the stimulus or material delivery or exogenous antigens that are foreign to that host. The antigens may be in the form of soluble peptides or polypeptides or polynucleotides from which an expression product (e.g., protein or RNA) is producible. Suitable endogenous antigens include, but are not restricted to, cancer or tumor antigens. Non-limiting examples of cancer or tumor antigens include antigens from a cancer or tumor selected from ABL1 proto-oncogene, AIDS related cancers, acoustic neuroma, acute lymphocytic leukemia, acute myeloid leukemia, adenocystic carcinoma, adrenocortical cancer, agnogenic myeloid metaplasia, alopecia, alveolar soft-part sarcoma, anal cancer, angiosarcoma, aplastic anemia, astrocytoma, ataxia-telangiectasia, basal cell carcinoma (skin), bladder cancer, bone cancers, bowel cancer, brain stem glioma, brain and CNS tumors, breast cancer, CNS tumors, carcinoid tumors, cervical cancer, childhood brain tumors, childhood cancer, childhood leukemia, childhood soft tissue sarcoma, chondrosarcoma, choriocarcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancers, cutaneous T-cell lymphoma, dermatofibrosarcoma protuberans, desmoplastic small round cell tumor, ductal carcinoma, endocrine cancers, endometrial cancer, ependymoma, oesophageal cancer, Ewing's Sarcoma, Extra-Hepatic Bile Duct Cancer, Eye Cancer, Eye: Melanoma, Retinoblastoma, Fallopian Tube cancer, Fanconi anemia, fibrosarcoma, gall bladder cancer, gastric cancer, gastrointestinal cancers, gastrointestinal-carcinoid-tumor, genitourinary cancers, germ cell tumors, gestational-trophoblastic-disease, glioma, gynecological cancers, haematological malignancies, hairy cell leukemia, head and neck cancer, hepatocellular cancer, hereditary breast cancer, histiocytosis, Hodgkin's disease, human papillomavirus, hydatidiform mole, hypercalcemia, hypopharynx cancer, intraocular melanoma, islet cell cancer, Kaposi's sarcoma, kidney cancer, Langerhan's cell histiocytosis, laryngeal cancer, leiomyosarcoma, leukemia, Li-Fraumeni syndrome, lip cancer, liposarcoma, liver cancer, lung cancer, lymphedema, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, male breast cancer, malignant-rhabdoid tumor of kidney, medulloblastoma, melanoma, Merkel cell cancer, mesothelioma, metastatic cancer, mouth cancer, multiple endocrine neoplasia, mycosis fungoides, myelodysplastic syndromes, myeloma, myeloproliferative disorders, nasal cancer, nasopharyngeal cancer, nephroblastoma, neuroblastoma, neurofibromatosis, Nijmegen breakage syndrome, non-melanoma skin cancer, non-small-cell-lung-cancer (NSCLC), ocular cancers, esophageal cancer, oral cavity cancer, oropharynx cancer, osteosarcoma, ostomy ovarian cancer, pancreas cancer, paranasal cancer, parathyroid cancer, parotid gland cancer, penile cancer, peripheral-neuroectodermal tumors, pituitary cancer, polycythemia vera, prostate cancer, rare cancers and associated disorders, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, Rothmund-Thomson syndrome, salivary gland cancer, sarcoma, schwannoma, Sezary syndrome, skin cancer, small cell lung cancer (SCLC), small intestine cancer, soft tissue sarcoma, spinal cord tumors, squamous-cell-carcinoma-(skin), stomach cancer, synovial sarcoma, testicular cancer, thymus cancer, thyroid cancer, transitional-cell-cancer-(bladder), transitional-cell-cancer-(renal-pelvis-/-ureter), trophoblastic cancer, urethral cancer, urinary system cancer, uroplakins, uterine sarcoma, uterus cancer, vaginal cancer, vulva cancer, Waldenstrom's macroglobulinemia, Wilms' tumor. In certain embodiments, the cancer or tumor relates to melanoma. Illustrative examples of melanoma-related antigens include melanocyte differentiation antigen (e.g., gp100, MART, Melan-A/MART-1, TRP-1, Tyros, TRP2, MC1R, MUC1F, MUC1R or a combination thereof) and melanoma-specific antigens (e.g., BAGE, GAGE-1, gp100In4, MAGE-1 (e.g., GenBank Accession No. X54156 and AA494311), MAGE-3, MAGE4, PRAME, TRP2IN2, NYNSO1a, NYNSO1b, LAGE1, p97 melanoma antigen (e.g., GenBank Accession No. M12154) p5 protein, gp75, oncofetal antigen, GM2 and GD2 gangliosides, cdc27, p21ras, gp100Pmel117 or a combination thereof. Other tumor-specific antigens include, but are not limited to: etv6, aml1, cyclophilin b (acute lymphoblastic leukemia); Ig-idiotype (B cell lymphoma); E-cadherin, α-catenin, β-catenin, γ-catenin, p120ctn (glioma); p21ras (bladder cancer); p21ras (biliary cancer); MUC family, HER2/neu, c-erbB-2 (breast cancer); p53, p21ras (cervical carcinoma); p21ras, HER2/neu, c-erbB-2, MUC family, Cripto-1protein, Pim-1 protein (colon carcinoma); Colorectal associated antigen (CRC)-CO17-1A/GA733, APC (colorectal cancer); carcinoembryonic antigen (CEA) (colorectal cancer; choriocarcinoma); cyclophilin b (epithelial cell cancer); HER2/neu, c-erbB-2, ga733 glycoprotein (gastric cancer); α-fetoprotein (hepatocellular cancer); Imp-1, EBNA-1 (Hodgkin's lymphoma); CEA, MAGE-3, NY-ESO-1 (lung cancer); cyclophilin b (lymphoid cell-derived leukemia); MUC family, p21ras (myeloma); HER2/neu, c-erbB-2 (non-small cell lung carcinoma); Imp-1, EBNA-1 (nasopharyngeal cancer); MUC family, HER2/neu, c-erbB-2, MAGE-A4, NY-ESO-1 (ovarian cancer); Prostate Specific Antigen (PSA) and its antigenic epitopes PSA-1, PSA-2, and PSA-3, PSMA, HER2/neu, c-erbB-2, ga733 glycoprotein (prostate cancer); HER2/neu, c-erbB-2 (renal cancer); viral products such as human papillomavirus proteins (squamous cell cancers of the cervix and esophagus); NY-ESO-1 (testicular cancer); and HTLV-1 epitopes (T cell leukemia).
- Foreign antigens are suitably selected from transplantation antigens, allergens as well as antigens from pathogenic organisms. Transplantation antigens can be derived from donor cells or tissues from, e.g., heart, lung, liver, pancreas, kidney, neural graft components, or from the donor antigen-presenting cells bearing MHC loaded with self antigen in the absence of exogenous antigen.
- Non-limiting examples of allergens include Fel d 1 (i.e., the feline skin and salivary gland allergen of the domestic cat Felis domesticus, the amino acid sequence of which is disclosed International Publication WO 91/06571), Der p I, Der p II, Der fI or Der fII (i.e., the major protein allergens from the house dust mite dermatophagoides, the amino acid sequence of which is disclosed in International Publication WO 94/24281). Other allergens may be derived, for example from the following: grass, tree and weed (including ragweed) pollens; fungi and molds; foods such as fish, shellfish, crab, lobster, peanuts, nuts, wheat gluten, eggs and milk; stinging insects such as bee, wasp, and hornet and the chirnomidae (non-biting midges); other insects such as the housefly, fruitfly, sheep blow fly, screw worm fly, grain weevil, silkworm, honeybee, non-biting midge larvae, bee moth larvae, mealworm, cockroach and larvae of Tenibrio molitor beetle; spiders and mites, including the house dust mite; allergens found in the dander, urine, saliva, blood or other bodily fluid of mammals such as cat, dog, cow, pig, sheep, horse, rabbit, rat, guinea pig, mouse and gerbil; airborne particulates in general; latex; and protein detergent additives.
- Exemplary pathogenic organisms include, but are not limited to, viruses, bacteria, fungi parasites, algae and protozoa and amoebae. Illustrative viruses include viruses responsible for diseases including, but not limited to, measles, mumps, rubella, poliomyelitis, hepatitis A, B (e.g., GenBank Accession No. E02707), and C (e.g., GenBank Accession No. E06890), as well as other hepatitis viruses, influenza, adenovirus (e.g.,
types 4 and 7), rabies (e.g., GenBank Accession No. M34678), yellow fever, Epstein-Barr virus and other herpesviruses such as papillomavirus, Ebola virus, influenza virus, Japanese encephalitis (e.g., GenBank Accession No. E07883), dengue (e.g., GenBank Accession No. M24444), hantavirus, Sendai virus, respiratory syncytial virus, othromyxoviruses, vesicular stomatitis virus, visna virus, cytomegalovirus and human immunodeficiency virus (HIV) (e.g., GenBank Accession No. U18552). Any suitable antigen derived from such viruses are useful in the practice of the present invention. For example, illustrative retroviral antigens derived from HIV include, but are not limited to, antigens such as gene products of the gag, pol, and env genes, the Nef protein, reverse transcriptase, and other HIV components. Illustrative examples of hepatitis viral antigens include, but are not limited to, antigens such as the S, M, and L proteins of hepatitis B virus, the pre-S antigen of hepatitis B virus, and other hepatitis, e.g., hepatitis A, B, and C, viral components such as hepatitis C viral RNA. Illustrative examples of influenza viral antigens include, but are not limited to, antigens such as hemagglutinin and neuraminidase and other influenza viral components. Illustrative examples of measles viral antigens include, but are not limited to, antigens such as the measles virus fusion protein and other measles virus components. Illustrative examples of rubella viral antigens include, but are not limited to, antigens such as proteins E1 and E2 and other rubella virus components; rotaviral antigens such as VP7sc and other rotaviral components. Illustrative examples of cytomegaloviral antigens include, but are not limited to, antigens such as envelope glycoprotein B and other cytomegaloviral antigen components. Non-limiting examples of respiratory syncytial viral antigens include antigens such as the RSV fusion protein, the M2 protein and other respiratory syncytial viral antigen components. Illustrative examples of herpes simplex viral antigens include, but are not limited to, antigens such as immediate early proteins, glycoprotein D, and other herpes simplex viral antigen components. Non-limiting examples of varicella zoster viral antigens include antigens such as 9P1, gpII, and other varicella zoster viral antigen components. Non-limiting examples of Japanese encephalitis viral antigens include antigens such as proteins E, M-E, M-E-NS 1,NS 1, NS 1-NS2A, 80%E, and other Japanese encephalitis viral antigen components. Representative examples of rabies viral antigens include, but are not limited to, antigens such as rabies glycoprotein, rabies nucleoprotein and other rabies viral antigen components. Illustrative examples of papillomavirus antigens include, but are not limited to, the L1 and L2 capsid proteins as well as the E6/E7 antigens associated with cervical cancers, See Fundamental Virology, Second Edition, eds. Fields, B. N. and Knipe, D. M., 1991, Raven Press, New York, for additional examples of viral antigens. - Illustrative examples of fungi include Acremonium spp., Aspergillus spp., Basidiobolus spp., Bipolaris spp., Blastomyces dermatidis, Candida spp., Cladophialophora carrionii, Coccoidiodes immitis, Conidiobolus spp., Cryptococcus spp., Curvularia spp., Epidermophyton spp., Exophiala jeanselmei, Exserohilum spp., Fonsecaea compacta, Fonsecaea pedrosoi, Fusarium oxysporum, Fusarium solani, Geotrichum candidum, Histoplasma capsulatum var. capsulatum, Histoplasma capsulatum var. duboisii, Hortaea werneckii, Lacazia loboi, Lasiodiplodia theobromas, Leptosphaeria senegalensis, Madurella grisea, Madurella mycetomatis, Malassezia furfur, Microsporum spp., Neotestudina rosatii, Onychocola canadensis, Paracoccidioides brasiliensis, Phialophora verrucosa, Piedraia hortae, Piedra iahortae, Pityriasis versicolor, Pseudallesheria boydii, Pyrenochaeta romeroi, Rhizopus arrhizus, Scopulariopsis brevicaulis, Scytalidium dimidiatum, Sporothrix schenckii, Trichophyton spp., Trichosporon spp., Zygomcete fungi, Absidia corymbifera, Rhizomucor pusillus and Rhizopus arrhizus. Thus, representative fungal antigens that can be used in the compositions and methods of the present invention include, but are not limited to, candida fungal antigen components; histoplasma fungal antigens such as heat shock protein 60 (HSP60) and other histoplasma fungal antigen components; cryptococcal fungal antigens such as capsular polysaccharides and other cryptococcal fungal antigen components; coccidiodes fungal antigens such as spherule antigens and other coccidiodes fungal antigen components; and tinea fungal antigens such as trichophytin and other coccidiodes fungal antigen components.
- Illustrative examples of bacteria include bacteria that are responsible for diseases including, but not restricted to, diphtheria (e.g., Corynebacterium diphtheria), pertussis (e.g., Bordetella pertussis, GenBank Accession No. M35274), tetanus (e.g., Clostridium tetani, GenBank Accession No. M64353), tuberculosis (e.g., Mycobacterium tuberculosis), bacterial pneumonias (e.g., Haemophilus influenzae.), cholera (e.g., Vibrio cholerae), anthrax (e.g., Bacillus anthracis), typhoid, plague, shigellosis (e.g., Shigella dysenteriae), botulism (e.g., Clostridium botulinum), salmonellosis (e.g., GenBank Accession No. L03833), peptic ulcers (e.g., Helicobacter pylori), Legionnaire's Disease, Lyme disease (e.g., GenBank Accession No. U59487). Other pathogenic bacteria include Escherichia coli, Clostridium perfringens, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus pyogenes. Thus, bacterial antigens which can be used in the compositions and methods of the invention include, but are not limited to: pertussis bacterial antigens such as pertussis toxin, filamentous hemagglutinin, pertactin, F M2, FIM3, adenylate cyclase and other pertussis bacterial antigen components; diphtheria bacterial antigens such as diphtheria toxin or toxoid and other diphtheria bacterial antigen components; tetanus bacterial antigens such as tetanus toxin or toxoid and other tetanus bacterial antigen components, streptococcal bacterial antigens such as M proteins and other streptococcal bacterial antigen components; gram-negative bacilli bacterial antigens such as lipopolysaccharides and other gram-negative bacterial antigen components; Mycobacterium tuberculosis bacterial antigens such as mycolic acid, heat shock protein 65 (HSP65), the 30 kDa major secreted protein, antigen 85A and other mycobacterial antigen components; Helicobacter pylori bacterial antigen components, pneumococcal bacterial antigens such as pneumolysin, pneumococcal capsular polysaccharides and other pnermiococcal bacterial antigen components; Haemophilus influenza bacterial antigens such as capsular polysaccharides and other Haemophilus influenza bacterial antigen components; anthrax bacterial antigens such as anthrax protective antigen and other anthrax bacterial antigen components; rickettsiae bacterial antigens such as rompA and other rickettsiae bacterial antigen component. Also included with the bacterial antigens described herein are any other bacterial, mycobacterial, mycoplasmal, rickettsial, or chlamydial antigens.
- Illustrative examples of protozoa include protozoa that are responsible for diseases including, but not limited to, malaria (e.g., GenBank Accession No. X53832), hookworm, onchocerciasis (e.g., GenBank Accession No. M27807), schistosomiasis (e.g., GenBank Accession No. LOS 198), toxoplasmosis, trypanosomiasis, leishmaniasis, giardiasis (GenBank Accession No. M33641), amoebiasis, filariasis (e.g., GenBank Accession No. J03266), borreliosis, and trichinosis. Thus, protozoal antigens which can be used in the compositions and methods of the invention include, but are not limited to: plasmodium falciparum antigens such as merozoite surface antigens, sporozoite surface antigens, circumsporozoite antigens, gametocyte/gamete surface antigens, blood-stage antigen pf 155/RESA and other plasmodial antigen components; toxoplasma antigens such as SAG-1, p30 and other toxoplasmal antigen components; schistosomae antigens such as glutathione-S-transferase, paramyosin, and other schistosomal antigen components; leishmania major and other leishmaniae antigens such as gp63, lipophosphoglycan and its associated protein and other leishmanial antigen components; and trypanosoma cruzi antigens such as the 75-77 kDa antigen, the 56 kDa antigen and other trypanosomal antigen components.
- The present invention also contemplates toxin components as antigens. Illustrative examples of toxins include, but are not restricted to, staphylococcal enterotoxins, toxic shock syndrome toxin; retroviral antigens (e.g., antigens derived from HIV), streptococcal antigens, staphylococcal enterotoxin-A (SEA), staphylococcal enterotoxin-B (SEB), staphylococcal enterotoxin1-3 (SE1-3), staphylococcal enterotoxin-D (SED), staphylococcal enterotoxin-E (SEE) as well as toxins derived from mycoplasma, mycobacterium, and herpes viruses.
- In specific embodiments, the antigen is delivered to antigen-presenting cells. Such antigen-presenting cells include professional or facultative antigen-presenting cells. Professional antigen-presenting cells function physiologically to present antigen in a form that is recognized by specific T cell receptors so as to stimulate or energies a T lymphocyte or B lymphocyte mediated immune response. Professional antigen-presenting cells not only process and present antigens in the context of the major histocompatability complex (MHC), but also possess the additional immunoregulatory molecules required to complete T cell activation or induce a tolerogenic response. Professional antigen-presenting cells include, but are not limited to, macrophages, monocytes, B lymphocytes, cells of myeloid lineage, including monocytic-granulocytic-DC precursors, marginal zone Kupffer cells, microglia, T cells, Langerhans cells and dendritic cells including interdigitating dendritic cells and follicular dendritic cells. Non-professional or facultative antigen-presenting cells typically lack one or more of the immunoregulatory molecules required to complete T lymphocyte activation or energy. Examples of non-professional or facultative antigen-presenting cells include, but are not limited to, activated T lymphocytes, eosinophils, keratinocytes, astrocytes, follicular cells, microglial cells, thymic cortical cells, endothelial cells, Schwann cells, retinal pigment epithelial cells, myoblasts, vascular smooth muscle cells, chondrocytes, enterocytes, thymocytes, kidney tubule cells and fibroblasts. In some embodiments, the antigen-presenting cell is selected from monocytes, macrophages, B lymphocytes, cells of myeloid lineage, dendritic cells or Langerhans cells. In certain advantageous embodiments, the antigen-presenting cell expresses CD11c and includes a dendritic cell or Langerhans cell. In some embodiments the antigen-presenting cell stimulates an immune response. In other embodiments, the antigen-presenting cell induces a tolerogenic response.
- The delivery of exogenous antigen to an antigen-presenting cell can be enhanced by methods known to practitioners in the art. For example, several different strategies have been developed for delivery of exogenous antigen to the endogenous processing pathway of antigen-presenting cells, especially dendritic cells. These methods include insertion of antigen into pH-sensitive liposomes (Zhou and Huang, 1994, Immunomethods, 4:229-235), osmotic lysis of pinosomes after pinocytic uptake of soluble antigen (Moore et al., 1988, Cell, 54:777-785), coupling of antigens to potent adjuvants (Aichele et al., 1990, J. Exp. Med., 171: 1815-1820; Gao et al., 1991, J. Immunol., 147: 3268-3273; Schulz et al., 1991, Proc. Natl. Acad. Sci. USA, 88: 991-993; Kuzu et al., 1993, Euro. J. Immunol., 23: 1397-1400; and Jondal et al., 1996, Immunity 5: 295-302) and apoptotic cell delivery of antigen (Albert et al. 1998, Nature 392:86-89; Albert et al. 1998, Nature Med. 4:1321-1324; and in International Publications WO 99/42564 and WO 01/85207). Recombinant bacteria (e.g., E. coli) or transfected host mammalian cells may be pulsed onto dendritic cells (as particulate antigen, or apoptotic bodies respectively) for antigen delivery. Recombinant chimeric virus-like particles (VLPs) have also been used as vehicles for delivery of exogenous heterologous antigen to the MHC class I processing pathway of a dendritic cell line (Bachmann et al., 1996, Eur. J. Immunol., 26(11): 2595-2600).
- Alternatively, or in addition, an antigen may be linked to, or otherwise associated with, a cytolysin to enhance the transfer of the antigen into the cytosol of an antigen-presenting cell of the invention for delivery to the MHC class I pathway. Exemplary cytolysins include saponin compounds such as saponin-containing Immune Stimulating Complexes (ISCOMs) (see, e.g., Cox and Coulter, 1997, Vaccine 15(3): 248-256 and U.S. Pat. No. 6,352,697), phospholipases (see, e.g., Camilli et al., 1991, J. Exp. Med. 173: 751-754), pore-forming toxins (e.g., an a-toxin), natural cytolysins of gram-positive bacteria, such as listeriolysin O (LLO, e.g., Mengaud et al., 1988, Infect. Immun. 56: 766-772 and Portnoy et al., 1992, Infect. Immun. 60: 2710-2717), streptolysin O (SLO, e.g., Palmer et al., 1998, Biochemistry 37(8): 2378-2383) and perfringolysin O (PFO, e.g., Rossjohn et al., Cell 89(5): 685-692). Where the antigen-presenting cell is phagosomal, acid activated cytolysins may be advantageously used. For example, listeriolysin exhibits greater pore-forming ability at mildly acidic pH (the pH conditions within the phagosome), thereby facilitating delivery of vacuole (including phagosome and endosome) contents to the cytoplasm (see, e.g., Portnoy et al., Infect. Immun. 1992, 60: 2710-2717).
- The cytolysin may be provided together with a pre-selected antigen in the form of a single composition or may be provided as a separate composition, for contacting the antigen-presenting cells. In one embodiment, the cytolysin is fused or otherwise linked to the antigen, wherein the fusion or linkage permits the delivery of the antigen to the cytosol of the target cell. In another embodiment, the cytolysin and antigen are provided in the form of a delivery vehicle such as, but not limited to, a liposome or a microbial delivery vehicle selected from virus, bacterium, or yeast. Suitably, when the delivery vehicle is a microbial delivery vehicle, the delivery vehicle is non-virulent. In a preferred embodiment of this type, the delivery vehicle is a non-virulent bacterium, as for example described by Portnoy et al. in U.S. Pat. No. 6,287,556, comprising a first polynucleotide encoding a non-secreted functional cytolysin operably linked to a regulatory polynucleotide which expresses the cytolysin in the bacterium, and a second polynucleotide encoding one or more pre-selected antigens. Non-secreted cytolysins may be provided by various mechanisms, e.g., absence of a functional signal sequence, a secretion incompetent microbe, such as microbes having genetic lesions (e.g., a functional signal sequence mutation), or poisoned microbes, etc. A wide variety of nonvirulent, non-pathogenic bacteria may be used; preferred microbes are relatively well characterized strains, particularly laboratory strains of E. coli, such as MC4100, MC1061, DH5α, etc. Other bacteria that can be engineered for the invention include well-characterized, nonvirulent, non-pathogenic strains of Listeria monocytogenes, Shigella flexneri, mycobacterium, Salmonella, Bacillus subtilis, etc. In a particular embodiment, the bacteria are attenuated to be non-replicative, non-integrative into the host cell genome, and/or non-motile inter- or intra-cellularly.
- The delivery vehicles described above can be used to deliver one or more antigens to virtually any antigen-presenting cell capable of endocytosis of the subject vehicle, including phagocytic and non-phagocytic antigen-presenting cells. In embodiments when the delivery vehicle is a microbe, the subject methods generally require microbial uptake by the target cell and subsequent lysis within the antigen-presenting cell vacuole (including phagosomes and endosomes).
- In other embodiments, the antigen is produced inside the antigen-presenting cell by introduction of a suitable expression vector as for example described above. The antigen-encoding portion of the expression vector may comprise a naturally-occurring sequence or a variant thereof, which has been engineered using recombinant techniques. In one example of a variant, the codon composition of an antigen-encoding polynucleotide is modified to permit enhanced expression of the antigen in a target cell or tissue of choice using methods as set forth in detail in International Publications WO 99/02694 and WO 00/42215. Briefly, these methods are based on the observation that translational efficiencies of different codons vary between different cells or tissues and that these differences can be exploited, together with codon composition of a gene, to regulate expression of a protein in a particular cell or tissue type. Thus, for the construction of codon-optimized polynucleotides, at least one existing codon of a parent polynucleotide is replaced with a synonymous codon that has a higher translational efficiency in a target cell or tissue than the existing codon it replaces. Although it is preferable to replace all the existing codons of a parent nucleic acid molecule with synonymous codons which have that higher translational efficiency, this is not necessary because increased expression can be accomplished even with partial replacement. Suitably, the replacement step affects 5, 10, 15, 20, 25, 30%, more preferably 35, 40, 50, 60, 70% or more of the existing codons of a parent polynucleotide.
- The expression vector for introduction into the antigen-presenting cell will be compatible therewith such that the antigen-encoding polynucleotide is expressible by the cell. For example, expression vectors of this type can be derived from viral DNA sequences including, but not limited to, adenovirus, adeno-associated viruses, herpes-simplex viruses and retroviruses such as B, C, and D retroviruses as well as spumaviruses and modified lentiviruses. Suitable expression vectors for transfection of animal cells are described, for example, by Wu and Ataai (2000, Curr. Opin. Biotechnol. 11(2):205-208), Vigna and Naldini (2000, J. Gene Med. 2(5):308-316), Kay, et al. (2001, Nat. Med. 7(1):33-40), Athanasopoulos, et al. (2000, Int. J. Mol. Med. 6(4):363-375) and Walther and Stein (2000, Drugs 60(2):249-271).
- Experimental Results
- Preliminary data in a mouse model, using a virus as a delivery vehicle to the skin using an embodiment of the
patches 100 described above elicited significantly higher cytotoxic T-lymphocyte responses than conventional intradermal injection of the same antigenic preparation, with the same payload. - Accordingly, the above described examples provide a device for the delivery of a bioactive material (agent) or other stimulus to an internal site in the body, comprising a plurality (number) of projections that can penetrate a body surface so as to deliver the bioactive material or stimulus to the required site.
- In one example, the number of projections is selected to be at least 500, to thereby induce a biological response. Typically the exact number of projections is determined in accordance with the above described equations, thereby maximizing the chance of delivery of material or stimulus to the target.
- The delivery end portion of the projection may also be dimensioned so as to be capable of insertion into targeted cells to deliver the bioactive material or stimulus without appreciable damage to the targeted cells or specific sites therein. Thus, the dimensions of the delivery end portion of the microprojections, including the length or diameter, can be selected which enables delivery of the agent or stimulus to targeted cells and internal components within cells.
- The nanoneedles are typically solid (non-hollow) in cross-section. This leads to a number of technical advantages which include: reliable delivery of bioactive material or stimulus; ease and cost of manufacturing, and increased strength.
- A number of variations and options for use with the above described devices will now be described.
- Herein, the terms “projection”, “micro-nanoprojection”, “nanoneedle”, “nanoprojection”, “needle”, “rod”, etc., are used interchangeably to describe the solid projections.
- In cases where a material or agent is to be transported, projections may be coated on the outside of the nanoneedles. This provides a higher probability of delivering the coating to the depth of interest compared to microparticle delivery from a gene gun and thus is more efficient.
- A further feature is that the nanoneedles may be used for delivery not only through the skin but through other body surfaces, including mucosal surfaces, to cellular sites below the outer layer or layers of such surfaces. The term “internal site”, as used herein, is to be understood as indicating a site below the outer layer(s) of skin and other tissues for which the devices of the present invention are to be used.
- Furthermore, these nanoneedles may be used to deliver stimuli to cells or cell components other than those resulting from the administration of bioactive agents such as drugs and antigenic materials for example. Mere penetration of cellular sites with nanoneedles may be sufficient to induce a beneficial response, as indicated hereinafter.
- The device is suitable for intracellular delivery. The device is suitable for delivery to specific organelles within cells. Examples of organelles to which the device can be applied include a cell nucleus, endoplasmic reticulum, ribosome, or lysosome for example.
- In one embodiment the device is provided having a needle support section, that is to say the projections comprise a suitable support section, of sufficient length to reach the desired site and a (needle) delivery end section having a length no greater than 20 microns and a maximum width no greater than 5 microns, preferably no greater than 2 microns.
- In one example, the maximum width of the delivery end section is no greater than 1000 nm, even more preferably the maximum width of the delivery end section is no greater than 500 nm.
- In one embodiment, the device can be used for delivery intradermally. This device may have a needle support section, that is to say the projections comprise a suitable support section, of length at least 10 microns and a (needle) delivery end section having a length no greater than 20 microns and a maximum width no greater than 5 microns, preferably no greater than 2 microns.
- The maximum width of the delivery end section is usually no greater than 1000 nm, even more preferably the maximum width of the delivery end section is no greater than 500 nm.
- In a further embodiment, the device is for mucosal delivery. This device may have a needle support section, that is to say the projections comprise a suitable support section, of sufficient length to reach the desired site, such as of length at least 100 microns and a (needle) delivery end section having a length no greater than 20 microns and a maximum width no greater than 5 microns, preferably no greater than 2 microns.
- In one embodiment, the device of the invention is for delivery to lung or other internal organ or tissue. In a further embodiment, the device is for in-vitro delivery to tissue, cell cultures, cell lines, organs, artificial tissues and tissue engineered products. This device typically has a needle support section, that is to say the projections comprise a suitable support section, of length at least 5 microns and a needle delivery end section having a length no greater than 20 microns and a maximum width no greater than 5 microns, preferably no greater than 2 microns.
- In one embodiment, the device comprises projections in which the (needle) delivery end section and support length, that is to say the “needle support section”, is coated with a bioactive material across the whole or part of its length. The (needle) delivery end section and support length may be coated on selective areas thereof. This may depend upon the bioactive material being used or the target selected for example.
- In a further embodiment, a bioactive material is releasably incorporated into the material of which the needle, or projection, is composed. All, or part of the projection may be constructed of a biocompatible, biodegradable polymer (such as Poly Lactic Acid (PLA), PolyGlycolic Acid (PGA) or PGLA or Poly Glucleic Acid), which is formulated with the bioactive material of choice. The projections may then be inserted into the appropriate target site and, as they dissolve, the bioactive material will enter the organelle(s)/cells.
- In one example, at least the delivery end section of the needle is composed of a biodegradable material.
- In an alternative embodiment of the invention, a device is also provided in which the needle has no bioactive material on or within it. The targeted cell or organelle is perturbed/stimulated by the physical disruption caused by the (delivery end of the) nanoneedle (projection). This physical stimulus may, for example, be coupled with electric stimulus as a form of specific nanoelectroporation of particular organelles or the cell.
- The bioactive material or stimulus delivered by the device of the invention may be any suitable material or stimulus which gives the desired effect at the target site.
- Examples of bioactive materials, which are not intended to be limiting with respect to the invention include polynucleotides and nucleic acid or protein molecules, antigens, allergens, adjuvants, molecules, elements or compounds. In addition, the device may be coated with materials such as biosensors, nanosensors or MEMS.
- In one aspect, the device is provided in the form of a patch containing a plurality of needles (projections) for application to a body surface. A multiplicity of projections can allow multiple cells and organelles to be targeted and provided with a bioactive material or stimulus at the same time. The patch may be of any suitable shape, such as square or round for example. The overall number of projections per patch depends upon the particular application in which the device is to be used. Preferably, the patch has at least 10 needles per mm, and more preferably at least 100 needles per mm2. Considerations and specific examples of such a patch are provided in more detail below.
- Examples of specific manufacturing steps used to fabricate the device are described in greater detail below. In one preferred aspect, the device of the invention is constructed from biocompatible materials such as Titanium, Gold, Silver or Silicon, for example. This may be the entire device, or alternatively it may only be the projections or the delivery end section of the projections which are made from the biocompatible materials.
- One manufacturing method for the device utilizes the Deep Reactive Ion Etching (DRIE) of the patterns direct from silicon wafers, see the construction section below.
- Another manufacturing method for the device utilizes manufacturing from a male template constructed with X-ray lithography, electrodeposition and molding (LIGA). The templates are then multiply inserted into a soft polymer to produce a plurality of masks. The masks are then vacuum deposited/sputtered with the material of choice for the nanoprojections, such as titanium, gold, silver, or tungsten. Magnetron sputtering may also be applied, see the construction section below.
- An alternative means for producing masks is with 2 photon Stereolithography, a technique which is known in the art and is described in more detail below.
- In one embodiment, the device is constructed of silicon.
- The device may be for a single use or may be used and then recoated with the same or a different bioactive material or other stimulus, for example.
- In one embodiment, the device comprises projections which are of differing lengths and/or diameters (or thicknesses depending on the shape of the projections) to allow targeting of different targets within the same use of the device.
- An example of the practical application of such a device is explained in further detail below (see section 6.2.4).
- Also provided throughout the specification are numerous uses of the device, which has many useful medical applications in the treatment of a number of diseases.
- Further examples will now be described in more detail. For the purpose of these examples, the explanation will focus on the targeting of cells, cell organelles or cell nuclei. However it will be appreciated that the techniques may be used to deliver material/stimulus to any suitable specific target.
- In one example, the target of interest is within the cells. The position and shape of key organelles within the cells are shown in
FIG. 15 . All eucaryotic cells have the same basic set of membrane enclosed organelles. The number and volume of the key organelles varies with cell type. As to the targeting of specific organelles, there is a probability attached to each event on the basis of volume. Consider the non-specific targeting of the cell (i.e., at the correct depth, but without the precise targeting with the aid of imaging techniques). The probability of targeting the nucleus, for example, in a cell is given by the volume of the nucleus vs. the remainder of the cell. - In Table 1 below, the scale of organelles and their mass fraction and number are listed. The primary data for this summary is from “Genes VI” by Benjamin Lewin and “The Molecular Biology of the Cell” Alberts et al., 4th Ed. This information pertains to the Liver Cell. Also listed in Table 1 are example applications and that may be induced or enhanced as a result of targeting these organelles.
- Working in increasing scale, the starting point is the cell membrane, which is ˜10 nm thick. In piercing these membranes with a minimal disruption to the viability of the cell, a range of drugs, vaccines and other compounds can be delivered to cells. Specifically, the Endoplasmic Reticulum (a convoluted envelope, 75 nm in thickness) may be targeted within RNA to transfect cells in the areas of Vaccination or Gene Therapy. Lysosomes, which are 200-500 nm in size can be targeted for release of enzymes to induce autolysis (cell death). For an effective cellular response (MHC Class I) with DNA vaccination and gene therapy, it is important that the DNA material is delivered intact to the cell nucleus.
- Most of these organelles are of the submicron scale.
-
TABLE 1 The scale, number and potential targets of key organelles within cells. (http://niko.unl.edu/bs101/notes/sizes.html and “Molecular Biology of the Cell” 4′′′ Ed, Alberts et al.) Mass/ Volume Number per Utility as Scale Organelle Fraction cell target Application ~0.1 nm Hydrogen Atom ~0.8 nm Amino Acid ~2 nm DNA Alpha ~2% (diameter) helix ~2 nm mRNA ~2% ~2,500 ~2 nm tRNA ~3% ~160,000 ~2 nm RNA ~21% ~4 nm Globular Protein ~10 nm Cell ~10% Use To enhance membranes nanoneedles drug/vaccine to pierce delivery of these cells through membranes perfusion with minimal disruption to the cell. ~11 nm Ribosome ~9% ~25 nm Microtubule diameter ~75 nm Endoplasmic ~15% Target with Vaccination, (envelope reticulum RNA, gene therapy thickness) (smooth, mRNA, for rough, iRNA for up cancerous Golgi) regulating or cells. interfering the production of proteins ~100 nm Large Virus ~200-500 Lysosomes ~1% Pierce the Inducing cell nm lysosomes to death in release cancerous enzymes and cells. induces autolysis (self digestion of the cell). ~3 μm × Mitochondri ~22% 200 nm on ~3-6 μm Nucleus ~6% (Liver) 1 Target for DNA 16% (LC) DNA vaccination delivery to or gene the cell therapy. directly and/or disturb the double membrane. ~10-30 μm Cell Langerhans (diameter) cells are ~10 in diameter. - The type and scale of organelles within cells has been presented. Now the location of these cells within the tissue is identified. The selected tissue routes are.
- Intradermal
- Mucosal
- Lung
- Internal tissues
- In-vitro sites.
- The skin is one convenient route for drug and vaccine delivery. A schematic of the skin is shown in
FIG. 16 . A full description of the anatomy of the skin is given in textbooks. A closer view of a histology section of skin is shown inFIG. 17 in a photomicrograph. Respective thicknesses of layers vary between species and sites. - A key barrier to many drugs and vaccines is the Stratum Corneum (SC). In humans, this barrier is 10-20 μm thick with large variations from site-to-site with different ages and sexes. Below the SC is the Viable Epidermis (VE), which is typically 40-60 μm thick in humans. Within the VE are immunologically sensitive Langerhans Cells (LC).
FIG. 17 shows a stained LC, marked as “L”, residing above the basal layer. The spatial distribution of LC is illustrated in a 3D distribution of LC in a mouse,FIG. 18 (Kendall M. A. F., Mulholland W. J., Tirlapur U. K., Arbuthnott E. S., and Armitage, M. (2003) “Targeted delivery of micro-particles to epithelial cells for immunotherapy and vaccines: an experimental and probabilistic study”, The 6th International Conference on Cellular Engineering, Sydney, August 20-22). - There are typically about 1000 LC per square mm and they reside just above the basement membrane of the viable epidermis (i.e., 30-80 μm deep). Importantly, the depth of LC varies significantly with the biological variability of the tissue, including rete ridges etc.
- One objective in vaccination and gene therapy applications is to target LC residing 30-80 μm below the skin surface. In order to do this, the SC and cell membranes are to be breached. Furthermore, the organelles within the LC are to be targeted to elicit particular responses. One example is in the triggering of MHC I responses, whereby intact DNA is to be delivered to cell the nucleus. Alternatively, mRNA can be delivered to the Endoplasmic Reticulum or the cytoplasm.
- Similarly, in the treatment of skin cancers such as Squamous Cell Carcinoma, cancerous cells within the VE may be directly targeted.
- In some applications it may be beneficial to target cells deeper into the dermis. For example, in Basal Cell Carcinoma, the cells to be targeted are deeper in the tissue, approaching hundreds of microns (600 82 m to 800 μm) (British Journal of Dermatology 149(5) Page 1035-2003).
-
FIG. 19A shows a photomicrograph of a histology section of the mucosa andFIG. 19B shows the structure of the mucosa. The physiology of the mucosa is similar to the skin. However there are some notable differences: - the mucosa does not have a stratum corneum
- the epithelium is 600-800 82 m thick. This is considerably deeper than the epidermis of the skin (the exact thickness varies with site, age and species).
- Therefore, to target organelles within cells at the basement membrane of the epithelium, a depth Dc of 600-800 82 m is required.
- The epithelial cells on the lining of the lung are the target for various gene therapy approaches. These cells are underneath a mucous/liquid lining, which may be 10-100 82 m thick. Therefore this lining needs to be overcome. In the example of gene therapy for the treatment of Cystic Fibrosis, this lining is to be overcome to target celial cells on the surface of the epithelium.
- Cells within other the internal organs can also be targeted for a range of applications, such as:
- Internal cancers
- Liver (e.g., for Malaria treatment) 1
- Heart (e.g., for angiogenesis blood vessel formation).
- Tissue, cell-lines, tissue culture, excised organs, tissue engineered constructs and artificial tissues may also be targeted, in-vitro. Examples include:
- stimulation of cell lines and cell monolayers in culture.
- stimulation/delivery of growth factors and/or genes (e.g., in tissue engineering and wound healing).
- 3. Constructional Features of the Micro-Nanoprojections
- 3.1 General Micro-Nanoprojection Dimensions
- With typical cell and organelle scales described and locations in tissues highlighted, the structural terms of the nanoneedles individually are described, and then as examples of arrays for targeting cells at different tissue sites.
- Nanoneedles are configured to penetrate the cell membrane with minimal damage, targeting the organelles of interest. The overall dimensions of the nanoneedle projection are shown in
FIG. 20 . The nanoneedle is divided into two main sections: - Referring to
FIG. 20 , the radius of the tip (r) is to be as small as practicable with limits set by manufacturing methods and material considerations, where usually the diameter at the distal end of l is d1. Usually di˜2r. The diameter of the upper end of l is defined as d2. Over the length l, the effective diameter, tapering from d1 to d2 is to be considerably less than the diameter of the cell (dcell) or other target. It is shown in Table 1 approximately that 10 μm<dcell<30 μm. So, approximately, d1<<10 μm, preferably <1 ideally in some cases <500 nm. Ideally, the scale of d1 is to be of the order of the organelle of interest. - For practical engineering and manufacturing and purposes (e.g., buckling/loading/fracture) it is often preferred that the projection along l tapers out to a larger diameter (d2>d1) that still is less than the diameter of the cell (<dcell). However, along the length of l, the profile may be configured such that the diameter is constant (i.e., d1=d2).
- The length of the targeting section (l) is sufficient to ensure that the organelle of interest is targeted (i.e., l>organelle dimension). For example, in targeting the cell nucleus, l>3-6 μm). Ideally, l is even longer to account for variation in cell depth location (e.g., as shown by the variation in the Langerhans cell depth Figure A) and increase the probability of the desired needle-organelle contact. The upper length of l is determined by the combination of material properties, needle shape and loading to ensure that the needle does not break under mechanical loading. Engineering analyses shows this mechanical loading is mostly compression, with tension and bending moments. Good engineering practice to ensure the material does not break includes Euler buckling, fracture mechanics, and work-to-failure. In considering a population of projections in an array, statistical methods (e.g., Weibull statistics) and other related methods may be applied to ensure a very small fraction of the projection population breaks.
- Consider, as an example, the case of compression loading with the primary mode of projection failure is by buckling. This compression buckling criteria set by the Euler Bucking force (Pcr)
-
- where (E) is the Young's modulus of the nanoneedle material, I is the moment of inertia (I=
-
- for a cylinder). Therefore the material properties of the nanoneedle and shape determine the maximum force permitted for buckling (Pcr). Good engineering practice dictates that Pcr must be less than the insertion force of the needle, to ensure it does not break.
- Referring again to
FIG. 20 , the support section of the micro-nanoprojection (a) is sufficient to bring the targeting section of the cell (l) into contact with the cells/organelles of interest. The diameter of the support section along the length a tapers at the distal end from d2 to d3 at the base, where usually engineering and material considerations result in d3>d2 to ensure it does not buckle or break by another mode of failure. In some cases, the diameter along the length of a may be constant (i.e., d3=d2).FIG. 20 shows that a, l and the overall length of the projection (L) are related by: -
L=a+l - In
section 2 the depths of cells for various applications in intradermal, mucosal, lung and internal organ delivery are outlined. The rationale and approximate values of a for targeting these individual sites are presented as examples. - In epidermal delivery, a is the sum of the desired depth in the tissue and an allowance above the target (for instance for tissue surface curvature). This dimension in epidermal delivery is usually <200 μm in length, and preferably <100 μm in length-depending on the tissue species and site. In the targeting of dermal cells, this depth is even greater with a <1000 μm, and preferably <600 μm. In another example, the targeting of basal cells in the epithelium of the mucosa, an a of 600-800 μm is required. In lung delivery, the local bather of the mucous lining to the cells is 50-100 μm thus a would be of the order of 100 μm in this case.
- 3.2 Specific Applications
- Targeting the nuclei of LC in the viable epidermis, 40-50 μm deep in the tissue. The force to insert the needle is estimated with the Unified Penetration Model (proposed by Dehn J: A unified theory of penetration. International Journal of Impact Engineering, 5:239-248.1987).
-
- where σy is the yield stress of the tissue.
- Assume, in the highest loading case, the upper value of the yield stress of the SC of 20 MPa applies to all the skin (from Wildnauer R H, Bothwell J W, Douglas A B: Stratum corneum properties I. influence of relative humidity on normal and extracted stratum corneum. Journal of Investigative Dermatology, 56(1):72-78. 1971). Note, this estimate of insertion force is a factor of 10 greater than calculations inferred from measurements with a probe in the skin (unpublished results, by Crowley (2003, 4th Year Project, Engineering Science, University of Oxford).
- By setting Finsert=Pcr we arrive at
-
- which approximates the Euler Buckling relationship between the maximal permissible length of extension for a probe of diameter d, constructed of a material with a Young's modulus (E), penetrating into a tissue with a Yield Stress (σy).
-
FIG. 21 plots the cell/organelle targeting section length (l) as a function of diameter for six materials. Note that these are upper limit calculations of the loading effects. - Consider the curve for titanium (E=116 GPa) in which a 400 nm diameter (d1=d2) cell/organelle targeting section corresponds to a length of 7 82 m, and a 1 82 m diameter corresponds to a maximum length of 14.1 μm. In this case, the nucleus of the LC is the organelle of interest with a size of 3-6 μm. Here, we choose a organelle targeting section of d1=d2=1 μm and a length (l) of 10 μm (symbols corresponding to the diagram of
FIG. 20 ). The support length (a) is 40 μm, tapering to a base diameter (d3) of 5 82 m. These dimensions are summarized in Table 2. - Alternatively, a nanoneedle constructed of a stiffer material such as silicon (E=189 GPa) results in a smaller cell/organelle targeting section of d1=d2=200 nm over a length (l) of 5 82 m. Of course, a brittle material such as silicon would also require fracture (and other) analyses that may lead to more conservative (i.e., larger) dimensions-these numbers throughout this section are simply illustrative.
- Utility of an even stiffer material such as Tungsten (E=400 GPa) results in the same nanoneedle diameter of d1=d2=200 nm extended over a length (l) of >6 μm-or alternatively the possibility of a smaller diameter d1=d2<200 nm for a length of 5 μm.
- Targeting the Endoplasmic Reticulum LC of the Viable Epidermis. Table 1 lists the thickness of the Endoplasmic Reticulum envelope to be 75 nm. Choosing titanium, the organelle targeting section is set at 400 nm over a length of 5 μm. As shown in Table 2, the remainder of the components are identical to those set out in Example 1.
- Targeting cell nuclei at a depth of 600 82 m in the tissue. Here, the targeting section is identical to Example 1, whereas the considerably longer length (a=600 82 m) requires a significantly wider base (d3=50 82 m).
-
FIG. 20 shows an axi-symmetric design for the nanoneedle. Alternative shapes may be used with: - higher values of mass-moment of inertia (I)
- more knife-like geometries with sharper leading edges.
- One possible example of an alternative shape taking on these features is shown in plan view in
FIG. 27 . -
TABLE 2 The geometry of three nanoneedle examples. r d1 d2 l d3 a Example (nm) (nm) (nm) (μm) (μm) (μm) 1. Nucleus of LC, 40-50 μm deep <1000 1000 1000 10 5 40 2. Endoplasmic Reticulum of <400 400 400 5 5 45 LC 40-50 μm deep 3. Cell nuclei, 600 pm deep. <400 1000 1000 10 50 600 - Consider the generic shape of the micro-nanoprojection (
FIG. 20 ). The bioactive material is coated to the outer surface of the micro-nanoprojection. The following lists two example protocols on how this is done, followed by a list of possible coating combinations. - Consider the case of coating eGFP to tungsten micro-nanoprojections. Essentially, published and well established protocols devised for coating gold microcarriers for biolistic delivery are employed. Examples of these protocols are detailed in:
- PowderJect and Bio-Rad patents and protocols such as: http://plantsciences.montana.edu/wheat-transformation/biolisti.htm); J. E. Biewenga, O. H. Destree, L. H. Schrama, “Plasmid-mediated gene transfer in neurons using the biolistics technique”, J. Neurosci. Methods 71(1997) 67-75; S. Novakovic, M. Knezevic, R. Golouh, B. Jezersek, “Transfection of mammalian cells by the methods of receptor mediated gene transfer and particle bombardment”, J. Exp. Clin. Cancer Res. 18 (1999) 531-536; H. Wellmann, B. Kaltschmidt, C. Kaltschmidt, “Optimized protocol for biolistic transfection of brain slices and dissociated cultured neurons with a hand-held gene gun,” J. Neurosci. Methods 92 (1999) 55-64; and, John O'Brien, Sarah C. R. Lummis “An improved method of preparing microcarriers for biolistic transfection”, Brain Research Protocols 10 (2002) 12-15.
- In this example, subsequently applied to the Experimental Exemplification 1 (section 5.3) the protocol of O'Brien and Lummis (2002) is applied.
- Alternatively, in coating silicon, protocols developed for the sub-micron patterning of DNA oligonucleotides for “lab-on-a-chip” technology can be applied to coating the projections on the array (H. B. Yin, T. Brown, J. S. Wilkinson, R. W. Eason and T. Melvin (2004) “Submicron patterning of DNA oligonucleotides on silicon” Nucleic Acids Research, 2004, Vol. 32, No. 14 el 18). This process is an example of two-stage process for the covalent attachment of DNA oligonucleotides onto crystalline silicon (100) surfaces. In summary, UV light exposure of a hydrogen-terminated silicon (100) surface coated with alkenes functionalized with N-hydroxysuccinimide ester groups result in the covalent attachment of the alkene as a monolayer on the surface. Submicron-scale patterning of surfaces is achieved by illumination with an interference pattern obtained by the transmission of 248 nm excimer laser light through a phase mask. The N-hydroxysuccinimide ester surface act as a template for the subsequent covalent attachment of aminohexyl-modified DNA oligonucleotides. Oligonucleotide patterns, with feature sizes of 500 nm, are reliably produced over large areas. The patterned surfaces are characterized with atomic force microscopy, scanning electron microscopy, epifluorescence microscopy and ellipsometry. Complementary oligonucleotides are hybridized to the surface-attached oligonucleotides with a density of ˜7×1012 DNA oligonucleotides per square centimeter (for example).
- Some-possible coating combinations include:
- No coating: The cell is perturbed/stimulated by the physical disruption of the micro-nanoprojection structure. This physical stimulus can be coupled with electric stimulus as a form of specific nanoelectroporation of particular organelles or the cell.
- Coating entire nanoneedles: The bioactive material can coat the whole surface of the nanoneedle (over the length L).
- Selective coating: For certain applications only parts of the nanoneedle need be coated. For instance, the targeting section (l) can be selectively coated by only immersing this part of the needle in the coating media. Alternatively, different combinations of various coatings can be made on the one nanoneedle (combinations of DNA and adjuvants, proteins, cytokines, inhibitors etc.). Or, in the case of nanoneedle arrays, different coatings may be provided on different individual micro-nanoprojections.
- Coating materials: In addition to bioactive materials (such as DNA, RNA and proteins), the micro-nanoprojections may also be coated with nanobiosensors (e.g., quantum dots, nanomachines, MEMS) using a range of coating protocols.
- Material formulated in degradable micro-nanoprojections: All, or part of the micro-nanoprojection can be constructed of a biocompatible, biodegradable polymer (such as Poly Lactic Acid (PLA), Poly Glucleic Acid (PGA) or PGLA), which is formulated with the bioactive material of choice. The micro-nanoprojections may then be inserted and, as they dissolve, the bioactive material will enter the organelle(s)/cells.
- In the cases of bonding of the biomaterials to the surface of the micro-nanoprojections, access to the organelles may be by the following:
- The bioactive material can stay on the surface of the nanoneedle, but elicit the response within the organelle/cell.
- The bioactive material bonds can be broken by exposure of enzymes, proteins or hydration within the cell/organelle.
- This section outlines the simplest embodiment of the nanoneedle concept: an individual projection, coated on the surface with a bioactive material (here DNA coded for GFP to transfection), used to deliver this material to a living cell, in-vitro, where a biological response is measured (transfection) and the cell is alive.
- Following the engineering analyses discussed in
section 3, Tungsten was selected as the material for fabricating the individual nanoprojection, largely because of its high stiffness (E=400 GPa) and ease of fabrication. - Individual micro-nano projections were fabricated from tungsten rod of diameter 280 μm (Source, ADVENT Research Materials Ltd) using electropolishing (approximately following the protocol of Cerezo, A., Larson D. J. & Smith G. D. W. (2001) “Progress in the atomic-scale analysis of materials with the three-dimensional atom probe”. Materials Research Society Bulletin, 26(2): 102-107.
- The electropolishing set-up used a solution of distilled water with 4% NaOH molar. For the electropolishing tungsten probes with the sharpest tips, the following settings were used:
- 3 mm of probe submersed into the solution
- 10 volts A. C. for approx. 42 seconds.
- Following optimization, electropolishing was ceased when probe length began to diminish (detected by visual sighting by naked human eye).
- Recall the dimension parameters correspond to the generic micro-nanoprojection tip outlined in the schematic of
FIG. 20 . -
FIGS. 22A-B shows Transmission Electron Microscopy (TEM) of an electropolished Tungsten tip at two different resolutions, with the scale bar inFIG. 22A of 20 μm, and inFIG. 22B of 0.11 μm.FIGS. 22B and 22C show the minimum tip size (d1) is ˜100 nm (i.e., r˜50 nm). By using the electropolishing process, the projection gradually tapers to the full thickness of the original rod (i.e., d3=280 μm). In this case, the cell targeting length (l) is approximately 20 μm-defined by where the diameter (d2) remains less than ˜1 μm. - Individual micro-nano projections were glued into hole drilled into perspex cylindrical holders to allow fitting into microprojection systems (see section 5.5).
- The tungsten micro-nanoprojections were coated by adapting a protocol devised for the coating of gold microparticles for biolistic delivery developed by O'Brien and Lummis (2002) “An improved method of preparing microcarriers for biolistic transfection”, Brain Research Protocols 10 (2002) 12-15. The adapted protocol is as follows:
- Coat tungsten micro-nanoprojection in 50% glycerol/50% water solution by dipping the wire in the solution for 10 minutes.
- (ii) Remove the tungsten.
- (iii) Individual tungsten micro-nanoprojections were placed in a tube to which was added 50 ml of 1 M spermidine for 5 minutes.
- (iv) Add 1 μg/ml of 50 ml of DNA Spermidine and gently mix the two solutions with aspiration with the wire in the solution.
- (v) Gently, the tube was stirred for a few minutes, and then, whilst stirring, 1 M CaCl in solution was added in a drop wise manner.
- (vi) Gently mix the solution and let DNA precipitate on to the wire for 30 minutes.
- (vii) Remove wire from solution and dip it in 100% ethanol. Repeat this
process 3 times. - (viii) Let the wire dry before use.
- (ix) The process was then repeated for the other micro-nanoprojections.
-
FIGS. 23A and 23B show images of lengths of tungsten wire (280 82 m diameter) imaged with a fluorescent microscope with uncoated wire inFIG. 23A and DNA coated wire (using the described protocol, above) immersed in a liquid with a propidium iodide stain (red fluorescing dye) inFIG. 23B . As expected there is no red fluorescence with the uncoated wire, while the strong red fluorescence of the NDA coated tungsten qualitatively shows that the coating was successful. - To assess the delivery profile of DNA in the in-vitro equivalent of skin tissue, DNA coated projections were inserted into an agar (3%) gel stained with acridine orange (green fluorescing dye). This gel (without the stain) is routinely used for in-vitro testing of biolistic to devices for DNA vaccination and other applications.
- The uncoated and coated tungsten rods were inserted and removed by hand into the agar (to a depth >1 mm) for a cycle duration of approximately 1 second.
-
FIGS. 24A-24D show optically sectioned Multi-Photon Microscopy (MPM) images of the agar after insertion of a DNA coated tungsten probe on the surface inFIG. 24A , at a depth of 13 μm inFIG. 24B , at a depth of (32 82 m) inFIG. 24C .FIG. 24D shows an optical section at 32 82 m of agar gel following insertion of a probe without a DNA coating. - On the surface of the agar, there is very little fluorescence, indicating little DNA. In contrast, at depth sections of 13 μm and 32 82 m the fluorescence in the coated case is significant-indicating that DNA remained intact on the surface of the probe during insertion and then came off by exposure of the gel and/or by the action of removing the probe. This fluorescent signal was very strong compared with the uncoated probe control at 32 82 m.
- The described electropolished tungsten micro-nanoprojections coated with GFP plasmid DNA were tested, with the objective of determining whether the DNA could be delivered to transfect the cell, without damaging the cell.
- The cell line is called A549 which is a human lung carcinoma (epithelial) cell line. Cells were cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal calf serum at 37° C., 5% CO2.
- These cells were mounted on three separate Petri dishes with an optical slide underneath. The adherent properties of the cells ensured they remained in contact with the base of the dish.
- One of the Petri dishes with cells was set aside as a control. The other two Petri dishes were probed with the micro-nanoprojections. In total, 6 micro-nanoprojection systems were used.
- Probing of the cells was performed with a microinjection system (Eppendorf Femtoject and Injectman NI2 microinjection kit) fitted to an inverted fluorescent microscope (
Zeiss Axiovert 25 microscope with stage heater). - The micro-nanoprojection were fitted into the standard microinjection holder and then moved with course and fine adjustment of a motorized X-Y-Z axis controller to just contact the cell membrane, before retraction of less than 1 82 m.
- A cycle time of probing was set between limits of 0.1 and 15 seconds, with a traverse distance of 3-5 μm-then the cycle was automatically performed on the system.
- After 3 cells, the probe was replaced and refitted with a replacement. In total 10 cells were perturbed with a micro-nanoprojection coated in eGFP plasmid DNA.
- All the cell samples were then incubated for 24 hours before viewing with a wide field fluorescent microscope, with the appropriate fluorescent filters. The observed results show: in the control there is no sign of eGFP transfection, as expected. However, in the cell micro-nanoprojection cases, we see that 10 cells have transfected. Thus we have a 100% transfection efficiency and no evidence of cell death.
- These data prove the micro-nanoprojections, coated in DNA can individually target cells, transfecting them and not kill them.
- Also, subsequent analysis of the micro-nanoprojections showed they remained intact, illustrating that unlike biolistic delivery, the “carrier” material is not left behind.
- With the biological result achieved on a single cell, in-vitro (Experimental exemplification 1). this section outlines a logical progression, which is the physical testing of an individual micro-nano projection into a representative skin sample for structural integrity-thereby testing the engineering analyses outlined in
section 3. - Using the electroporation process described in
Embodiment 1, a micro-nanoproprojection was fabricated of Tungsten with a tip radius (r) of <400 nm. - The tissue was freshly excised Balb/C mice ears (age 8-10 weeks), which were glued to a metal cylinder holder. The reported stratum corneum and viable epidermis thicknesses of these samples are respectively ˜5 82 m and 12 82 m (Arbuthnott (2003)).
- The tissue was indented by fitting the micro-nanoprojection to a Nanoindenter (MTS systems, UK), measuring a force displacement curve.
FIG. 26 shows two typical sample results of loading-unloading curves achieved to a depth of ˜50 μm. These results show that the micro-nanoprojection probe penetrated through the epidermis and well into the dermis without damage. The difference in magnitude between the curves is typical of biological variability observed in bio-viscoelastic tissue. Importantly, unlike ballistic particle delivery, the depth of penetration is not dependent upon this variability-rather the length of projection. - Indeed, the projections did not break-the loading experiment was simply stopped at a 50 82 m setting on the experimental apparatus. This was confirmed by imaging with projections with a microscope after the experiment. This experiment was repeated 20 times, confirming the engineering analyses of probe structure required to target cells in the skin is applicable and valid.
- With the biological and engineering criteria investigated on an individual projection, the next logical step is to extend the concept to arrays of patches targeting tissue sites. Presented are several patch arrangements, each designed for a particular targeting need of cells, organelles and/or tissue sites.
-
FIG. 28 shows a schematic of an array of the described micro-nanoprojections configured on a patch, with the spacing between micro-nanoprojections defined as (S) and the patch breadth defined as (B). Recall, the basic dimensions and definitions of an individual micro-nanoprojection are outlined insection 3 and shown schematically inFIG. 20 ; these are referred to again here. - Operation of the patch with the micro-nanoprojections is, for example:
- (a) the slow insertion, by hand (or other means, such as a spring) of the patch onto the tissue, with the micro-nanoprojections inserting into the target tissue of interest.
- (b) the patch including the micro-nanoprojections are held in place for a sufficient time for the “event” (biological, physical or other) to take place. This may be instantaneous, or in other cases could take days, weeks or months.
- (c) the patch including the micro-nanoprojections are then retracted.
- These three stages form a cycle, that may be operated by hand or automated with the aid of suitable mechanical, electrical or electro-mechanical devices.
- Patches may be applied to the tissue site once, or a multitude of times depending upon the effect desired.
- The case examples presented in 7.2 all center on the targeting of Langerhans cells or organelles within these cells and the overall dimensions of the individual micro-nanoprojections are configured, using the approximate guideline of Example 1 and 2 shown in Table 2. However, as Table 2 also shows, these parameters (r, d1, d2, d3, a) can vary significantly, depending on the cell/organelle and its position relative to the tissue surface.
- The overall size (B×B) of the patch and spacing (S) between the micro-nanoprojections is determined by the application. Note, in all cases, the patch could be square (B×B), circular, elliptic, or any other suitable shape. For simplicity, the square dimensions are quoted throughout. Generally the size is to be less than 15×15 mm (B), with 1<S<1000 μm, preferably with 10<S<100 μm.
- Note that an alternative for these and other patch examples is for larger-patches, giving amplified responses and/or which may be easier to handle having regard to end users/patients/practitioners.
- Consider Example 1 from Table 2, which is the targeting of nuclei of Langerhans cells. Kendall et al. (2003); Kendall M. A. F., Mulholland W. J., Tirlapur U. K., Arbuthnott E. S., and Armitage, M. “Targeted delivery of micro-particles to epithelial cells for immunotherapy and vaccines: an experimental and probabilistic study”, The 6 th International Conference on Cellular Engineering, Sydney, August 20-22), suggest that to trigger cellular responses in DNA vaccination, of the order of 100 nuclei of LC are effectively transfected in gene gun applications that lead to the desired cellular (MHC 1) systemic response. A probability analysis has been performed to determine the configuration of patch required to transfect 100 cells. The probability of one micro-nanoprojection making contact with an organelle (or cell) defined over an area and volume is set by:
-
- In the analysis, it is assumed:
- that there is no cell death.
- the cell/organelle targeting sections (l) are configured to be at the correct depth (i.e., the depth of the Langerhans cells), and, for simplicity, parallel and 1im in diameter (d1=d2=1 μm).
- the cell/organelle targeting sections (l) are coated in DNA. Of course, for simplicity of coating, it is possible that most or all of the micro-nanoprojection structure is coated in DNA.
- contact of any part of the micro-nanoprojection along the cell/organelle targeting section with the nucleus is the only mode that leads to transfection (i.e., cytoplasm delivery, cross-priming and other modes are ignored).
- With a 1 μm diameter cell/organelle targeting section (1), the probability of contact with a LC nucleus is 0.0131. This probability is ˜1000-1500 times higher than a typical probability of a direct “hit” with the biolistics approach and microparticles. Furthermore, the transfection comparison is even more favorable for the micro-nanoprojection patch, given far fewer cells are killed than by the gene gun.
- Table 3 is a summary of configurations of patches that may be used. At one end of the range, a spacing of 100 rods/mm2 corresponds to a patch surface area of 76 mm2, with a spacing (S) of 100 82 m, a breadth of 8.7 mm and a total number of rods of over 7000. Increasing density of rods to 1000/nm2 results in a reduction in patch size to less than 3 mm×3 mm.
-
TABLE 3 Calculated Patch Configurations for the Targeting of Nuclei of LC. Area of patch Spacing (S) Breadth of Rod/mm2 (mm2) (μm) patch (B) (μm) Total Rods 100 76.4 100 8.7 7639 500 15.3 45 3.9 7639 1000 7.6 32 2.8 7639 - In Table 4, this analysis is extended to the configuration of patch required to target 100 LC (i.e., anywhere within the complete cell), using micro-nanoprojections with the same geometry as above, with the probability of the event 0.063. Not surprisingly, this is higher to than the probability of targeting the nuclei. Hence, fewer rods are needed and the patch size can be smaller (4×4 mm down to 1.25×1.25 mm).
-
TABLE 4 Calculated Patch Configurations for the Targeting of Anywhere Within Complete LC. The Nanoneedle Diameter d1 Is Assumed to Be 1 μm. Area of patch Spacing (S) Breadth of Rod/mm2 (mm2) (μm) patch (B) (μm) Total Rods 100 15.8 100 4.0 1578 500 3.2 45 1.8 1578 1000 1.5 32 1.3 1578 - In Table 5, the analysis is also applied to the targeting of the Endoplasmic Reticulum (Example 2 from Table 2), which may be required for targeted RNA delivery. Using the assumptions from above, with a probe diameter of 400 nm the probability of a single needle contacting the Endoplasmic Reticulum is 0.031. In this case, the size of patch ranges from 8×8 mm to 2.5×2.5 mm
-
TABLE 5 Calculated Patch Configurations for the Targeting of the Endoplasmic Reticulum of LC. The Nanoneedle Diameter Is Assumed to be 400 nm Area of patch Spacing (S) Breadth of Rod/mm2 (mm2) (μm) patch (B) (μm) Total Rods 100 65 100 8.0 6451 500 13 45 3.60 6451 1000 6.5 32 2.54 6451 - A patch may also have combinations of micro-nanoprojections, with different geometries. For example the length (L) or indeed the other parameters in
FIG. 20 may be varied throughout the patch, either in defined sequences, clusters and/or randomly (within limits). Within this, or separately, the diameter of the projection may be increased on individual micro-nanoprojections significantly in order to induce cell death at controlled locations. This, for example, may be used to induce bystander biological responses (e.g., stimulation/inflammation/activation) to neighboring healthy cells-which could have or will be interacting with described, smaller micro-nanoprojections configured for minimal cell damage. - The bioactive or other stimulus is to be coated or part of the nanoneedle array. The choice of bioactive is determined by the application and target organelles or cells of interest. This range encompasses, but is not restricted to:
- No coating
- Polynucleotides, DNA (all variants), RNA (all variants), proteins, antigens, allergens and adjuvants, molecules, compounds.
- Biosensor molecules and compounds and materials.
- Nanosensors (MEMS etc.).
- Combinations of the above, on a
- General requirements of the manufacturing method are:
- a radial resolution of <200 nm;
- to construct the nanoneedle array on a patch (e.g.,
FIG. 19 ) in a scaleable process for high throughput manufacturing with minimal human input. - Construction to be of a medical grade material (e.g., Gold, Silver, Titanium, Tungsten or PLA, PGA, PGLA, Silicon)
- A range of techniques for micro-nanofabrication methods described in text books, papers and in other literature (e.g., Madou M. J. “Fundamentals of Microfabrication. The science of miniaturization”, CRC Press, 2002; McAllister et al. 2003, PNAS, Nov. 25, 2003,
Vol 100, number 4) are applicable to the nanoneedle device here. - Furthermore there are a range of materials and fabrication methods being developed that also have potential utility as part of a micro-nanoprojection array. Three construction embodiments are shown here as examples.
- In these constructional embodiment example cases, the patch geometry of manufacture is summarized in Table 3, with an area of patch ˜76.4 mm2, a spacing of 100 μm and the minimum tip size of 1 82 m (d1). A schematic of this array on patch is shown in
FIG. 29 . Of course, the techniques can be applied to a range of geometries. - As an example of the fabrication of silicon micro-nanoprojections, the following is applied. Deep Reactive Ion Etching (DRIE) is used as a process ideal for these high aspect ratio structures, where in one example (Oxford
Instruments Plasmalab System 100, Modular ICP180 Etch System-S12), etch rates of >2.5 μm/min, and sometimes >5 82 m/min, are possible. Full details of etch protocols for this system are available in the literature, including Oxford Instruments company manuals. - Briefly, chromium was sputter deposited then lithographically patterned as an array of dots onto 3 inch (75 mm) 100 oriented silicon wafers. The array of dots had a center-to-center spacing of 100 μm, and in some earlier test cases, 10-20 μm. Similarly, through iteration with the conditions and exploring the extent of undercut, the diameter of the
dots 1 82 m, and in other cases, 3 82 m, 5 82 m, and 10 μm. Deep Reactive Ion Etching (DRIE, Oxford Instruments, Bristol, UK) was then carried out to obtain the desired by profile by adjusting the etch rate. - The typical instrument conditions included a 20 standard cm3/min (sccm) SF6 and 15 sccm (O2) at a pressure of 20 Pa. Power was varied. The etching process was performed at cryo-cooled conditions, achieving temperatures of −100 to −150° C. Lower etch rates were used for the tapered sections, whereas higher rates were used for the more parallel sections. Micro-nanoprojection fabrication was finished when the chromium masks became fully undercut and fell off the projection tips. The process is completed in less than 100 minutes, resulting in several patch configurations on the wafer.
- The patches were then cut from the silicon wafer, with a dedicated cutter.
- To increase the strength of the base of the patch, an additional, thicker material is affixed to the back surface (i.e., the surface without the projections).
- This process is repeated to fabricate a large quantity of micro-nanoprojection array patches.
- A variation of the described DRIE method may also be applied to other materials, including Silicon Carbide (SiC).
- This constructional embodiment example applies to a broader range of micro-nanoprojections materials than those described in the constructional embodiment Example 1. These materials include Metals, polymers, silicon and oxides/carbides.
- As an example, this case illustrates a method of fabricating tungsten micro-nanoprojection arrays on a patch. Three of the steps in this production process are discussed.
-
Step 1. Construction of a Template (Male) - To construct a male template with the profile of the micro-nanoprojections, LIGA is used (a German acronym for X-ray lithography, electrodeposition and molding). This template will serve in the production of several molds in a soft polymer. LIGA, which utilizes a Synchroton, is ideal for creating the template because it has a very high resolution (<20 nm), can fabricate in metals, and will easily fabricate a patch (maximum component size is 3.4 inches in the Axsun technologies system). Fabrication protocols to construct the template are detailed in
Chapter 6 of Madou M. J. “Fundamentals of Microfabrication. The science of miniaturization”, CRC Press, 2002 manuals and literature from companies (e.g., AXSUN Technologies, Ca, USA). The choice of materials for fabrication include Nickel (Ni), Nickel-Iron (NiFe), Nickel-Cobalt (Ni—Co) Gold, Copper and Silver. In this example, Nickel is selected as the material from which the micro-nanoprojection array template is constructed. - It should be noted here that as an alternative, LIGA could be used to make individual patches directly (e.g., of gold or silver-which are both biocompatible) in large quantities. With current costs of the LIGA technology, this is not practical-but with LIGA technology advances, this could be feasible in the future.
- Step 2: Construction of a Mask (Female Component)
- Because of the discussed current characteristics of LIGA (e.g., cost), LIGA is not used to mass-fabricate micro-nanoprojection array patches for direct use with the tissue in large numbers. However, here it can be used as a template for many multi-stage processes. As one example, the template is used for multiple insertions into a soft polymer to produce a mask, as shown in
FIGS. 30A-30C , performed in the following steps: -
FIG. 30A Insertion of the template directly into the soft polymer. This is repeated several times to produce many indentations in the polymer with a given mask. -
FIG. 30B Allowing the soft polymer to harden, or “cure” with the addition of catalysts and or temperature. -
FIG. 30C Remove the template to leave behind a mask. - Step 3: Final Construction of the Nanoneedle Array with the Mask
- The masks are then be placed in a vacuum chamber and deposited with a vacuum deposition/sputtering process. The material to be sputtered is a biocompatible inert material, such as titanium, gold, or silver. In this process, the polymer surface is treated with an air discharge before the chamber is pumped down to a vacuum at 27 degrees C. The titanium, gold or silver film is then deposited. Commercial sputtering machines may be used in this process (such as the VarianVM8 Sputterer).
- If a charge is required to produce an anode to enhance the coating of the nanoneedle section, then the end extension of this piece can be “opened up” to expose a stronger anode which the positive charged metallic ions in solution are attracted to. This technique makes use of Magnetron Sputtering.
- Step 4: Constructional Embodiment Example 3 Method
- The mask can then be removed by immersion of a liquid (e.g., alcohols) to dissolve it.
- Alternatively, a mask (female) can be directly manufactured using Two-Photon Stereo Lithography (2PSL), in which the geometry co-ordinates shown in
FIG. 30(C) are applied to construct the desired shape with the photosensitive resin. Femtosectond two-photon stereo-lithography (2PSL) is described in detail by Miwa et al. (2001, Appl Physics. A 73, 561-566). Zhou et al. (2002, Vol 296, Science), Stellacci et al. (2002, Adv. Mater. 14 (3)) and Halik et al. (2003, Chem Commun 1490-1491). This to approach has demonstrated the ability to construct complicated 3D shapes with a resolution of <200 nm out of materials including photosensitive polymer resins and metals in conjunction with dyes. Lattice structures of the desired scale have been constructed with the technique using resins impregnated with Silver (from Stellacci et al. 2002). - Briefly, the technique works by scanning with a femtosecond laser in a liquid photosensitive resin bath. The two-photon effect ensures that solidification occurs only where the energy of the laser is concentrated to a femtolitre volume (typically 200 nm×200 nm×400 nm, x, y, z). The method of manufacture is to start at the tip of the nanoneedle (marked A in
FIG. 29 ) and then work up the needle to the base. - The same approach applies to the rest of the nanoneedles. The process is fully automated with a motorized x-y stage with the laser co-ordinates determined from engineering drawings of the structure. Therefore, thousands of nanoneedles can be constructed in a scaleable process. The technique allows complicated 3D structures to be constructed by the scanning of a pulsed (80 MHz), femtosecond pulse length laser concentrating light at 400-1000 nm to a femtolitre volume to induce a two photon excitation of the material and induce solidification.
- The nanoneedles may be constructed with a photosensitive polymer/resin, (such as the commercial grade SCR 500) or an alternative impregnated with Silver (following Stellacci et al. 2002).
- These materials are currently not suited to be used directly in the skin due to insufficient stiffness. Young's Modulus of
SCR 500 is 0.49 Gpa compared with - 116 Gpa for Titanium or 77.2 Gpa for Gold.
- Not medical grade material. At the time of writing, photosensitive resins such as
SCR 500 had not gained approval for medical grade purposes. - However, the technique is rapidly improving and may be a possible fabrication method in the future.
- In this case nanoneedles are constructed with silicon, with a 200 nm tip for a length of 5 μm followed by two other parallel sections separated by tapered sections. This structure may be constructed by Electron Beam Lithography and Reactive Ion Etching, a standard technique in to the microelectronics industry. The manufacturing approach has been applied by Henry et al. (Journal of Pharmaceutical Sciences 87(8), 1998) and in Lebouitz and Pisano et al. (U.S. Pat. No. 5,928,207) in the construction of microneeedles.
-
FIG. 31 shows the structure produced with one of these techniques. In this case of the nanoneedles, each parallel section may be constructed withsilicon 100 wafers and the tapered sections constructed with silicon 111 (or other) wafer material-where the angle of the taper is a preferred etching line of the material. The shown shape is made from 5 wafers (one wafer per geometry). A gradual taper mold can be constructed from the one silicon wafer. - Alternatively, the silicon arrays may be used as masters for microarray molds.
- Recall in
section 1 the specific target sites of key cells and organelles are described, followed insection 2 by their location within many tissue and in-vitro sites. With the described approach of targeting individual cells, then several cells and the shape/coating/fabrication considerations outlined, the methods of applying these micro-nanoprojection arrays to various tissue sites are now discussed. - With the described embodiments for the skin previously described, the patch is inserted into the skin either by user control or by mechanical, electrical or other controlled means. All these options are possible, as the magnitude of the forces is low. For example, the insertion force is approximately calculated to be less than 1 N (based on 7000 probes, 1 82 m in diameter piercing tissue with a yield of 20 MPa).
- Similarly, the time of insertion, residence and removal from the tissue can be controlled by user and/or the described mechanical/electrical means.
- One embodiment of a simple application system for the patch is shown in
FIGS. 32A and 32B . - In this example, the
application system 3300 is formed from a structure in the form of a housing orbody 3310. Thebody 3310 defines acavity 3320 having anopening 3330. In use, apatch 100, having a number ofprojections 110 provided on abase 120, is moveably mounted within thecavity 3320. This may be achieved in any one of a number of manners, to but typically involves having thepatch 100 suitable sized to allow movement along the cavity towards and away from theopening 3330. - The
patch 100 is mounted to an actuator, so that in use the patch may be moved from a retracted position shown inFIG. 32A , to an extended position shown in 32B. The actuator may be of any suitable form, but in one example, includes aspring 3340 and a releasingmeans 3350. - In the retracted position, the
spring 3340 is biased against thepatch 100, thereby urging thepatch 100 towards theopening 3330, with thepatch 100 being retained in the retracted position by the releasingmember 3350. When the releasing means is activated, for example, by having an operator release the wire, thespring 3340 urges thepatch 100 towards theopening 3330, so that theprojections 110 extend therethrough. - It will be appreciated from this that if the
structure 3310 is positioned within theopening 3330 adjacent a subject's skin 3360, then operation of the releasingmeans 3350 causes thepatch 100 to be pressed against the subject's skin 3360, so that theprojections 110 enter the viable epidermis as described above. - In the retracted position (
FIG. 32(a) ) the micro-nanoprojections patch is recessed and thus protected, preventing accidental administration. Other packaging/devices may also be used for these purposes, for example a protective cap to be removed before administration. - In this example, the patch is attached to a compressed spring that is held in place by a tensioned string. It will be appreciated that the releasing means typically is arranged so that the
patch 100 is retained in the retracted position until the releasing means is activated. Thus, thepatch 100 may be retained in position by a clip that is released upon activation of the releasing means. This allows the operator to position the device against the subject's skin 3360 without having to retain the patch in the retracted position. When located on the tissue, the string. is released by a means (e.g., pressing a button, not shown inFIG. 32 ) and the patch is released to enter the tissue surface (FIG. 32(b) ). - To effectively target mucosal sites (e.g., mouth, nasal, rectal, vaginal), the described patch arrangements may be fitted to an applicator designed to safely transport the patch into the mouth and to accurately locate on to the mucosal site. This could be done by using the described intradermal patch in the mouth.
- Alternatively,
FIG. 33 shows one example of and applicator for mucosal delivery for the buccal mucosa (mouth). In this example, the patch arrangement fromFIG. 32 in the form of theapplication system 3300 is coupled to anarm 3400, allowing theapplication system 3300 to be positioned in otherwise hard to reach places. The spring arrangement allows the patch to be applied, but other mechanisms equally could be used. The applicator could have a button at the distal end of thearm 3400 from the patch to allow the operator to release the patch onto the mucosal site. - Other features may include a knurled surface towards the distal end to aid user grip.
-
FIG. 34 shows a schematic of the physiology of the airways in a human. To apply the micro-nanoprojections to targeting cells in the tracheal or lung lining, an applicator that can flexibly and compactly reach these sites, target the sites, and then retract, is required. - As one example,
FIGS. 35A-35C show a deployable structure embodiment for targeting these sites. - In this example, the apparatus includes an
application system 3600 mounted to a flexible structure, such as an arm, allowing theapplication system 3600 to be inserted into apassageway 3620, such as an airway, of the subject. To allow theapplication system 3600 to be guided to the correct location, the flexible structure may be in the form of a manipulable fiberscope, or the like. - The application system includes a structure such as a
body 3630, having a number ofarms 3640 movably mounted thereto, to allow the arms to move between a retracted position shown inFIG. 35B and an extended position shown inFIG. 35C . In use, thearms 3640 are typically biased towards the extended position, and are retained in the retracted position, using a releasing mechanism, such as a clip or the like. It will be appreciated that this may be similar to the releasing means described above with respect toFIG. 34 . - In any event,
patches 100 are mounted to the arms, so that when the arms are released, the patches are urged against asurface 3621 of thepassageway 3620, allowing theprojections 110 provided on each patch to penetrate thesurface 3621, and deliver material or stimulus to prospective targets. - In the example shown, the eight
arms 3640 are provided in two sets of four, with the four arms in each set being circumferentially spaced around thebody 3630, as shown inFIG. 35C . - The method of operation is as follows. The flexible structure (
FIG. 35A ) is guided through the throat to the site of interest. This device may be fitted with imaging/illumination systems to help guidance.FIG. 35B shows the system in location in a “retracted” position. The arms fitted with the patches are held in place against a spring load with pivot points. Then, by mechanical actuation, the arms are released (FIG. 35C ), with the springs providing the force for location on the tissue. - The device does not need to be exactly centralized as the arms are self-locating. By tension with wires, the arms are retracted, and the device is removed through the throat.
- In another embodiment, the arms are replaced by an inflatable structure (a “sock”) fully coated by the micro-nanoprojections on the outside surface. When deflated, this sock would be held in a structure which would look similar to
FIG. 35A on the outside. When in place, the sock would be inflated via a pressurized gas, locating on the tissue wall. This approach would be particularly useful where large surfaces need targeting, such as the lung. At the required time, the pressure is released with a valving arrangement and the sock collapses back into flexible targeting system and the device is removed. - Other internal organs or tissues (e.g., liver, kidney, heart) are not as readily accessed as those described above. Here, more invasive means are required to expose the site of interest before targeting. One example is a more compact “catheter” version of the described lower airway/lung targeting devices, reaching the site via keyhole routes.
- Another embodiment is surgery to fully open the site before application with the patch.
- The micro-nanoprojections may be fitted to patches for in-vitro targeting, allowing a high-throughput targeting of cells. In one example, larger patches with thousands and perhaps millions of projections could be mechanically lowered onto cell monolayers, and then removed, similar to a mechanical “press” arrangement. This could, for instance, allow a mass transfection of cells, in-vitro.
- As another variation, cells are dynamically moving in a shallow fluid stream. As these cells move, they pass below large plates with thousands, and perhaps millions of micro-nanoprojections. These plates pressing into this cell layer repeatably, in a synchronized manner so that each pressing cycle targets the appropriate batch of cells.
Claims (8)
1.-45. (canceled)
46. A method of designing a microprojection array targeting a particular target in a subject's skin comprising microprojections having a targeting section and a support section comprising:
selecting a target below the surface of the skin in a layer of the skin wherein the skin layer has an upper portion and a lower portion;
selecting a diameter of the targeting section to be smaller than the diameter of the target;
selecting a microprojection length based on the target depth below the skin such that the microprojection penetrates the upper portion of the layer but does not exceed the lower portion of the layer;
determining the likelihood of a single targeting event;
determining the number of targeting events required for a desired effect;
determining the number of microprojections;
determining the spacing between microprojections based on the target diameter and target spacing; and
combining the information to design a microprojection array targeting a particular target in a subject's skin.
47. The method of claim 46 wherein the target is Langerhans cells.
48. The method of claim 47 wherein the desired effect is an immunological response in the subject
49. The method of claim 48 wherein the length of the support section is:
(D c +h layer/2)≥a≥(Dc −h layer/2)
(D c +h layer/2)≥a≥(Dc −h layer/2)
where:
Dc is the depth of the target layer;
hlayer is the height of the layer in the skin; and,
a is the length of the support section.
50. The method of claim 49 wherein the length of the targeting section is l≥hlayer.
51. The method of claim 49 wherein the likelihood of a single target event is determined by:
where:
σ is the standard deviation from a mean location, accounting for the skin surface undulations.
Dc is a distance of the cells of interest below a surface of the body against which the device is to be applied in use;
Q is a number of standard deviations from a mean level of the surface of the body at which the device comes to rest in use;
a is the length of the support section; and,
l is the length of the targeting section.
52. The method of claim 51 wherein the spacing between the microprojections is less than or equal to the diameter of the target.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/326,064 US20220039812A1 (en) | 2004-01-30 | 2021-05-20 | Method of delivering material or stimulus to a biological subject |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0402131.7A GB0402131D0 (en) | 2004-01-30 | 2004-01-30 | Delivery method |
GB0402131.7 | 2004-01-30 | ||
PCT/GB2005/000336 WO2005072630A1 (en) | 2004-01-30 | 2005-01-31 | Device for delivery of bioactive materials and other stimuli |
US11/496,053 US8052633B2 (en) | 2004-01-30 | 2006-07-27 | Delivery device |
US13/251,920 US9888932B2 (en) | 2004-01-30 | 2011-10-03 | Method of delivering material or stimulus to a biological subject |
US15/849,134 US11207086B2 (en) | 2004-01-30 | 2017-12-20 | Method of delivering material or stimulus to a biological subject |
US17/326,064 US20220039812A1 (en) | 2004-01-30 | 2021-05-20 | Method of delivering material or stimulus to a biological subject |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/849,134 Continuation US11207086B2 (en) | 2004-01-30 | 2017-12-20 | Method of delivering material or stimulus to a biological subject |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220039812A1 true US20220039812A1 (en) | 2022-02-10 |
Family
ID=31971794
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/496,053 Active - Reinstated 2028-03-30 US8052633B2 (en) | 2004-01-30 | 2006-07-27 | Delivery device |
US13/251,891 Active 2027-08-01 US9572969B2 (en) | 2004-01-30 | 2011-10-03 | Delivery device |
US13/251,920 Active 2027-08-24 US9888932B2 (en) | 2004-01-30 | 2011-10-03 | Method of delivering material or stimulus to a biological subject |
US15/401,950 Active US10751072B2 (en) | 2004-01-30 | 2017-01-09 | Delivery device |
US15/849,134 Active 2026-10-24 US11207086B2 (en) | 2004-01-30 | 2017-12-20 | Method of delivering material or stimulus to a biological subject |
US16/896,387 Pending US20200405331A1 (en) | 2004-01-30 | 2020-06-09 | Delivery device |
US17/326,064 Pending US20220039812A1 (en) | 2004-01-30 | 2021-05-20 | Method of delivering material or stimulus to a biological subject |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/496,053 Active - Reinstated 2028-03-30 US8052633B2 (en) | 2004-01-30 | 2006-07-27 | Delivery device |
US13/251,891 Active 2027-08-01 US9572969B2 (en) | 2004-01-30 | 2011-10-03 | Delivery device |
US13/251,920 Active 2027-08-24 US9888932B2 (en) | 2004-01-30 | 2011-10-03 | Method of delivering material or stimulus to a biological subject |
US15/401,950 Active US10751072B2 (en) | 2004-01-30 | 2017-01-09 | Delivery device |
US15/849,134 Active 2026-10-24 US11207086B2 (en) | 2004-01-30 | 2017-12-20 | Method of delivering material or stimulus to a biological subject |
US16/896,387 Pending US20200405331A1 (en) | 2004-01-30 | 2020-06-09 | Delivery device |
Country Status (3)
Country | Link |
---|---|
US (7) | US8052633B2 (en) |
GB (1) | GB0402131D0 (en) |
WO (1) | WO2005072630A1 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0402131D0 (en) | 2004-01-30 | 2004-03-03 | Isis Innovation | Delivery method |
DK1994139T3 (en) | 2006-03-10 | 2016-10-24 | Pasteur Institut | Live, attenuated Bordetella strain as a single dose vaccine against whooping cough. |
US8865288B2 (en) | 2006-07-17 | 2014-10-21 | University Of Utah Research Foundation | Micro-needle arrays having non-planar tips and methods of manufacture thereof |
EP2077821B1 (en) | 2006-10-12 | 2019-08-14 | The University Of Queensland | Compositions and methods for modulating immune responses |
EP2231257A4 (en) | 2007-12-24 | 2013-11-06 | Univ Queensland | Coating method |
CA2749347C (en) | 2008-02-07 | 2018-03-27 | The University Of Queensland | Patch production |
CA2760680A1 (en) | 2008-05-23 | 2009-11-26 | The University Of Queensland | Analyte detection by microneedle patch with analyte selective reagents |
US8886279B2 (en) | 2008-06-03 | 2014-11-11 | University Of Utah Research Foundation | High aspect ratio microelectrode arrays enabled to have customizable lengths and methods of making the same |
US8639312B2 (en) | 2008-12-10 | 2014-01-28 | University Of Utah Research Foundation | System and method for electrically shielding a microelectrode array in a physiological pathway from electrical noise |
CA2760573A1 (en) | 2008-12-22 | 2010-07-01 | The University Of Queensland | Patch production |
JP5678034B2 (en) | 2009-04-28 | 2015-02-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Vaccines for the prevention or treatment of allergen-driven airway conditions |
US8834423B2 (en) | 2009-10-23 | 2014-09-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Dissolvable microneedle arrays for transdermal delivery to human skin |
CN102985131B (en) | 2010-04-28 | 2016-06-29 | 金伯利-克拉克环球有限公司 | For delivering the medical treatment device of siRNA |
AU2011246879C1 (en) | 2010-04-28 | 2016-03-24 | Sorrento Therapeutics, Inc. | Device for delivery of rheumatoid arthritis medication |
AU2011288209C1 (en) | 2010-04-28 | 2016-03-24 | Kimberly-Clark Worldwide, Inc. | Injection molded microneedle array and method for forming the microneedle array |
AU2011311255B2 (en) | 2010-04-28 | 2015-10-08 | Sorrento Therapeutics, Inc. | Method for increasing permeability of an epithelial barrier |
US9943673B2 (en) | 2010-07-14 | 2018-04-17 | Vaxxas Pty Limited | Patch applying apparatus |
JP5770055B2 (en) * | 2010-09-29 | 2015-08-26 | 富士フイルム株式会社 | Method for manufacturing needle-like array transdermal absorption sheet |
JP2013545453A (en) | 2010-11-01 | 2013-12-26 | ユニバーシティ・オブ・テクノロジー、シドニー | Immunomodulators and their use |
WO2012149166A1 (en) * | 2011-04-27 | 2012-11-01 | Brigham Young University | Delivery of biological materials into cellular organelles |
EP2765927B1 (en) | 2011-10-12 | 2021-02-24 | Vaxxas Pty Limited | Delivery device |
BR112014009712A2 (en) | 2011-10-27 | 2017-04-18 | Kimberly Clark Co | implantable devices for the administration of bioactive agents |
WO2013061208A1 (en) | 2011-10-27 | 2013-05-02 | Kimberly-Clark Worldwide, Inc. | Transdermal delivery of high viscosity bioactive agents |
US20170246439A9 (en) | 2011-10-27 | 2017-08-31 | Kimberly-Clark Worldwide, Inc. | Increased Bioavailability of Transdermally Delivered Agents |
DE102012100308A1 (en) * | 2012-01-13 | 2013-07-18 | Technische Universität Berlin | Device for applying an active substance to or in an organic tissue and method |
MX370579B (en) | 2012-05-01 | 2019-12-17 | Univ Pittsburgh Commonwealth Sys Higher Education | Tip-loaded microneedle arrays for transdermal insertion. |
GB2517707B (en) | 2013-08-28 | 2020-09-02 | Pci Biotech As | A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen |
EP3111985B1 (en) * | 2014-02-24 | 2021-01-13 | Toppan Printing Co., Ltd. | Hollow needle-shaped body manufacturing method and hollow needle-shaped body |
JP6625566B2 (en) * | 2015-01-20 | 2019-12-25 | テルモ株式会社 | Injection needle assembly and syringe for injecting a drug solution into the upper layer of skin having the same |
EP3253440B1 (en) | 2015-02-02 | 2022-12-21 | Vaxxas Pty Limited | Microprojection array applicator |
US10765851B2 (en) * | 2015-03-03 | 2020-09-08 | Guided Therapy Systems Llc | Methods and systems for material transport across an impermeable or semi-permeable membrane via artificially created microchannels |
US10441768B2 (en) | 2015-03-18 | 2019-10-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bioactive components conjugated to substrates of microneedle arrays |
US11103259B2 (en) | 2015-09-18 | 2021-08-31 | Vaxxas Pty Limited | Microprojection arrays with microprojections having large surface area profiles |
US11684763B2 (en) | 2015-10-16 | 2023-06-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Multi-component bio-active drug delivery and controlled release to the skin by microneedle array devices |
WO2017120322A1 (en) | 2016-01-05 | 2017-07-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Skin microenvironment targeted delivery for promoting immune and other responses |
US20180028755A1 (en) | 2016-07-28 | 2018-02-01 | Portal Instruments, Inc. | Connected health platform including needle-free injector system |
DK3606760T3 (en) | 2017-03-31 | 2023-11-06 | Vaxxas Pty Ltd | ARRANGEMENT AND PROCEDURE FOR COATING SURFACES |
WO2018227246A1 (en) | 2017-06-13 | 2018-12-20 | Vaxxas Pty Limited | Quality control of substrate coatings |
EP3661587A4 (en) | 2017-08-04 | 2021-06-09 | Vaxxas Pty Limited | Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (map) |
AU2018315629A1 (en) * | 2017-08-10 | 2020-02-27 | Vaxxas Pty Limited | Differential coating of microprojections and microneedles on arrays |
WO2019077028A1 (en) * | 2017-10-18 | 2019-04-25 | Institut Pasteur De Lille | Bordetella strains expressing serotype 3 fimbriae |
US20210030467A1 (en) * | 2018-02-12 | 2021-02-04 | Flagship Pioneering Innovations V, Inc. | Devices and methods for delivering material into a biological tissue or cell |
TWI698263B (en) * | 2018-07-19 | 2020-07-11 | 淡江大學 | Method for manufacturing micro-needle device and method for manufacturing micro-needle mold |
JP7379505B2 (en) | 2018-10-02 | 2023-11-14 | ウェアオプティモ ピーティーワイ リミテッド | Determining fluid level |
WO2020069567A1 (en) | 2018-10-02 | 2020-04-09 | WearOptimo Pty Ltd | Electrode arrangement |
AU2020255670A1 (en) * | 2019-03-29 | 2021-11-18 | Vaxxas Pty Ltd | Vaccination using high-density microprojection array patch |
US20220218971A1 (en) * | 2019-05-10 | 2022-07-14 | Cornell University | Nanoprojection devices as well as methods of making and using such devices |
IL293214A (en) * | 2019-11-22 | 2022-07-01 | Veradermics Incorporated | Microneedle patch for immunostimulatory drug delivery |
WO2022150872A1 (en) * | 2021-01-13 | 2022-07-21 | Women's and Children's Local Health Network Inc. | Methods and devices for delivering agents to the respiratory system |
US11872111B2 (en) | 2021-03-23 | 2024-01-16 | Orlucent Inc. | Patches for localized use |
WO2023147535A2 (en) * | 2022-01-28 | 2023-08-03 | The Trustees Of Columbia University In The City Of New York | Microneedle apparatus and system for perforation of the round window membrane |
WO2024054187A1 (en) | 2022-09-06 | 2024-03-14 | Bilkent Universitesi Ulusal Nanoteknoloji Arastirma Merkezi | A micro-needle production method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020177839A1 (en) * | 2001-04-20 | 2002-11-28 | Cormier Michel J. N. | Microprojection array having a beneficial agent containing coating |
US6551849B1 (en) * | 1999-11-02 | 2003-04-22 | Christopher J. Kenney | Method for fabricating arrays of micro-needles |
US6558361B1 (en) * | 2000-03-09 | 2003-05-06 | Nanopass Ltd. | Systems and methods for the transport of fluids through a biological barrier and production techniques for such systems |
US6589202B1 (en) * | 2000-06-29 | 2003-07-08 | Becton Dickinson And Company | Method and apparatus for transdermally sampling or administering a substance to a patient |
US20030199811A1 (en) * | 1999-09-24 | 2003-10-23 | Sage Burton H. | Method and device for abrading skin |
US8052633B2 (en) * | 2004-01-30 | 2011-11-08 | Mark Anthony Fernance Kendall | Delivery device |
Family Cites Families (217)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2213830A (en) | 1938-12-10 | 1940-09-03 | Anastasi John Joseph | Suturing and ligating instrument |
US2881500A (en) | 1958-07-03 | 1959-04-14 | Charles W Furness | Corneal clamp |
EP0139286B1 (en) | 1983-10-14 | 1991-08-21 | Sumitomo Pharmaceuticals Company, Limited | Prolonged sustained-release preparations |
US4530363A (en) | 1983-10-20 | 1985-07-23 | General Electric Company | Transducer array for sector scan and doppler flow measurement applications |
US4702799A (en) | 1985-09-03 | 1987-10-27 | Nestec S.A. | Dryer and drying method |
US5017007A (en) | 1989-07-27 | 1991-05-21 | Milne Christopher G | Apparatus and microbase for surface-enhanced raman spectroscopy system and method for producing same |
WO1991006571A1 (en) | 1989-11-03 | 1991-05-16 | Immulogic Pharmaceutical Corporation | A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor |
US5201992A (en) | 1990-07-12 | 1993-04-13 | Bell Communications Research, Inc. | Method for making tapered microminiature silicon structures |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US5657138A (en) | 1991-10-13 | 1997-08-12 | Lewis; Aaron | Generating defined structures on materials using combined optical technologies for transforming the processing beam |
WO1994024281A1 (en) | 1993-04-14 | 1994-10-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
AT397458B (en) | 1992-09-25 | 1994-04-25 | Avl Verbrennungskraft Messtech | SENSOR ARRANGEMENT |
US5461482A (en) | 1993-04-30 | 1995-10-24 | Hewlett-Packard Company | Electrical interconnect system for a printer |
US5449064A (en) | 1994-03-03 | 1995-09-12 | University Of Kansas | On-line interface and valve for capillary electophoresis system |
US5457041A (en) * | 1994-03-25 | 1995-10-10 | Science Applications International Corporation | Needle array and method of introducing biological substances into living cells using the needle array |
FR2720003B1 (en) | 1994-05-23 | 1998-06-26 | Samsung Electro Mech | Device used to incise the skin for transcutaneous medication. |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5499474A (en) | 1994-11-28 | 1996-03-19 | Knooihuizen; Louis D. | Method and apparatus for liquid application |
JP3366146B2 (en) | 1995-03-06 | 2003-01-14 | セイコーエプソン株式会社 | Ink jet head |
AU5869796A (en) | 1995-05-22 | 1996-12-11 | Ned A. Godshall | Micromechanical patch for enhancing the delivery of compound s through the skin |
US6969635B2 (en) | 2000-12-07 | 2005-11-29 | Reflectivity, Inc. | Methods for depositing, releasing and packaging micro-electromechanical devices on wafer substrates |
DE69719761T2 (en) | 1996-06-18 | 2003-12-18 | Alza Corp | DEVICE FOR IMPROVING THE TRANSDERMAL ADMINISTRATION OF MEDICINAL PRODUCTS OR THE DETECTION OF BODY LIQUIDS |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
EP0957972B1 (en) | 1996-12-20 | 2003-03-19 | Alza Corporation | Device and method for enhancing transdermal agent flux |
AU5706598A (en) | 1996-12-24 | 1998-07-17 | Alza Corporation | Method and device for controlling mammalian reproductive cycle |
US5859937A (en) * | 1997-04-04 | 1999-01-12 | Neomecs Incorporated | Minimally invasive sensor |
KR100219848B1 (en) | 1997-04-22 | 1999-09-01 | 이종수 | Method and apparatus for the structural analysis of a structure |
US5928207A (en) | 1997-06-30 | 1999-07-27 | The Regents Of The University Of California | Microneedle with isotropically etched tip, and method of fabricating such a device |
AUPP807899A0 (en) | 1999-01-08 | 1999-02-04 | University Of Queensland, The | Codon utilization |
WO1999002694A1 (en) | 1997-07-09 | 1999-01-21 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
US5943075A (en) | 1997-08-07 | 1999-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Universal fluid droplet ejector |
NL1008315C2 (en) | 1998-02-16 | 1999-08-25 | Stichting Fund Ond Material | Microdialysis probe integrated with Si chip. |
AU2872199A (en) | 1998-02-20 | 1999-09-06 | Rockefeller University, The | Apoptotic cell-mediated antigen presentation to dendritic cells |
JP3372862B2 (en) | 1998-03-25 | 2003-02-04 | 株式会社日立製作所 | Biological fluid mass spectrometer |
FI103399B (en) | 1998-04-03 | 1999-06-30 | Nextrom Holding Sa | Method and arrangement for double bobbin winding |
WO1999064580A1 (en) | 1998-06-10 | 1999-12-16 | Georgia Tech Research Corporation | Microneedle devices and methods of manufacture and use thereof |
US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
GB9815819D0 (en) * | 1998-07-22 | 1998-09-16 | Secr Defence | Transferring materials into cells and a microneedle array |
US6004815A (en) | 1998-08-13 | 1999-12-21 | The Regents Of The University Of California | Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells |
US7048723B1 (en) * | 1998-09-18 | 2006-05-23 | The University Of Utah Research Foundation | Surface micromachined microneedles |
US6414501B2 (en) | 1998-10-01 | 2002-07-02 | Amst Co., Ltd. | Micro cantilever style contact pin structure for wafer probing |
US6610382B1 (en) | 1998-10-05 | 2003-08-26 | 3M Innovative Properties Company | Friction control article for wet and dry applications |
US20020004041A1 (en) | 1999-02-19 | 2002-01-10 | Albert Matthew L. | Methods for abrogating a cellular immune response |
US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
EP1187653B1 (en) | 1999-06-04 | 2010-03-31 | Georgia Tech Research Corporation | Devices for enhanced microneedle penetration of biological barriers |
US6256533B1 (en) * | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
US6312612B1 (en) | 1999-06-09 | 2001-11-06 | The Procter & Gamble Company | Apparatus and method for manufacturing an intracutaneous microneedle array |
US6299621B1 (en) | 1999-06-18 | 2001-10-09 | Novare Surgical Systems, Inc. | Surgical clamp pads with elastomer impregnated mesh |
EP1065823A1 (en) | 1999-06-29 | 2001-01-03 | Siemens Aktiengesellschaft | Method for monitoring the bit transmission quality in a packet oriented transmission |
US6233797B1 (en) * | 1999-07-13 | 2001-05-22 | Groz Beckert Kg | Felt needle |
DE19935165A1 (en) | 1999-07-28 | 2001-02-01 | Roche Diagnostics Gmbh | Method and arrangement for determining the concentration of glucose in a body fluid |
DE60024312T2 (en) * | 1999-12-10 | 2006-08-17 | Alza Corp., Mountain View | Transdermal drug delivery of macromolecular agents and device therefor |
US6565532B1 (en) | 2000-07-12 | 2003-05-20 | The Procter & Gamble Company | Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup |
US6537242B1 (en) * | 2000-06-06 | 2003-03-25 | Becton, Dickinson And Company | Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance |
US6540675B2 (en) | 2000-06-27 | 2003-04-01 | Rosedale Medical, Inc. | Analyte monitor |
GB0017999D0 (en) | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
US6749575B2 (en) | 2001-08-20 | 2004-06-15 | Alza Corporation | Method for transdermal nucleic acid sampling |
US6533949B1 (en) * | 2000-08-28 | 2003-03-18 | Nanopass Ltd. | Microneedle structure and production method therefor |
US7828827B2 (en) | 2002-05-24 | 2010-11-09 | Corium International, Inc. | Method of exfoliation of skin using closely-packed microstructures |
IL155583A0 (en) | 2000-10-26 | 2003-11-23 | Alza Corp | Transdermal drug delivery devices having coated microprotrusions |
US9302903B2 (en) * | 2000-12-14 | 2016-04-05 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
US6663820B2 (en) | 2001-03-14 | 2003-12-16 | The Procter & Gamble Company | Method of manufacturing microneedle structures using soft lithography and photolithography |
WO2002074173A1 (en) | 2001-03-16 | 2002-09-26 | Alza Corporation | Method and apparatus for coating skin piercing microprojections |
US20020193729A1 (en) | 2001-04-20 | 2002-12-19 | Cormier Michel J.N. | Microprojection array immunization patch and method |
US6591124B2 (en) | 2001-05-11 | 2003-07-08 | The Procter & Gamble Company | Portable interstitial fluid monitoring system |
US7186235B2 (en) | 2001-06-08 | 2007-03-06 | Becton, Dickinson And Company | Device for manipulating a needle or abrader array and method of use |
US6767341B2 (en) | 2001-06-13 | 2004-07-27 | Abbott Laboratories | Microneedles for minimally invasive drug delivery |
US6557849B2 (en) * | 2001-06-21 | 2003-05-06 | Da La Rue International | Sheet handling apparatus |
AT412060B (en) | 2001-07-06 | 2004-09-27 | Schaupp Lukas Dipl Ing Dr Tech | METHOD FOR MEASURING CONCENTRATIONS IN LIVING ORGANISMS BY MEANS OF MICRODIALYSIS AND AND DEVICE FOR IMPLEMENTING THIS METHOD |
US6881203B2 (en) | 2001-09-05 | 2005-04-19 | 3M Innovative Properties Company | Microneedle arrays and methods of manufacturing the same |
US20040087992A1 (en) | 2002-08-09 | 2004-05-06 | Vladimir Gartstein | Microstructures for delivering a composition cutaneously to skin using rotatable structures |
CA2500452A1 (en) | 2001-09-28 | 2003-04-03 | Biovalve Technologies, Inc. | Switchable microneedle arrays and systems and methods relating to same |
JP3835532B2 (en) | 2001-10-26 | 2006-10-18 | リコープリンティングシステムズ株式会社 | Inkjet printer |
AU2002367965A1 (en) | 2001-11-06 | 2003-12-31 | Dermal Systems International Inc. | High throughput methods and devices for assaying analytes in a fluid sample |
EP1485317A2 (en) | 2001-11-30 | 2004-12-15 | Alza Corporation | Methods and apparatuses for forming microprojection arrays |
EP1465535B1 (en) | 2001-12-20 | 2007-11-28 | ALZA Corporation | Skin-piercing microprojections having piercing depth control |
US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
DE10209763A1 (en) | 2002-03-05 | 2003-10-02 | Bosch Gmbh Robert | Device and method for anisotropic plasma etching of a substrate, in particular a silicon body |
US7385707B2 (en) | 2002-03-14 | 2008-06-10 | Taylor Hobson Limited | Surface profiling apparatus |
AU2003222691A1 (en) | 2002-04-30 | 2003-11-17 | Morteza Shirkhanzadeh | Arrays of microneedles comprising porous calcium phosphate coating and bioactive agents |
JP3693115B2 (en) | 2002-05-13 | 2005-09-07 | セイコーエプソン株式会社 | Actuator device, liquid jet head, and inspection method thereof |
US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
CN100591386C (en) * | 2002-06-25 | 2010-02-24 | 权圣润 | Rapidly dissolving micro-perforator for drug delivery and other applications |
US7052117B2 (en) | 2002-07-03 | 2006-05-30 | Dimatix, Inc. | Printhead having a thin pre-fired piezoelectric layer |
US7250037B2 (en) * | 2002-07-22 | 2007-07-31 | Becton, Dickinson And Company | Patch-like infusion device |
US7081118B2 (en) | 2002-08-22 | 2006-07-25 | Helmut Weber | Medical tool |
AU2003275311A1 (en) | 2002-09-16 | 2004-04-30 | Sung-Yun Kwon | Solid micro-perforators and methods of use |
US7045069B2 (en) * | 2002-11-14 | 2006-05-16 | Gennady Ozeryansky | Microfabrication method based on metal matrix composite technology |
US20040161470A1 (en) * | 2002-11-22 | 2004-08-19 | Alexander Andrianov | Preparation of polyphosphazene microspheres |
EP1605835A4 (en) | 2003-03-06 | 2007-12-05 | Applied Med Resources | Spring clip and method for assembling same |
DE10328730B4 (en) | 2003-06-25 | 2006-08-17 | Micronas Gmbh | Method for producing a microarray and device for providing a carrier for a microarray with coating materials |
US20050089554A1 (en) * | 2003-10-24 | 2005-04-28 | Cormier Michel J. | Apparatus and method for enhancing transdermal drug delivery |
WO2005044139A2 (en) | 2003-10-28 | 2005-05-19 | Alza Corporation | Method and apparatus for reducing the incidence of tobacco use |
ATE539687T1 (en) | 2003-10-31 | 2012-01-15 | Alza Corp | SELF-ACTUATED APPLICATOR FOR A MICROPROJECTION ARRANGEMENT |
WO2005044364A1 (en) | 2003-11-10 | 2005-05-19 | Agency For Science, Technology And Research | Microneedles and microneedle fabrication |
MXPA06005509A (en) | 2003-11-13 | 2007-05-23 | Johnson & Johnson | System and method for transdermal delivery. |
US7753888B2 (en) * | 2003-11-21 | 2010-07-13 | The Regents Of The University Of California | Method and/or apparatus for puncturing a surface for extraction, in situ analysis, and/or substance delivery using microneedles |
IL160033A0 (en) | 2004-01-25 | 2004-06-20 | Transpharma Medical Ltd | Transdermal delivery system for polynucleotides |
WO2005072360A2 (en) | 2004-01-27 | 2005-08-11 | Buyerleverage | System and method for granting deposit-contingent e-mailing rights |
US20080312669A1 (en) | 2004-03-31 | 2008-12-18 | Vries Luc De | Surgical instrument and method |
US7591806B2 (en) | 2004-05-18 | 2009-09-22 | Bai Xu | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
ES2650188T3 (en) | 2004-06-10 | 2018-01-17 | 3M Innovative Properties Company | Device and patch application kit |
JP2006029881A (en) | 2004-07-14 | 2006-02-02 | Hitachi High-Technologies Corp | Inspection method of pattern defect and inspection device thereof |
TWI246929B (en) | 2004-07-16 | 2006-01-11 | Ind Tech Res Inst | Microneedle array device and its fabrication method |
US7316665B2 (en) | 2004-08-25 | 2008-01-08 | Becton, Dickinson And Company | Method and device for the delivery of a substance including a covering |
US7524430B2 (en) | 2004-09-10 | 2009-04-28 | Lexmark International, Inc. | Fluid ejection device structures and methods therefor |
US20080009811A1 (en) | 2004-11-18 | 2008-01-10 | 3M Innovative Properties Company | Non-Skin-Contacting Microneedle Array Applicator |
EP1827564B1 (en) | 2004-11-18 | 2015-07-29 | 3M Innovative Properties Company | Masking method for coating a microneedle array |
WO2006055795A1 (en) | 2004-11-18 | 2006-05-26 | 3M Innovative Properties Company | Low-profile microneedle array applicator |
WO2006101459A1 (en) | 2005-03-23 | 2006-09-28 | Agency For Science, Technology And Research | Microneedles |
WO2006108185A1 (en) | 2005-04-07 | 2006-10-12 | 3M Innovative Properties Company | System and method for tool feedback sensing |
US20060253079A1 (en) | 2005-04-25 | 2006-11-09 | Mcdonough Justin | Stratum corneum piercing device |
US20070270738A1 (en) | 2005-04-25 | 2007-11-22 | Wu Jeffrey M | Method of treating ACNE with stratum corneum piercing patch |
WO2006121510A2 (en) | 2005-05-09 | 2006-11-16 | Theranos, Inc. | Point-of-care fluidic systems and uses thereof |
US8043250B2 (en) | 2005-05-18 | 2011-10-25 | Nanomed Devices, Inc. | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
CA2612005C (en) | 2005-06-17 | 2013-10-29 | Georgia Tech Research Corporation | Coated microstructures and method of manufacture thereof |
CA2612307A1 (en) | 2005-06-21 | 2007-01-04 | Alza Corporation | Method and device for coating a continuous strip of microprojection members |
CA2613111C (en) | 2005-06-27 | 2015-05-26 | 3M Innovative Properties Company | Microneedle array applicator device and method of array application |
AU2006261899B2 (en) | 2005-06-27 | 2012-05-10 | Kindeva Drug Delivery L.P. | Microneedle cartridge assembly and method of applying |
US20070027474A1 (en) | 2005-07-15 | 2007-02-01 | Jeffrey Lasner | Pressure limiting forceps |
JP2009502261A (en) | 2005-07-25 | 2009-01-29 | ナノテクノロジー ビクトリア ピーティーワイ リミテッド | Microarray device |
CA2629393C (en) | 2005-09-06 | 2014-06-10 | Theraject, Inc. | Solid solution perforator containing drug particle and/or drug-adsorbed particles |
US20070078376A1 (en) | 2005-09-30 | 2007-04-05 | Smith Gregory A | Functionalized microneedles transdermal drug delivery systems, devices, and methods |
WO2007054090A1 (en) | 2005-11-09 | 2007-05-18 | Pharmexa A/S | Therapeutic vaccines targeting hmgb1 |
EP1948139A4 (en) | 2005-11-18 | 2012-04-04 | 3M Innovative Properties Co | Coatable compositions, coatings derived therefrom and microarrays having such coatings |
US8524303B2 (en) | 2005-11-23 | 2013-09-03 | The Coca-Cola Company | High-potency sweetener composition with phytosterol and compositions sweetened therewith |
US8554317B2 (en) | 2005-11-30 | 2013-10-08 | 3M Innovative Properties Company | Microneedle arrays and methods of use thereof |
US8308960B2 (en) | 2005-12-14 | 2012-11-13 | Silex Microsystems Ab | Methods for making micro needles and applications thereof |
BRPI0520480B1 (en) | 2005-12-14 | 2019-05-07 | Thomson Licensing | LNB SATELLITE POWER SUPPLY ADAPTIVE CHARGE |
US7658728B2 (en) | 2006-01-10 | 2010-02-09 | Yuzhakov Vadim V | Microneedle array, patch, and applicator for transdermal drug delivery |
GB0600795D0 (en) | 2006-01-16 | 2006-02-22 | Functional Microstructures Ltd | Method of making microneedles |
JP5028872B2 (en) | 2006-03-02 | 2012-09-19 | 凸版印刷株式会社 | Manufacturing method of needle-shaped body |
US20070224252A1 (en) | 2006-03-27 | 2007-09-27 | Trautman Joseph C | Microprojections with capillary control features and method |
US9119945B2 (en) * | 2006-04-20 | 2015-09-01 | 3M Innovative Properties Company | Device for applying a microneedle array |
WO2007127815A2 (en) | 2006-04-25 | 2007-11-08 | Alza Corporation | Microprojection array application with multilayered microprojection member for high drug loading |
EP2010269A4 (en) | 2006-04-25 | 2009-06-03 | Alza Corp | Microprojection array application with sculptured microprojections for high drug loading |
US7800698B2 (en) | 2006-04-27 | 2010-09-21 | Qualcomm Incorporated | Weight adjustment in color correction |
WO2007127976A2 (en) | 2006-05-01 | 2007-11-08 | Georgia Tech Research Corporation | Particle based molding |
US7425465B2 (en) | 2006-05-15 | 2008-09-16 | Fujifilm Diamatix, Inc. | Method of fabricating a multi-post structures on a substrate |
WO2008011625A2 (en) | 2006-07-21 | 2008-01-24 | Georgia Tech Researh Corporation | Microneedle devices and methods of drug delivery or fluid withdrawal |
KR100793615B1 (en) | 2006-07-21 | 2008-01-10 | 연세대학교 산학협력단 | A biodegradable solid type microneedle and methods for preparing it |
EP2062612A4 (en) | 2006-08-18 | 2010-01-06 | Toppan Printing Co Ltd | Microneedle and microneedle patch |
WO2008053481A1 (en) | 2006-11-01 | 2008-05-08 | Svip 6 Llc | Microneedle arrays |
JP2008114561A (en) | 2006-11-08 | 2008-05-22 | Ricoh Co Ltd | Liquid discharge head, liquid discharge device, and image forming device |
KR20080051342A (en) | 2006-12-05 | 2008-06-11 | 연세대학교 산학협력단 | A microneedle device and methods for applicating it |
WO2008083209A2 (en) | 2006-12-29 | 2008-07-10 | Amir Genosar | Hypodermic drug delivery reservoir and apparatus |
DE102007002832A1 (en) | 2007-01-19 | 2008-07-24 | Robert Bosch Gmbh | Method for manufacturing device with arrangement of micro-needles, involves preparing silicon semiconductor substrate, whose surface is applied and structured with masking layer |
EP2121111B1 (en) | 2007-01-22 | 2018-03-14 | Corium International, Inc. | Applicators for microneedle arrays |
US20090017210A1 (en) * | 2007-07-09 | 2009-01-15 | Andrianov Alexander K | Methods and systems for coating a microneedle with a dosage of a biologically active compound |
US20090041810A1 (en) | 2007-07-09 | 2009-02-12 | Andrianov Alexander K | Immunostimulating polyphosphazene compounds for intradermal immunization |
WO2009040548A1 (en) | 2007-09-28 | 2009-04-02 | The Queen's University Of Belfast | Delivery device and method |
WO2009051147A1 (en) | 2007-10-18 | 2009-04-23 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle device |
US8491534B2 (en) | 2007-11-21 | 2013-07-23 | Bioserentach Co., Ltd. | Preparation for body surface application and preparation for body surface application-holding sheet |
GB0725018D0 (en) | 2007-12-21 | 2008-01-30 | Univ Cardiff | Monitoring system for microneedle delivery |
EP2231257A4 (en) | 2007-12-24 | 2013-11-06 | Univ Queensland | Coating method |
CN101214395A (en) | 2008-01-02 | 2008-07-09 | 西南交通大学 | Inorganic material surface biological method |
CA2749347C (en) | 2008-02-07 | 2018-03-27 | The University Of Queensland | Patch production |
CA2760680A1 (en) | 2008-05-23 | 2009-11-26 | The University Of Queensland | Analyte detection by microneedle patch with analyte selective reagents |
CN101297989B (en) | 2008-06-19 | 2010-06-23 | 上海交通大学 | Batch preparation of hollow micro-needle based on molding |
KR101578420B1 (en) | 2008-06-30 | 2015-12-17 | 히사미쓰 세이야꾸 가부시키가이샤 | Microneedle device, and method for enhancing the efficacy of influenza vaccine by using microneedle device |
JP2010071845A (en) | 2008-09-19 | 2010-04-02 | Toppan Printing Co Ltd | Inspection device |
US20110288484A1 (en) | 2008-10-16 | 2011-11-24 | The Univeristy Of Queensland | Method and associated apparatus for coating projections on a patch assembly |
US20110021996A1 (en) | 2008-12-18 | 2011-01-27 | Miti Systems Inc. | Structure of micro-needle with side channel and manufacturing method thereof |
US20100156998A1 (en) | 2008-12-19 | 2010-06-24 | Nobuo Matsumoto | Method and apparatus for printing |
CA2760573A1 (en) | 2008-12-22 | 2010-07-01 | The University Of Queensland | Patch production |
WO2012018486A2 (en) | 2010-07-26 | 2012-02-09 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
US20120078293A1 (en) | 2009-03-27 | 2012-03-29 | Technion Research & Development Foundation Ltd. | Applicators for patches and adhesives |
EP2429627B1 (en) | 2009-04-24 | 2017-06-14 | Corium International, Inc. | Methods for manufacturing microprojection arrays |
ES2826882T3 (en) | 2009-07-23 | 2021-05-19 | Hisamitsu Pharmaceutical Co | Microneedle array |
CN102740800A (en) | 2010-01-29 | 2012-10-17 | 爱尔康医药有限公司 | Biodegradable protrusions on inflatable device |
US8911422B2 (en) | 2010-02-24 | 2014-12-16 | Hisamitsu Pharmaceutical Co., Inc. | Micro-needle device |
US20110306853A1 (en) | 2010-03-19 | 2011-12-15 | Michael Darryl Black | Body fluid sampling/fluid delivery device |
AU2011311255B2 (en) | 2010-04-28 | 2015-10-08 | Sorrento Therapeutics, Inc. | Method for increasing permeability of an epithelial barrier |
WO2011140240A2 (en) | 2010-05-04 | 2011-11-10 | Corium International, Inc. | Applicators for microneedles |
US9943673B2 (en) | 2010-07-14 | 2018-04-17 | Vaxxas Pty Limited | Patch applying apparatus |
US9017289B2 (en) | 2010-11-03 | 2015-04-28 | Covidien Lp | Transdermal fluid delivery device |
US8540672B2 (en) | 2010-12-22 | 2013-09-24 | Valeritas, Inc. | Microneedle patch applicator |
WO2012103257A2 (en) | 2011-01-25 | 2012-08-02 | The Regents Of The University Of California | Transcutaneous multimodal delivery systems |
CA2829352A1 (en) | 2011-03-07 | 2012-09-13 | 3M Innovative Properties Company | Microneedle devices and methods |
EP2497463A1 (en) | 2011-03-09 | 2012-09-12 | Rogier Biemans | Method of protecting biologically active substances against denaturation |
US8512286B2 (en) | 2011-04-18 | 2013-08-20 | Medtronic, Inc. | Detecting a full reservoir of an implantable infusion device |
JP2014516644A (en) | 2011-04-29 | 2014-07-17 | セブンス センス バイオシステムズ,インコーポレーテッド | Devices and methods for collection and / or manipulation of blood spots or other body fluids |
KR102013466B1 (en) | 2011-04-29 | 2019-08-22 | 세븐쓰 센스 바이오시스템즈, 인크. | Delivering and/or receiving fluids |
JP5682513B2 (en) | 2011-09-06 | 2015-03-11 | 株式会社村田製作所 | Fluid control device |
JP6265740B2 (en) | 2011-10-06 | 2018-01-24 | 久光製薬株式会社 | applicator |
CA2851620A1 (en) | 2011-10-12 | 2013-04-18 | 3M Innovative Properties Company | Integrated microneedle array delivery system |
EP2765927B1 (en) | 2011-10-12 | 2021-02-24 | Vaxxas Pty Limited | Delivery device |
US20150080844A1 (en) | 2012-04-02 | 2015-03-19 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure by intradermal infusion |
ES2761255T3 (en) | 2012-04-05 | 2020-05-19 | Hisamitsu Pharmaceutical Co | Lancing device |
WO2014058746A1 (en) | 2012-10-10 | 2014-04-17 | 3M Innovative Properties Company | Force-controlled applicator for applying a microneedle device to skin |
EP2974768A4 (en) | 2013-03-12 | 2017-05-17 | Takeda Pharmaceutical Company Limited | Micro-needle patch |
US10624865B2 (en) * | 2013-03-14 | 2020-04-21 | Pathak Holdings Llc | Methods, compositions, and devices for drug/live cell microarrays |
CA2904335C (en) | 2013-03-15 | 2022-03-29 | Corium International, Inc. | Microstructure array for delivery of active agents |
EP2968116A1 (en) | 2013-03-15 | 2016-01-20 | Corium International, Inc. | Microarray with polymer-free microstructures, methods of making, and methods of use |
WO2014150285A2 (en) | 2013-03-15 | 2014-09-25 | Corium International, Inc. | Multiple impact microprojection applicators and methods of use |
RU2720808C2 (en) | 2013-09-03 | 2020-05-13 | Джорджия Тек Рисёч Корпорейшн | Thermostable vaccines and microneedles |
US20160310412A1 (en) | 2013-12-16 | 2016-10-27 | Takeda Pharmaceutical Company Limited | Microneedle |
WO2015152360A1 (en) | 2014-04-04 | 2015-10-08 | 富士フイルム株式会社 | Microneedle array preparation comprising inactivated whole virus vaccine and method for administering same |
WO2015168738A1 (en) | 2014-05-06 | 2015-11-12 | Mupharma Pty Ltd | Non-invasive agent applicator |
JP6565906B2 (en) | 2014-05-20 | 2019-08-28 | 凸版印刷株式会社 | Needle-like body manufacturing method and needle-like body |
EP3216482B1 (en) | 2014-11-06 | 2019-03-20 | Toppan Printing Co., Ltd. | Transdermal delivery device and method for manufacturing transdermal delivery device |
EP3253440B1 (en) | 2015-02-02 | 2022-12-21 | Vaxxas Pty Limited | Microprojection array applicator |
JP6268114B2 (en) | 2015-03-09 | 2018-01-24 | 富士フイルム株式会社 | Microneedle inspection method |
JP6411395B2 (en) | 2015-03-10 | 2018-10-24 | 富士フイルム株式会社 | Method for producing transdermal absorption sheet |
JP6487728B2 (en) | 2015-03-10 | 2019-03-20 | 富士フイルム株式会社 | Measuring system, measuring method and measuring program |
CN107405477B (en) | 2015-03-18 | 2020-06-16 | 凸版印刷株式会社 | Drug administration device and method for manufacturing drug administration device |
US10441768B2 (en) | 2015-03-18 | 2019-10-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bioactive components conjugated to substrates of microneedle arrays |
JPWO2017047437A1 (en) | 2015-09-17 | 2018-08-02 | Aof株式会社 | Micro needle |
US11103259B2 (en) | 2015-09-18 | 2021-08-31 | Vaxxas Pty Limited | Microprojection arrays with microprojections having large surface area profiles |
CA2999538A1 (en) | 2015-09-28 | 2017-04-06 | Vaxxas Pty Limited | Microprojection arrays with enhanced skin penetrating properties and methods thereof |
CA3007753C (en) | 2015-12-28 | 2021-07-06 | Endoderma Co., Ltd. | Microstructure for transdermal absorption and method for manufacturing same |
CA3010974A1 (en) | 2016-01-11 | 2017-07-20 | Verndari, Inc. | Microneedle compositions and methods of using same |
JP2017176460A (en) * | 2016-03-30 | 2017-10-05 | 富士フイルム株式会社 | Method of manufacturing sheet with needle-like protrusion part |
JP6736337B2 (en) * | 2016-04-15 | 2020-08-05 | 富士フイルム株式会社 | Micro needle array |
US11241563B2 (en) | 2016-12-22 | 2022-02-08 | Johnson & Johnson Consumer Inc. | Microneedle arrays and methods for making and using |
DK3606760T3 (en) | 2017-03-31 | 2023-11-06 | Vaxxas Pty Ltd | ARRANGEMENT AND PROCEDURE FOR COATING SURFACES |
CN113993560A (en) * | 2019-02-01 | 2022-01-28 | 麻省理工学院 | System and method for liquid injection |
-
2004
- 2004-01-30 GB GBGB0402131.7A patent/GB0402131D0/en not_active Ceased
-
2005
- 2005-01-31 WO PCT/GB2005/000336 patent/WO2005072630A1/en active Application Filing
-
2006
- 2006-07-27 US US11/496,053 patent/US8052633B2/en active Active - Reinstated
-
2011
- 2011-10-03 US US13/251,891 patent/US9572969B2/en active Active
- 2011-10-03 US US13/251,920 patent/US9888932B2/en active Active
-
2017
- 2017-01-09 US US15/401,950 patent/US10751072B2/en active Active
- 2017-12-20 US US15/849,134 patent/US11207086B2/en active Active
-
2020
- 2020-06-09 US US16/896,387 patent/US20200405331A1/en active Pending
-
2021
- 2021-05-20 US US17/326,064 patent/US20220039812A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030199811A1 (en) * | 1999-09-24 | 2003-10-23 | Sage Burton H. | Method and device for abrading skin |
US6551849B1 (en) * | 1999-11-02 | 2003-04-22 | Christopher J. Kenney | Method for fabricating arrays of micro-needles |
US6558361B1 (en) * | 2000-03-09 | 2003-05-06 | Nanopass Ltd. | Systems and methods for the transport of fluids through a biological barrier and production techniques for such systems |
US6589202B1 (en) * | 2000-06-29 | 2003-07-08 | Becton Dickinson And Company | Method and apparatus for transdermally sampling or administering a substance to a patient |
US20020177839A1 (en) * | 2001-04-20 | 2002-11-28 | Cormier Michel J. N. | Microprojection array having a beneficial agent containing coating |
US8052633B2 (en) * | 2004-01-30 | 2011-11-08 | Mark Anthony Fernance Kendall | Delivery device |
US9888932B2 (en) * | 2004-01-30 | 2018-02-13 | Vaxxas Pty Limited | Method of delivering material or stimulus to a biological subject |
US11207086B2 (en) * | 2004-01-30 | 2021-12-28 | Vaxxas Pty Limited | Method of delivering material or stimulus to a biological subject |
Non-Patent Citations (1)
Title |
---|
Masters et al., "Multiphoton Excitation Microscopy and Spectroscopy of Cells, Tissues and Human Skin In Vivo", Biophys J. 1997 Jun;72(6):2405-12. * |
Also Published As
Publication number | Publication date |
---|---|
US9572969B2 (en) | 2017-02-21 |
US20120083762A1 (en) | 2012-04-05 |
US20200405331A1 (en) | 2020-12-31 |
US20170182301A1 (en) | 2017-06-29 |
GB0402131D0 (en) | 2004-03-03 |
WO2005072630A1 (en) | 2005-08-11 |
US9888932B2 (en) | 2018-02-13 |
US11207086B2 (en) | 2021-12-28 |
US10751072B2 (en) | 2020-08-25 |
US20110245776A1 (en) | 2011-10-06 |
US20180161050A1 (en) | 2018-06-14 |
US20120083741A1 (en) | 2012-04-05 |
US8052633B2 (en) | 2011-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220039812A1 (en) | Method of delivering material or stimulus to a biological subject | |
AU2019201051B2 (en) | Delivery device | |
US10022322B2 (en) | Coating method | |
US9943673B2 (en) | Patch applying apparatus | |
US20110288484A1 (en) | Method and associated apparatus for coating projections on a patch assembly | |
US8734697B2 (en) | Patch production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |